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Abstract
Recent advances in biotechnology have yielded an explosion of data describing biolo-
gical systems, creating rich opportunities for new insights into cellular inner-workings
and therapeutic discoveries. To keep up with this rapid growth and increase in data
complexity, we need novel static, integrative, and dynamic methodologies to continue
mining these networked systems. In this thesis we introduce new static, integrative,
and dynamic computational frameworks for network analysis, and combine existing
ones in new ways, to elucidate the biotechnological biases and functional principles
governing molecular interactions and their implications in disease. We focus on
mining new knowledge from the yeast and human interactomes, since these are
currently the most complete data in biology. We perform three lines of experimental
work: 1) the macro-scale study, where we model the yeast and human interactomes
and show that their interactome data are growing in structurally and functionally
principled ways, characterised by a non-random dual topological nature; 2) the micro-
scale study, where we zoom into the specifics of wiring patterns around individual
genes and uncover a unique core sub-structure within the human interactome, which
contains driver genes dubbed to be the main triggers for disease onset; and 3) the
data integration study, where we introduce a new computational framework for fusing
multiple types of molecular interaction data and use it to construct the first unified
model of the cell’s functional organisation and cross-communication lines. Similarly,
a new field of systems economics has gained recent attention, with more financial and
economic network data emerging at an increasing pace. Hence, we introduce a new
computational methodology for tracking network dynamics and use it to quantify
the micro- and macro-scale topological changes in the world trade network over the
past 50 years, and to demonstrate the fundamental relationship between topological
perturbations and indicators of countries’ political and economic stabilities.
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1
Introduction
Modern advances in biotechnology have led to previously unseen rates of growth in
acquisition of systems-level biological data, as well as to an increase in understand-
ing how that data can be used to benefit human life.1 For example, genome-wide
association studies are enabling assaying of more than a million single-nucleotide
polymorphisms in thousands of individuals;2,3 and it is to be expected that under-
standing the functioning of disease-associated genetic variants and elucidating the
underlying architecture of diseases will bridge the gap between scientific research
and its ultimate application in clinical practice.4 A decade-long effort to map human
disease loci, followed by positional cloning and genome-wide association studies has
produced an impressive database of disease–gene associations. The Online Mendelian
Inheritance in Man5 database contains over 4 500 phenotypes for which the molecular
basis is known and describes almost 3 000 genes with phenotype-causing mutations.5
We are currently witnessing the shift from a single-gene–single-disease paradigm
towards the interplay of different disease modules6,7 and ultimately to the notion
of a personalised genome/diseasome,8–10 but this shift is yet to gain momentum.
Understanding these data and extracting biological information from them to benefit
human life is a foremost challenge which comes not only from vast amounts of systems
biology data, but also from computational intractability of many techniques for their
analyses. Hence, new methods for analysing these data that can cope with these
complexities and give new biological insight are needed.11
This dissertation focuses on the computational analysis of static, dynamic and
integrated network data. It develops a new graph-based methodology for network
neighbourhood analysis, and introduces a new framework and integration model for
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describing the functional organisation of a cell. In the remainder of this chapter,
we first give a short overview of proteins and their role as the building blocks of
life (Section 1.1). Then we talk about using networks to represent different types of
molecular interaction data and what underlying problems we face in constructing
these networks (Section 1.2). After that, we describe the basic network properties
and tools used throughout the dissertation for modelling and comparing molecular
interaction networks (Sections 1.3 to 1.5), and introduce the concept of molecular
data integration (Section 1.6). Finally, we present the structure of the dissertation
(Section 1.7), and give a list of publications which resulted from the work done for
this dissertation (Section 1.8).
1.1 Proteins and their interactions
Proteins are essential macromolecules of life, so it is important to understand their
function and role in diseases. They do not act in isolation, but bind to each other
to perform a function.12 Data about these binding events — called protein–protein
interactions, or PPIs for brevity — exist for many model organisms,13–20 humans,21–23
bacteria24–30 and viruses,31–33 and are obtained using high-throughput screens, such
as yeast two-hybrid (Y2H) assays13–16,21,22,34 and affinity purification linked with
mass spectrometry (AP/MS).17,18,35,36
Since techniques for detecting physical interactions between proteins do not
work well for membrane proteins, new technology of membrane yeast-two hybrid
assays is becoming available.37–44 Discovering membrane-interacting proteins is a
key to understanding disease, since integral membrane-interacting proteins have a
role in cell signalling and hence, their alterations can produce disorders rooted in
disruption of signalling pathways. Membrane proteins account for one third of the
proteome. The difficulty in studying them lies in their hydrophobic nature, which
makes conventional biochemical and genetic assays unusable. The above mentioned
new technology allows for large-scale screening of membrane proteins’ interactors in
a range of organisms by utilising the split-ubiquitin principle which overcomes this
limitation. The effectiveness of this methodology was demonstrated over a decade
ago by using the mammalian ErbB3 receptor as a bait to identify previously unknown
ErbB3 interactors.37
Data for physical molecular interaction are publicly available from several data-
bases, including Human Protein Reference Database (HPRD)45, the Biological
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General Repository for Interaction Datasets (BioGRID) 46, IntAct47, Molecular IN-
Teraction database (MINT)48, Biomolecular Interaction Network Database (BIND)49,
Saccharomyces Genome Database (SGD)50 and the Database of Interacting Pro-
teins (DIP)51. Databases such as Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING),52 Interologous Interaction Database (I2D),53 and iRe-
fIndex54 aggregate some or all of the above mentioned sources into single data
sets.
1.2 Representing molecular interactions via net-
works
Molecular causes of diseases are explored through many different techniques, such as
through the examination of their causal genes, the disruption of related pathways,
analysis of age factors and various other external influences. Currently, not much
is known about the inter-connectivity of all these different causes, and elucidating
the relationship between the malfunctioning of a system and its genomic data would
provide insights into disease and set directions for future research. A scientific area
that is attempting to address this unification is that of biological networks. It brings
together the concepts of the human diseasome, a combined set of all known disorders
and their implicated genetic mutations, and all available systems-level molecular
data.
Networks, also called graphs, are defined as sets of nodes (also called vertices)
and edges (also called links), where nodes are singular entities and edges represent
relations between them. This seemingly simple mathematical concept is a powerful
approach for modelling real-world phenomena across various disciplines, including
biological data, such as physical interactions between proteins, or synthesis of meta-
bolic compounds. The above-described binding events between proteins are modelled
by protein–protein interaction (PPI) networks and analysing the topology of these
networks has already given new insight into proteins’ biological function55–57 and in-
volvement in disease.12,58–62 Networks have been used to model relationships between
diseases and they are a key part of the rising field of network medicine, which aims
to decipher the complex wirings that govern human diseases.6,7,59 An important part
of this complex cellular wiring is the network of protein–protein interactions.12 Since
proteins interact, a single gene mutation is not confined within the actions of its
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gene products, but can propagate throughout the system, influencing other gene
products that otherwise contain no aberrations. Hence, the final phenotypic effect is
a result of a combination of the initial defect along with the influence that it has on
other parts of the networked system.
The entire set of these interactions in humans is termed the human interactome.
The complexity of such a network is overwhelming, as humans have approximately
25 000 protein-coding genes and an unknown number of proteins due to many splicing
variants63 and post-translational modifications. Hence, the number of proteins that
take part in the interactome is argued to be in the six-digit range.64 The current
state-of-the-art data sets are approximated to around 50 000 unique proteins that
participate in close to 200 000 interactions.54 When the quality score of measurements
is taken into account, the human PPI data set is pruned down to around 10 000
proteins participating in some 50 000–60 000 high confidence interactions. This shows
that currently available interactome data are still noisy and incomplete. Numerous
biases are introduced by data collecting and data sampling techniques, as well as
averaging-out the species population by using universal models of the genome and
interactome.65–74 We study in Chapter 2 how some of these biases affect the resulting
interactome maps. Nevertheless, even such sparse data are often too large to be
efficiently analysed by present day network analysis algorithms. This is due to their
large sizes and the fact that many graph theoretic algorithms are computation-
ally intractable (NP-hard, or NP-complete).75 Hence, new approximate (also called
heuristic) methods for analysing network data that can cope with the underlying
complexities are being developed.11,76–82 In Chapters 2 to 5 of this dissertation we
introduce new computational approaches and combine existing ones in new ways, to
get insights into the workings of biological systems and the relationships between
molecular interactions and diseases.
1.2.1 Types of molecular interaction networks and biological
ontologies
Apart from PPI networks, which are the primary object of analyses in this dissertation
and which we described in the above sections, there is a wide range of other types of
molecular interaction networks and ontologies. We give a brief explanation of the
most widely studied ones below, and use them as additional sources of biological
information in Chapters 3 and 4 of this dissertation.
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Genetic interactions networks. Two genes are said to genetically interact when
a double mutant shows a significant deviation in fitness compared to the expected
multiplicative effect of combining two single mutants.83,84 Negative interactions
represent a more severe fitness defect than expected, with the extreme case being
synthetic lethality, while positive interactions represent a less severe fitness defects
than expected.85 The amount of deviation in the fitness represents the interaction
score. Each gene is then characterised by a genetic profile, which is the vector of
these interaction scores between that gene and every other gene. Then, the similarity
between two genes is measured by the Pearson’s correlation coefficient between their
genetic profiles.86 Two genes are connected by an edge in a genetic interaction (GI)
network if they have statistically significantly correlated genetic profiles (absolute
value of Pearson’s correlation coefficient ≥ 0.2 and p-value ≤ 0.05).
Gene co-expression networks. The expression of a gene can be measured over
time with experiments such as RNAseq.87 When the expressions of two genes are
significantly correlated over time, such genes are said to be co-expressed, and an
edge is placed between them in the network. For example Huttenhower et al. 88 give
a large integrated co-expression data set, where co-expressions of genes are based on
expression profiles from hundreds of data sets capturing responses to environmental
and genetic perturbations, all carefully and uniformly normalised and integrated in
a robust way.
Signal transduction networks. Signalling networks describe a system of com-
munication between proteins which coordinates cellular mechanisms and activity.89,90
Nodes in signalling networks are proteins and edges are placed between two nodes if
there is a known signalling cascade which propagates signals between them. These
networks are used in analysing the flow of information within the cell. Since many
systemic disruptions are caused by aberrations in signal transduction machinery,
these interactions play a critical role in a number of cancer triggering and recovery
processes.91,92
Transcriptional regulatory networks. Networks of transcriptional regulation
describe the impact of one gene on the transcription of another gene, i.e. how one
gene regulates the transcription process of the other.89,93 The nodes of these networks
are genes, and the edges placed between them are inherently directed, since the
regulation process is not symmetric: nodes A and B are connected if A binds to the
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regulatory DNA regions of B, which result in A controlling the expression of B. The
existence of such an interaction is identified by measuring the mRNA levels of the
expressed gene.
Gene Ontology (GO). In many areas of biomedical research ontologies play
an important role in unification of knowledge as a hierarchy of terms and their
mutual relationships. Among widely used ontologies is Gene Ontology (GO),94 which
describes genes and gene products in terms of their associated Biological Process
(BP), Molecular Function (MF) and Cellular Component (CC). GO is a current major
source of information for annotating genes and proteins across various species and
providing tools for systematic assessment of experimental gene sets via enrichment
analysis.
Disease Ontology (DO). Disease Ontology (DO)95 is a well established classific-
ation and ontology of human diseases. It integrates disease nomenclature through
inclusion and cross mapping of disease-specific terms and identifiers from Med-
ical Subject Headings (MeSH), 96 World Health Organization (WHO) International
Classification of Diseases (ICD),97 Systematized Nomenclature of Medicine Clinical
Terms (SNOMED CT), 98 National Cancer Institute (NCI) thesaurus 99 and Online
Mendelian Inheritance in Man (OMIM). 100 It relates and classifies human diseases
based on pathological analysis and clinical symptoms. In Chapter 4 we fuse a large
number of molecular interaction data sources to find new links between diseases,
which are currently not captured by DO.
1.2.2 Problems with network representation of interaction
data: a metabolic networks example
Constructing a graph model that accurately represents the observed underlying
biological process is often not straight forward. It depends on the way in which
the data will be analysed and thus must be tailored for the specific question that
is to be answered. For instance, metabolism is a process which keeps the organism
in homeostasis. The current representation of metabolism in literature is through
metabolic pathways which describe smaller parts of the metabolic system that act
upon molecules via a series of reactions. Thus, this description of metabolism can be
hierarchically broken down into pathways and further into specific chemical reactions
22
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that comprise these pathways. The reactions themselves constitute processes that
transform sets of chemical substances. However, modelling this system using a
network can be done in a number of different ways, with substantially different
outputs.101–114 Consequently, this dimensionality reduction from the complex inter-
twined metabolic system down to a graph requires logically splitting up the entire
metabolism into two categories: its basic elements and the relations between them;
that is, it requires determining which parts of it will be described by nodes and
which by edges.
One way of making this simplification is to represent elementary metabolic
compounds as nodes, and reactions between them as edges of a network. This is
known as the metabolite-centric mapping,106–109 and is the most common one in use
for general-purpose extraction of knowledge about metabolism from these networks,
as it closely mirrors the real structure of metabolic reactions. The second way is
enzyme-centric:110,111 nodes represent enzymes, and a pair of nodes is connected by
an edge if the corresponding enzymes catalyse at least one common reaction. This
representation is used for understanding molecular wirings around enzymes. The
third model, a reaction-centric map,112–114 is obtained by having nodes represent
individual reactions and placing links between them if they are commonly catalysed
by at least one enzyme, or if they act upon the same chemical compounds. However,
even when we choose the nodes in the network representation of metabolism, it is still
not clear how the edges between them should be drawn (details given in Figure 1.1).
Similarly, there are analysis-dependent options in representing the seemingly
simple diseaseome bipartite graph, which is a bipartite graph linking diseases to genes
known to be causing them;59 a bipartite graph is a graph whose nodes can be divided
into two separate sets, U and V , such that every edge in the graph connects a node
from U to one node in V . From this bipartite graph, two networks are made: that of
diseases, in which nodes are disorders and a pair of disorders is linked if they share at
least one gene whose mutation is known to be involved in both disorders; and that of
genes, where nodes are genes and a pair of genes is linked if they are both involved in
at least one same disorder. When the former projection network is clustered, major
disease classes are discovered, such as the cancer cluster, which is densely connected
due to the fact that many genes are associated with multiple types of cancers.59
Similarly, neurological disorders cluster together, but metabolic disorders do not,
and are dispersed throughout the network.59 Subsequent studies have shown that
metabolic disorders are better modelled using adjacency via metabolic pathways,
23
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+ +→
c)
a)
A C
B D
A C
b)
Figure 1.1. Different approaches to metabolic network reconstruction. If we
consider a metabolite-centric map of the following irreversible metabolic reaction from
substrates A and B to products C and D, A+B → C+D, we can chose (a) — to link only
the main substrate-product pair (say, A and C) while leaving out the transitive elements,
such as energy or water (say, B and D). But, it is not always the case that a reaction
has transitive elements. If there are no transitive elements in this reaction, (b) — the
metabolite-centric network map would usually link A to both C and D, as well as B to
both C and D, even though this might not be completely biologically accurate, since for
the production of C (and D) both A and B are needed together, and this subtlety is lost
in this type of network representation. The issue could be solved by using more involved
mathematical concepts, such as hypergraphs instead of graphs, as edges in hypergraphs
consist of any subsets of nodes and not just node pairs. By using hypergraphs (c) —,
{A,B,C} and {A,B,D} would be hyperedges, which would better describe the real-world
product-substrate relationships. However, algorithms for analysing hypergraphs are more
mathematically and conceptually involved than those for graphs115.
24
1.3 Basic network properties
rather then via sharing of disease-related genes.116
But despite all these caveats, network representations of molecular data and their
subsequent graph-theoretic analyses have given us a lot of valuable insights into
the inner-workings of living organisms. The following two sections describe basic
graph-theoretic concepts which are commonly used in network analysis.
1.3 Basic network properties
The way in which nodes and edges are placed within a network represents the
topology of that network, also called wiring or structure. Characterising topological
properties of a network is important as it gives us a “feel” of what that network
“looks like”, but more importantly it can be used as a formal mechanism of comparing
different networks and precisely quantifying differences and similarities between them.
A wide range of these network properties exists and below we only describe those
used throughout this thesis.
• Degree of a node in a network is the number of connections (edges) that node
has to other nodes in the network.
• Degree distribution of a network is a probability distribution of degrees of all
nodes in a given network. If P (k) is the percentage of nodes in the network that
have degree k, then the degree distribution is the distribution of P (k) for all
values of k.
• Clustering coefficient measures the level of cliquishness in a network: it computes
the concentration of triangles in the neighbourhood of a node. Therefore, the
clustering coefficient, Ci, of a node i is the proportion of the number of edges
between its neighbours, Ei, and the maximum number of edges that could exist
between the neighbours: Ci = 2Eiki(ki−1) , where ki is the number of neighbours of
i, i.e. the degree of node i. The average clustering coefficient is defined as the
average of clustering coefficients of all the nodes in the network: C¯ = 1
n
∑n
i=1Ci,
where n is the number of nodes in a network.117
• Shortest path between two nodes, u and v, is the minimum number of edges that
have to be traversed to get from u to v. The length of a shortest path between
u and v is the distance from u to v. The average path length is the average of
shortest path lengths between all pairs of nodes in the network.118
• Eccentricity of a node v, ϵ(v), is the largest distance between v and any other
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node in the network; in other words, it measures how far node v can possibly be
from any node given network.
• Diameter is the maximum eccentricity over all nodes in a network: d = max
v∈V
ϵ(v).
• Radius is the minimum eccentricity over all nodes in a network: r = min
v∈V
ϵ(v).
• Compactness of a network, e¯ is calculated as e¯ = diameter
radius
and tells us whether
nodes in that network can be divided into central and peripheral. Clearly, the
diameter can be at most twice the radius of the network. If the diameter of the
network is equal to the radius, then the network has no peripheral nodes.
So what can basic network properties tell us about molecular interaction data?
Although current knowledge of gene involvement in diseases is somewhat limited,
the differences in PPI network wiring around disease-causing and non-disease related
proteins have already been studied using notions of connectivity and neighbourhoods
in PPI networks.12,58–61,119,120 Immediate neighbours of a protein in the PPI network
were shown to be more likely to have the same or similar functionality compared to
those that are further away from the protein,55,56 and also to be more likely to cause
a similar disease.12,120 A machine learning classifier based on a number of topological
properties of the PPI network was proposed in order to predict genes involved in
disease, but it produced results that differed for literature-curated PPI networks,
high-throughput yeast two-hybrid network data, and predicted PPI data.121 An
initial observation that correlates a protein’s essentiality with its degree in the PPI
network of baker’s yeast122 was later refuted by re-examination of the hypothesis.123
Even on newer and more complete PPI network data, the correlation between
essentiality and connectivity was not observed74,124 and it appears to persist only
for networks that are literature-curated,125 or for some smaller Y2H-derived net-
works.14 Similarly, when compared to non-cancer genes, genes involved in cancer were
thought to have higher connectivities, 119 which was later disputed. 59 Utilising PPI
network data was contrasted with utilising sequence data to differentiate between
genes involved in human hereditary disease and those that are not, along with their
functions.126 A general consensus is that disease proteins have high connectivities
and are located in the middle rather than on the periphery of the PPI network.12
Although useful, it is clear that such simple analysis methods on noisy data that
are obtained by biased data collection and sampling may lead to some contradicting
conclusions;65–74 hence, more sophisticated methods that give consistent results even
in the presence of noise in the data have been designed. These are described in the
following sections.
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1.4.1 Network motifs
Rather than looking at the network as a whole on a global level, the local topology
of networks can also be examined. Network motifs, small sub-graphs that occur in
real networks much more often than is expected at random, have been introduced
to examine the structure of complex networks.127 The random model against which
motif counts are compared to determine whether a detected pattern is significant
(either over- or under-represented), is the Erdös-Rényi (ER) network model, where
pairs of nodes are randomly connected with a given probability p (for a detailed
description of ER random networks see Section 1.5.1 Random network models on
page 31). The score used for evaluating the significance of motif frequency is the
z-score: zi = xi−µσ , where xi is the frequency of sub-graph i (i.e. motif i) in the real
network, while µ and σ are, respectively, the mean and standard deviation of the
frequency of that sub-graph in the corresponding random network.
Motifs helped uncover some of the main structural principles in molecular net-
works, such as PPI and transcription–regulation networks,93 and led to the discovery
of feed-forward loops in signalling networks which gave insight into patterns of
signal propagation.90 Furthermore, motifs enabled systematic detection of repeated
appearances of topological sub-structures in Escherichia coli transcriptional regula-
tion network and related them to specific biological responses to external signals.89
However, since by definition motifs need to be overrepresented in the data when
compared to random graph models, the question is what models are the best fitting
to real biological networks; and motifs received a fair amount of criticism due to
this issue.128 This problem cannot be answered exactly due to NP-completeness
(i.e. provable computational intractability) of the underlying sub-graph isomorphism
problem that tests whether one network exists as a copy in another network.75
Hence, various other methods for approximately comparing129–131 and aligning132–140
networks have been proposed.
1.4.2 Graphlets and graphlet-based heuristics
To help resolve some of the controversies mentioned above that arose because simple
network properties, such as direct neighbourhoods, were used to study protein
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function in the context of PPI networks, more constraining measures of the position
of a node in a network have been introduced.57 Graphlets are small, connected,
induced sub-graphs of a large network129,131 whose frequencies around the node
of interest give additional insight into the topological position of the node in the
network (see Figure 1.2);57 a sub-graph is induced if it contains all edges between
its nodes that exist in the larger network. Graphlets are different from network
motifs,127 which are sub-graphs that are overrepresented in the data compared to
a chosen random graph model: graphlets are induced and they do not need to be
overrepresented.
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Figure 1.2. Graphlets. There are 30 graphlets with up to five nodes (G0, G1, G2,
. . . G29), and they contain 73 topologically unique node types, which are called automorph-
ism orbits. Nodes belonging to the same orbit are of the same shade.
The graphlet degree vector (GDV) of a node is a generalisation of the degree of a
node, but whereas the degree only measures the number of edges that a node touches
(i.e. graphlets denoted by G0 in Figure 1.2), the graphlet degree vector consists of
73 coordinates each of which represents the number of times the node touches a
particular graphlet at a particular automorphism orbit (an illustration is given in
Figure 1.3). The GDV of a node is also called the node signature.57 The similarity
between GDVs of nodes u and v in graph G is computed as follows. If ui is the ith
coordinate in the GDV of node u (i.e. the number of times node u is touched by orbit
i), and vi is the corresponding ith coordinate in the GDV of node v, the distance
between these two orbits is computed as:
Di(u, v) = wi × | log(ui + 1)− log(vi + 1)|log(max(ui, vi) + 2) ,
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where wi is the weight of orbit i that accounts for dependencies between orbits (see
Milenković and Pržulj 57 for details). The total distance between nodes u and v is
then
D(u, v) =
∑72
i=0Di∑72
i=0wi
.
This normalised distance is in the [0, 1] range, with the distance of 0 meaning that
nodes u and v have identical signatures (the signature similarity decreases as the
distance approaches 1). Finally, the signature similarity, S(u, v), between these nodes
is computed as
S(u, v) = 1−D(u, v).
Hence, higher signature similarity indicates higher topological similarity between the
two nodes.
V V V
Orbit 0 1 2 3 4 5 6 . . . 72
GDV(v) 2 1 1 0 0 1 0
Figure 1.3. An illustration of the GDV computation for node v. GDV (v) =
(2, 1, 1, 0, 0, 1, 0 . . . , 0), meaning that v is touched by two edges (orbit 0, illustrated in the
left panel), an end-node of one graphlet G1 (orbit 1, illustrated in the middle panel), the
middle node of one graphlet G1 (orbit 2), illustrated in the left panel again, no nodes of a
triangle (orbit 3 in graphlet G2), no end-node of graphlet G3 (orbit 4), one middle node of
graphlet G3 (orbit 5, illustrated in the right panel), and no other orbits.
This GDV-based measure of similarity between nodes in PPI networks has been
used to show that a protein’s function and the topology around it are closely linked
and to successfully predict protein function and involvement in disease.57,61,141,142
Also, it was used in network alignment algorithms to correctly reconstruct species
phylogeny and predict protein function solely from network topology,137–140 as well as
to find new members of melanin production pathways that have been phenotypically
validated.61,142
The statistics of frequencies of appearance of graphlets in entire networks, or
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around nodes in networks have been used to classify networks into models,129,131 as
well as to link the topology around a node in a network with the node’s biological
function and involvement in disease: proteins with similar wiring up to a 4-deep neigh-
bourhood (Figure 1.3) were shown to belong to the same protein complexes, perform
the same biological functions, are localised in the same sub-cellular compartments,
and are co-expressed in tissues.57,61,141–143 Furthermore, clustering of nodes based
solely on graphlet-based topology of human PPI networks was used to successfully
predict RNAi targets as novel components of melanogenesis regulatory pathways that
could not have been identified by other existing approaches.142 Similarly, involvement
of genes in cancer was successfully predicted and validated both through literature
curation and experimentally, thus providing evidence that topological wiring around
cancer genes differs from wiring around non-cancer genes. 61 We exploit this fact in
Chapter 3 to identify a core sub-network of the human interactome in which genes
involved in a multitude of diseases reside.
Graphlet degree distribution agreement (GDDA) is a measure which shows how
similar the structure of two networks is. It is based on counting the occurrences of
all small induced sub-graphs with k nodes (i.e. graphlets), where k ∈ {2, 3, 4, 5}. By
definition there are 73 graphlet degree distributions (GDDs) for each data-to-model
comparison. The distributions are scaled and normalised so that the dependencies
between graphlets are taken into account and then the arithmetic average of such
scaled and normalised distributions aggregates them into a single number in [0, 1].
Informally, GDDA is a generalisation of the degree distribution, so that instead of
comparing only the degree distributions of two networks, it also compares how similar
the two networks are in terms of distributions of sub-structures such as triangles and
squares.129,131
In this thesis, graphlet-based measures are used to show exactly how newly
screened proteins are added to and how they impacted the growth of the human
interactome, and to see how the human and yeast interactomes fit random network
models (Chapter 2) as well as to compare topological properties of proteins and
search for topologically similar sub-region within the human interactome. They are
also used as an additional source of information in molecular data integration for re-
constructing the Gene Ontology (GO)94 and Disease Ontology (DO)144 (Chapter 4).
Furthermore, we introduce a new graphlet-based computational method for network
neighbourhood analysis, and apply it to economic data where we find a link between
topology of a country’s trade and its economic and political stability (Chapter 5).
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1.5.1 Random network models
To get insight into the topology of a PPI network, the PPI network is compared to
different random network models. These random model networks are constructed
with the same number of nodes and edges as the original data. In Chapter 2, where
we model the yeast and human interactome networks, we consider the following five
most common network models:
• Erdös-Rényi random model (ER) represents uniformly distributed random
interactions. An ER network is constructed by generating a fixed number of
nodes and then randomly adding edges between uniformly chosen pairs of nodes,
until the desired number of edges is reached.145
•Generalised random model (ER-DD) represents an extension of the ER
model in that the degree distribution of the nodes in the generated network
matches the degree distribution of the nodes in the input network. An ER-DD
network is constructed as follows. Each node is first assigned a “connection
capacity”, after which edges are uniformly placed between randomly chosen pairs
of nodes and their available “connection capacities” are reduced.146
•Geometric model (GEO) captures the spatial proximity relationships between
nodes uniformly distributed inside a n-dimensional space.147 We construct a GEO
network in 3-dimensional space by placing an edge between two nodes if the
Euclidean distance between them is within a distance threshold, ϵ.
• Barabási-Albert Scale-free (SF-BA) model represents networks with power
law degree distributions (i.e. scale-free topology). A SF-BA network is constructed
from a small initial seed network and nodes are added iteratively: new nodes
are attached to existing ones based on attachment probabilities, which, in turn,
correspond to the degrees of existing nodes.148
• The Stickiness-index based model (STICKY) is based on the assumption
that the higher the degrees of two nodes, the more likely they are to interact.149
A STICKY network is constructed by randomly assigning stickiness-index values
to all nodes. These values are proportional to the degrees of nodes in the input
network. Then, pairs of nodes are connected with the probability corresponding
to the product of their stickiness-indices.
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Many others exist, along with theoretical results for them. For example, see book
by Bollobás 150 for ER graphs, and Brandstädt and Spinrad 151 for an in-depth survey
of more than 200 classes of graphs.
1.5.2 Network comparison
Comparing two networks can be done using three different approaches: 1) network
querying, 2) network topology comparison, and 3) network alignment. The network
querying approach is used when searching for a specific small topological pattern
in large network. The network topology comparison approach defines a distance
measure which is used in evaluating the topological agreement between two networks.
Finally, aligning networks is a process of mapping nodes of one network onto the
nodes of another with a goal of maximising the number of aligned edges between the
aligned nodes. All three of these problems are computationally intractable due to
the underlying sub-graph isomorphism problem which is NP-complete.75 This means
that there is no polynomial-time exact solution, but only approximate solutions
exist. In Chapter 2 we use the first two networks comparison approaches, namely
network topology comparison and network alignment, to study the topology of the
human and yeast interactome. The standard graph-theoretic properties of networks
described in Section 1.3 Basic network properties can be used as the simplest form
of comparative heuristics, while the most robust-to-noise and sophisticated methods
for network comparison rely on graph spectra,152,153 motifs,127 and graphlet-based
heuristics (see Section 1.4.2). To compare networks throughout this thesis, we choose
GDDA over motifs127 and spectral methods154 because it has been shown to be a
very robust, yet sensitive measure that encapsulates a large range of other commonly
used measures, such as the degree distribution (1st GDD), clustering coefficient (3rd
GDD), and various other sub-structures (Section 1.4.2).
1.6 Fusing multiple sources of molecular informa-
tion
The availability of genomic-level information from high-throughput measurements of
genetic and protein interactions, mRNA expression profiles and metabolic pathways
has created new opportunities for function prediction. Data from such heterogeneous
sources of information can be integrated by data fusion,155 however this is not a
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simple task. For example, a major challenge is how to integrate all these diverse data
to predict annotations of yet unannotated proteins. Among the widely used compu-
tational methods addressing this problem are Bayesian reasoning,156 network-based
analysis,157,158 kernel-based statistical learning 159 and matrix factorisation-based data
fusion.160 Common fusion approaches employ early or late integration strategies,
combining inputs161 or predictions,162 respectively. Another and often preferred
approach is intermediate integration, which preserves the structure of the data while
inferring a single model.159,163,164 An excellent example of intermediate integration
is multiple kernel learning that convexly combines several kernel matrices construc-
ted from available data sources.155,165 Data fusion has been successfully applied
for tasks such as gene prioritisation,155,165,166 or gene network reconstruction and
function prediction.161,167 All these methods have demonstrated that the integration
of complementary biological data significantly improves accuracy of gene function
annotation prediction. In Chapter 4 of this dissertation we apply data fusion to mine
new functional relationships between genes, and we present the first application of
data fusion to disease association mining.
1.7 Dissertation outline
Chapter 2 presents a macro-scale computational analysis of the human and yeast
interactomes, since these data are currently considered to be the most complete.
We show that different modern interaction detection biotechnologies are producing
topologically unbiased interactome maps. We demonstrate the dual nature present
in the wiring of the interactome, whereby we differentiate between the wiring of
function-performing proteins and the wiring of function-linking (communication)
proteins, both of which have their unique topological characteristics. We also look at
how the topology of the interactomes has evolved since the early days of interaction-
screening. Additionally, we devise a new measure of network topology and use it to
show that large cyclic wiring patterns rarely occur within the interactome.
Chapter 3 complements the macro-scale studies and focuses on the micro-levels
of interactome wiring. Using network decomposition, we find a topologically unique
sub-network in the core of the human interactome, which contains driver genes
dubbed to be the main triggers for disease onset. We then generalise this approach
and apply it to complex diseases such as breast cancer, cardiovascular disease, and
neuro-degenerative diseases, where we find potential key therapeutic targets. In
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addition, we identify a sub-graph of the human interactome whose wiring has been
conserved (i.e. topologically unchanged) since the initial high-throughput version of
a proteome-scale map of the interactome.
Having worked predominantly on protein–protein interaction data in these two
chapters, in Chapter 4 we include and analyse additional types of molecular in-
teraction data, and show that different molecular interaction data carry different
information about the functional organisation of the cell. Hence, we take an integ-
rative approach and ask what new insight can be obtained by looking at different
molecular interaction data together rather than in isolation. We introduce a new
integrative computational framework with the purpose of building the first functional
organisation map of the cell which captures the lines of cross-communication between
biological functions. Furthermore, we formally quantify the contribution of each
molecular source to current state-of-the-art knowledge of functional relationships
between genes. Finally, we perform two large-scale integration studies where we
integrate co-expression, protein–protein, genetic, signalling, metabolic, gene–disease,
and drug–target interaction data with various ontologies and measures of network to-
pology. Through this, we begin to address the open problem of disease reclassification
by finding new links between previously unrelated diseases.
Inspired by the variety of new insights that network-based approaches can yield
in the field of systems biology, in Chapter 5 we look at the applicability of network
analysis in an economic domain and introduce a new computational methodology
for network neighbourhood analysis which shows how the topological organisation
of world trade evolved over the past half-century. The results suggest that there is
a strong link between changes in the political and economic stability of a country
and the changes in its topology within the world trade network. We also use the
methodology to see the impact that oil crises and globalisation have had on the
network topology of the entire world.
In Chapter 6, we conclude the dissertation by summarising its main contributions:
1) the human and yeast interactomes are growing in a topologically and functionally
consistent way and are characterised by a dual structural nature; 2) the decomposition
of the interactome reveals a layered functional organisation, and contains important
disease-triggering genes in its core; 3) a new network metric is used to measure
the cycle content in network topology; 4) we find that different molecular data
sources contain complementary information about cell’s functional organisation;
5) a novel computational framework for integrating these data is used to build a
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high-confidence model of the cross-talk between biological functions, and we show
that data integration can help improve therapeutics by uncovering new relationships
between diseases; 6) we propose a new graph-based computational methodology
which is able to track the dynamics of global and local network topology changes, and
is applicable to any scientific domain which makes use of network data representation.
Finally, we demonstrate potentially interesting ways in which these contributions
can be further expanded, and highlight future research questions that come as a
results of the material presented in this dissertation.
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Biotechnological biases and the
growth of interactome data
It is interesting that over a decade after the sequencing of the human and yeast
genomes has been completed, it is still unclear what the final size of those, and many
other, interactomes will be. Recently, Stumpf et al. 168 estimated interactome sizes
of human and three eukaryotic organisms: they estimated the human interactome
to have ≈650 000 edges, C. elegans ≈200 000 edges, D. melanogaster ≈75 000 edges,
and S. cerevisiae ≈25 000–30 000 edges. Their results indicated that the size of
PPI networks of various organisms correlate well with the organism’s apparent
complexity, rather than the mere size of its genome.53,169 The topology (i.e. structure)
of these biological networks is thought to be a by-product of stochastic chance and
evolutionary necessity.170–174 On the other hand, there is a wide body of scientific
evidence that contradicts the “chance and necessity” principle and corroborates the
modular organisation of functions in biological networks.175–184 To adequately model
and analyse a network, we need to understand this apparent randomness coupled
with evolution. Yet, the issue of what networks in biology “look like” and whether
biotechnological biases play a role in the topological shaping of those networks is
still largely debated.
To address these questions and get a better understanding of the global topological
properties of the interactome and how they change over time, in this chapter we model
the yeast and human PPI networks and show that their topology is independent of
the interaction-screening biotechnology that produced them (Section 2.3.1). We also
show that the interactome is composed of two distinct wiring patterns caused by
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functional modules of proteins and communication links between them (Section 2.3.2).
Additionally, we observe that the topology of the interactome has been growing in
a structurally and functionally consistent way since the early days of interaction-
screening (Sections 2.3.4 and 2.3.5), and we explain the topological patterns in
which newly screened proteins and their interactions get added into the interactome
(Sections 2.3.6 and 2.3.7). We then examine how this addition of new PPI data
affects the large conserved human–yeast regions of their interactome networks, both
topologically and functionally (Section 2.3.8). Finally, Section 2.3.9 introduces a new
measure of network topology, which we call the cycle coefficient. It is a generalisation
of the clustering coefficient and represents the likelihood of any two nodes with a
common interactor to be connected through cycles within the network. Using this
measure, we find that large cycles are not common in the interactomes, i.e. that PPI
networks are tightly wired with short cycles between their proteins.
2.1 Motivation and previous studies
Although there were attempts to quantify the dependence of a network’s structure
on a given set of features such as age, or abundance of proteins in a cell,173 none of
them explored the dependency of network models on interaction-detection biotech-
nology. Also, to our knowledge, no other study addresses biotechnology-dependant
modelling of functional sub-modules in PPI networks. Two recent studies dealt with
characterising degree distributions of yeast transcriptional regulatory networks, and
attempted to identify and explain microscopic features of human regulatory networks,
such as motif patterns and highly connected network elements. 185,186 Other similar
studies undertook dynamical modelling of regulatory networks using state-transition
graphs while specifically focusing on regulatory control of T-helper cell activation
and differentiation;187 or tested for simple edge overlaps between only two data sets:
yeast two-hybrid and literature curated data sets.188
There were a couple of attempts to model full PPI networks of yeast, fruit fly,
worm and human;129,131,189 however the aim of those studies was not to quantify
the topological features of PPI networks produced by different interaction-detection
technologies, but rather to determine the best fitting theoretical model for various
model organisms. In contrast, a study by Fernandes et al. 190 aims to quantify
methodological biases in experimental data using a newly proposed measure for PPI
network comparison. They find that only sufficiently large PPI data can be used
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for inter- and intra- species comparisons using the mentioned novel measure based
on normalised correlations between node degrees, which is largely similar to one of
the five random network models that we use, namely, the STICKY random model.
In addition, they use a model akin to the ER-DD degree distribution preservation
model used in our study as the only random model against which they compare,
and some of the data sets they use are currently outdated by ten years or more.
Moreover, the PPI data analysed in most of the above mentioned studies is now largely
outdated and thus our work offers analysis on up-to-date yeast PPI data, comprising
roughly 75 000 interactions between almost 6 000 proteins. Also, unlike any of the
previous studies, we dissect and model PPI data in several ways: 1) we examine
networks created from all available protein–protein interaction data; 2) we examine
sub-networks (modules) based on cellular functions; 3) we examine sub-networks
based on interaction screening biotechnology; 4) we examine sub-networks based on
the combination of cellular functions and interaction screening biotechnology; 5) we
examine functional diversity between intra- and inter- function protein interactions;
and finally, 6) we compare the observed yeast results with those obtained for the
human PPI data, and PPI data of several other model organism. To achieve this,
we used the computational approach and interaction network data presented in the
next section.
2.2 Methods and data
2.2.1 Data preprocessing
2.2.1.1 Yeast data
For modelling the PPI network of baker’s yeast (S. cerevisiae), we use data from
BioGRID191 (version 3.1.93). Also, we use a set of literature curated PPIs from
Reguly et al. 125 which we consider to be a high confidence set of PPIs. All available
PPI data in BioGRID is obtained using the following 16 PPI detection technolo-
gies: affinity capture-luminescence (hereafter denoted by acl for brevity), affinity
capture/mass spectrometry (acms), affinity capture-RNA (acrna), affinity capture-
western (acw), biochemical activity (ba), co-crystal structure (cocs), co-fractionation
(cof), co-localisation (col), co-purification (cop), far western (fw), FRET (fret),
PCA (pca), protein–peptide (ppep), protein–RNA (prna), reconstituted complex
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(rc) and yeast two-hybrid (y2h). These raw interaction data are transformed in the
following two ways:
• Based on the above-listed experimental evidence codes assigned to each interaction
in BioGRID (e.g. acms, fret, y2h), we extract 16 networks of physical interactions
(Table A.1). Since currently some biotechnologies have low coverage of the
interaction space and generate very sparse PPI networks, we focus on only those
biotechnologies that produce PPI networks which are sufficiently dense to be
modelled (shown on the x-axis of Figure 2.2). Also, note that while acrna, col
and prna are not PPIs in their strictest form, they are akin to PPIs and BioGRID
classifies them into the physical protein interaction category alongside the rest
of the PPI data1. In addition, we include a network based on the full set of
BioGRID PPIs, which has 5 981 nodes and 74 542 edges. Together with the high
confidence PPI network mentioned above, this gives us 18 yeast PPI networks
(16 based on different biotechnology, 1 full from BioGRID, and 1 high confidence
from literature curation).
• Based on functional categories assigned to each protein, yeast networks are con-
structed as follows. For each of the 18 above-described networks, we extract
functional sub-networks in order to see whether there is any variation in the
topology of different functional sub-units within a cell and whether that variation
could be attributed to experimental technology that produced them. The func-
tional annotation of yeast proteins that we use represents an updated version of
the annotation used by Costanzo et al. 86 . The annotation covers 75% of proteins
in BioGRID and separates them into 14 categories based on biological function
(Table A.2). We construct a sub-network on a given function X by taking nodes
annotated with that particular function and all edges between them (i.e. we
construct an induced sub-graph on nodes involved in function X).
This results in 270 distinct yeast networks: 18 biotechnology-specific PPI networks
plus each of those 18 PPI networks broken down into 14 functional categories (18 +
18× 14 = 270).
2.2.1.2 Human data
We obtained human PPI data from the Center for Cancer Systems Biology (CCSB)
Interactome Database2. We used the following yeast two-hybrid (Y2H) human
1 http://wiki.thebiogrid.org/doku.php/experimental_systems
2 http://interactome.dfci.harvard.edu/
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interactomes: HI-2005, the data set from Rual et al. 22; HI-2011, the union of Yu
et al. 192 , Venkatesan et al. 64 and Rual et al. 22 data sets; HI-2013, the latest human
PPI data set from Rolland et al. 193 .
2.2.1.3 Data for other model organisms
Alongside human and yeast PPI data, we also use PPI networks of model organisms
to compare the human and yeast interactome with interactomes of other species. The
PPI network of A. thaliana (AI-1) is constructed from data published by the Ara-
bidopsis Interactome Mapping Consortium 194 . To increase coverage, we constructed
the worm and fly PPI networks as unions of multiple data sets: the worm (C. elegans)
PPI network (WI-2) is constructed as the union of WI-2004 16 and WI-200734 data;
and the fly (D. melanogaster) PPI network (FI-2) is constructed as the union of
data by Stanyon et al. 195 (Finley Lab), Formstecher et al. 196 (Hybrigenics) and Giot
et al. 15 (CuraGen). Further details on used PPI data sets of human and model
organisms can be found in Table A.3 on page 193.
2.2.2 Fitting random network models to network data
When modelling real-world network data, we use the five random network models
described in Section 1.5.1 Random network models on page 31. Since there is no
single standardised way of measuring data-to-model fit, below we elaborate on the
choice of the computational approach used in this thesis.
To compare the original input network with a random network model, the number
of generated model instances should be chosen so that it allows easy detection of
significant topological variation. A larger number of generated model instances
against which to compare increases the confidence of the comparison; but, increasing
the number of generated model instances also increases the required computational
time. It was previously shown that generating 30 model instances is a sufficient to
successfully model a network using acceptable computational time.197–199 Therefore,
we take the real-world network data that we want to model and generate 30 model
instances of each of the five random network models from Section 1.5.1. This gives
us 150 random model network instances for each of the 270 original input networks,
i.e. a total of 40 500 networks to analyse. We noticed that some of the original input
networks are very small and sparse so that they fall under a region of instability
recently described in Hayes et al. 200 In brief, what that region suggests is that when
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a network is small and sparse (i.e. has a small number of nodes and edges), the
structure of model networks of that size and density is unstable, so a model cannot
be fit to such data regardless of the modelling approach.
Next, we need a way to compare the generated networks to the original network.
However, comparing large networks is a computationally intractable, i.e. NP-hard,75
task since in order to demonstrate similarity between two such networks we need
to quantify the similarity between their exponentially many properties (such as the
degree distribution, clustering coefficient, diameter, and relative graphlet frequency
distribution). Imposing similarity constraints on only a few of these properties can
easily be achieved on two very large and different networks. For instance, it is easy to
construct two networks with exactly the same degree distributions but whose topology
and function differ substantially.129,201,202 So, it is computationally intractable to
analyse all network properties, but imposing a large number of such constraints will
increase the likelihood of detecting genuine similarity between networks.
For evaluating the fit of model networks to PPI networks, we use a range of six
global and local network properties explained in Sections 1.4.2 and 1.3: clustering
coefficient, degree distribution, average shortest path, diameter, radius and GDDA.
Since a network’s clustering coefficient (CC) is a value in the [0, 1] range, for each
of the 5 random network models we take the CC average (and standard deviation)
over all 30 instances and compare it to the CC of the original input PPI network
that the model is based on. The closer the model’s value of average CC is to the
CC of its corresponding real PPI network, the better that random model captures
the CC of the real PPI network. We compare degree distribution between each of
the 30 model network instances and their corresponding original PPI network by
scaling and normalising the area under the probability distributions (so that they
are easily comparable) and then taking the average and standard deviation of the 30
resulting similarity values. Since diameter and radiality measures, d and r, can vary
greatly from network to network, we summarise them into a single value as e = d2r
which is in the [0, 1] range. Again, the closer the average e value, e¯, of the 30 model
instances is to the e value of its corresponding PPI network, the better that model
fits the original PPI network. Also, recall that graphlet degree distribution (GDD)
agreement (GDDA, described in Section 1.4.2 Graphlets and graphlet-based heuristics
on page 27) is a network comparison measure which captures 73 network similarity
constraints. It generalises the notion of a degree distribution, which measures the
number of nodes touching k edges, into 73 distributions measuring the number
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of nodes touching k graphlets. In fact, the degree distribution is the first in the
spectrum of 73 GDDs. Other properties captured by GDD include multi-edge paths,
bi-partite sub-structures, triangles, squares, etc. GDDA then combines and reduces
this large space of 73 graphlet degree distributions into an agreement measure — a
number between 0 and 1, where 1 represents perfect agreement between networks.
So, in order to see which model fits the data, we measure the similarity between
the original network and each of the 150 generated model networks, which gives us
average and standard deviation values over 30 instances for each of the five random
network models. This gives us 18 (biotechnology-specific PPI networks)×15 (1 full
network + 14 functional sub-networks) ×6 (network properties) ×5 (random network
models) ×30 (instances of each model) = 243 000 similarity comparisons. Since
all six comparison measures give consistent results, we present only the results of
Graphlet Degree Distribution Agreement (GDDA) similarity measure since GDDA
is the most stringent and robust out of these measures and also encompasses other
network similarity measures as explained above.
2.2.3 Running time and required computational resources of
the modelling approach
Given that model network instances are created based on the size and edge density
of the original input PPI networks, the large scale of the modelling approach that we
undertake here requires a lot of computing resources. This is primarily due to two
major bottlenecks in the analysis pipeline: 1) generating a large number of random
network models which correspond to input network data, and 2) computing graphlet
frequencies on those network for the purpose of GDDA network comparison.
The computational time required to generate a single random network model
instance for one input network varies across the 5 used network models. The
computational complexity of the used C++ implementations is as follows:
• ER ∼ O(e(1 + ln( n2
n2−e))),
203 where n is the number of nodes and e the number
of edges.
• ER-DD ∼ O(Cn2), where C is a constant representing the number of repetitions
until the algorithm converges to a stable structure, and we set it to the default
value of 1 000.204
• GEO ∼ O(12n2).199
• SF ∼ O(ne).148,204
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• STICKY ∼ O(n2)149
The platform on which we ran the experiments had 128GB of RAM memory, 64×
2 600MHz AMD Opteron 6282 SE processors, and Ubuntu 12 (Linux kernel 3.13.0-36)
operating system. For each of our 270 original input networks, the time needed to
generate one model instance on one processor (since the used model generators have
single-threaded implementation) varied from a couple of seconds to over 20 hours,
depending on the size and density of the input network. Recall that we need to
generate 40 500 model instances for our experiments, and then compute graphlet
frequencies on all 40 500 networks for the purposes of GDDA comparison. The
running time needed for computing graphlet frequencies on our set of networks ranged
from a couple of hours to a couple of weeks, again depending on the network size and
density. This modelling approach would require hundreds of years of computing time
to complete on a single processor, so to make this study feasible we implement a job
scheduling and distribution service specifically for this purpose, which encapsulates
into an automated pipeline the three steps of our modelling approach: generating
random network models, counting graphlets, and comparing network using all 6
similarity measures explained above. We implemented it using the multiprocessing
package in Python in order to maximise the number of computations that can be
performed in parallel, and ran our experiments across 6 identical platforms with the
above CPU, RAM and operating system specifications, which gave us a total of 384
processors and 768GB RAM. The computations took approximately 6 months to
complete.
2.2.4 Testing the robustness of the modelling approach
We test the robustness of the approach for random networks applied to functional
sub-modules by swapping a percentage of IDs of nodes (10%, 20%, . . . , 100%) and
computing the GDD agreement with all five random models. We create 50 sub-
network instances for each of the 10 rewiring steps (e.g. 50 sub-network instances
with 10% of nodes IDs are swapped in the original network, 50 sub-network instances
with 20% of node IDs swapped in the original network, etc.); and for each rewired
instance we compute 30 model instances of each of the five random network models.
As this produces an extremely large number of networks — 270 input networks ×10
(rewiring steps from 10% to 100% in 10% increments) ×50 (instances of a rewiring)
×5 (random network models) ×30 (model instances) = 18 900 000 networks — and
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is computationally unfeasible to compute in a reasonable amount of time (we would
need to generate almost 20 million random network models, compute graphlet and
orbit counts for each of them, and then finally compute the GDDA score), thus we
focused on three largest and most representative networks instead of all 18: affinity
capture/mass spec, yeast two hybrid, and the full BioGRID network. The results
are consistent across the three data sets.
2.2.5 Network alignment
We have seen in Section 1.5.2 that network alignment is used as a network compar-
ison approach, just like topological network comparison is. Analogous to sequence
alignment, network alignment can be local and global, and there is wide range
of available algorithms.132–135,137–140,205–208 The topological quality of alignment is
usually measured by edge correctness, which is the percentage of edges of the smaller
network that are correctly aligned to edges of the larger network.135,137 Here, we use
network alignment to compare the interactomes of human, yeast and other commonly
used model organisms.
Since we are studying the interactome in terms of its topological features, we are
interested in performing a purely topological network alignment. To achieve this, we
use the Matching-based Integrative GRAph ALigner (MI-GRAAL).139 MI-GRAAL
was used to find a large topological regions which are identical in yeast and human
interactomes, to successfully predict functions of previously unannotated proteins,
and also to correctly reconstruct the phylogenetic relationships of different herpes
viruses based on their network topology. The high quality of the topological alignment
produced by this algorithm lies in the fact that it uses graphlets to compute the
topological similarity between all pairs of proteins across the two compared networks.
Apart from topological similarity, MI-GRAAL can integrate any number of additional
similarity measures between network nodes, such as sequence similarity, functional
similarity, and structural similarity. However, for our purposes, we limit it to purely
topological similarity.
2.2.6 Cycle coefficient as a measure of topology
The standard clustering coefficient can be interpreted as the likelihood of two nodes
being neighbours (connected by a path of length 1, i.e. an edge) given that they
share a common neighbour. We generalise this into a new cycle coefficient measure
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and use it to analyse the cycle content in PPI networks, as well as to compare it
across interactomes of yeast, human, and other species. The methodology is defined
as follows.
Definition — A cycle coefficient of order k of a node v, denoted as Ck(v), is a
fraction of all pairs of neighbours of v connected by some path of length ≤ k − 2 not
going through v. By definition, we put Ck(v) = 0 for any k, if the degree of node
v ≤ 1. Analogous to the standard average clustering coefficient of a network, the
average cycle coefficient of a network is the average of cycle coefficients of all nodes in
the network. In other words, it is the likelihood of two nodes being connected by some
path of length ≤ k − 2, given that they share a common neighbour. Equivalently,
the cycle coefficient of order k of network G, Ck(G), is the fraction of all node pairs
in the network that belong to some cycle of length ≤ k, given that they share a
common neighbour (note the importance of ≤ here and also see the example below).
Thus, C3(G) is the standard clustering coefficient of network G.
A) v B) u
Figure 2.1. Cycle coefficient computation example. A — Cycle coefficient for node
V is C(V ) = {0, 16 , 13 , . . .} (computation given in Example 1 in the main text) . B — Cycle
coefficient for node U is C(U) = {0, 0, 16 , . . .} (computation given in Example 2 in the main
text).
Example 1 — We compute C3(v), C4(v) and C5(v) of node v in the graph presen-
ted in Figure 2.1-A. Node v has 4 neighbours and therefore there are 6 possible
pairs of its neighbours. None of the neighbours of v are connected by an edge and
therefore, the standard clustering coefficient of this node is C3(v) = 06 = 0. Next, one
pair of neighbours of v is connected by a path of length 2 not passing through v and
therefore, C4(v) = 16 . To calculate C5(v), notice that there are two pairs of neighbours
of v that are connected by paths of length ≤ 3 and therefore C5(v) = 26 = 13 .
Example 2 — We compute C3(u), C4(u) and C5(u) of node u in the graph
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presented in Figure 2.1-B. Node u has 4 neighbours and therefore there are 6 possible
pairs of its neighbours. Its C3(u) = 0, C4(u) = 0 and ∀k ≥ 5 its Ck(u) = 16 . Therefore
even though node u in Figure 2.1-B is a member of many more cycles of length 5 than
node v in Figure 2.1-A, its C5(u) is less than C5(v) of node v in the Figure 2.1-A.
This is because the cycle coefficient of order k is concerned with the presence or
absence of the cycles between node pairs, not the number of cycles.
Note that the cycle coefficient is always less than 1. Also, ∀ k1 < k2, the average
cycle coefficients of network G satisfy Ck1(G) ≤ Ck2(G). In particular, the cycle
coefficient is always greater than or equal to the clustering coefficient. Since this is an
NP-hard problem and the time complexity of the algorithm3 is ∼ O((k−2)nγ) (where
γ is an exponent value between 3 and 4, and k is the order of the cycle coefficient,
Ck, being computed), we were only able to run the cycle coefficient experiments for
up to k = 10, that is, we were able to search for up to 10-cycle wiring patterns in
the PPI networks.
2.3 Results and discussion
2.3.1 Topology of yeast protein–protein interaction (PPI) data
through a random network lens
As mentioned above, we use a range of six network properties to measure the fit
between yeast PPI networks and models, and they all yield consistent results. We
find the yeast PPI networks to be best fit by GEO and STICKY random graph
models (Figure 2.2): STICKY provides the best fit for the full PPI network from
BioGRID and the acms network, it is tied with GEO to provide the best fit for ba
and y2h networks, while GEO provides the best fit for all other data including the
literature curated PPI network.125 Since acms and y2h have high coverage (81% and
60% of all proteins in BioGRID, respectively), and the literature curated data are
likely of high confidence, it may be argued that STICKY fits higher coverage while
GEO fits higher confidence data the best. However, if this is the case, it is not clear
why acw and rc — which are also of high coverage (including 49% and 36% of all
proteins in BioGRID, respectively) — are best fit by a GEO model.
3 implemented in C++ using the Library of Efficient Data types and Algorithms
(LEDA)203 for graph data structure and manipulation purposes. We thank Dr. Oleksii Kuchaiev
for help with this work.
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GEO random graph model has previously been shown to model yeast PPI net-
works well. 129,149 STICKY random graph model is based on the normalised degree
of a node and captures the fact that a pair of proteins is more likely to interact if
both proteins have high stickiness indices than if this were not the case and it has
also been shown to model PPI networks well.149 In Figure 2.2 and in all subsequent
figures containing results of random graph modelling, the plots contain points and
error bars, which correspond to the obtained averages of model-to-data fit, and
standard deviations, respectively. Testing what effect different inference models (e.g.
spoke versus matrix models), or different types of experiments (e.g. high- versus
low-throughput) have on PPI network topology is beyond the scope of this analysis.
acms acrna acw ba cof col cop pca rc y2h biogrid lc
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Figure 2.2. The fit of random graph models to yeast PPI networks. The fit of
five random graph models (ER, ER-DD, GEO, SF and STICKY) to yeast PPI networks.
The first 10 PPI networks listed on the x-axis are extracted from BioGRID according
to their evidence codes and labelled as described in Section 2.2.1 Data preprocessing on
page 39. Label biogrid denotes a network comprised of all PPIs from BioGRID. Label lc
denotes a network based on the Reguly et al. 125 literature curated set of PPIs.
Next, we look at whether any topological difference exists between the PPI
network as a whole and its sub-networks containing only one biological function, or
whether any topological difference exists between sub-networks containing different
biological functions. To this end, we extract and model functional sub-networks of
yeast PPI data (explained in Section 2.2.1 Data preprocessing on page 39). Interest-
ingly, we find that: (1) functional sub-modules tend to be organised geometrically
regardless of their biological function, while (2) communication links between them
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tend to be STICKY. The following sections describe these structural differences
between yeast’s functional sub-modules and their linkers.
2.3.2 Linked functional sub-modules of yeast PPI networks
We extract functional sub-modules from yeast PPI data based on a functional an-
notation recently used in Costanzo et al. 86 This gives us 14 categories of biological
function from which we can create functional sub-networks (see Table A.2 on page
193 for a list of functional categories). When extracted from full yeast PPI net-
works (acms, acw, rc, y2h, literature curated and BioGRID), most functional
sub-networks are best modelled either by GEO or STICKY random graph models
(Figure 2.3). However, many functional sub-networks that are neither GEO nor
STICKY are, in fact, insufficiently large to be modelled accurately (i.e. fall into the
region of instability described above, resulting in large error bars over all five random
models).
In all networks except for BioGRID, functional sub-networks A and B (i.e. cell
cycle progression/meiosis and nuclear-cytoplasmic transport) have around
50 nodes and interactions, and should be disregarded when viewing the results
since such tiny (sparse) networks cannot be modelled with confidence as previously
described (we include it for completeness). The same holds true for modules E, G,
K and L of the y2h and literature curated networks; modules E and K of the rc
network; and module K of the acw network. Still, a consistent topological structure
for functional sub-modules emerges (Figure 2.3): GEO networks provide the best fit
for all functional sub-modules in PPI networks (irrespective of biotechnology) while
STICKY is a competitor to GEO only for BioGRID data (Figure 2.3-E).
This suggests that yeast proteins which belong to functional modules within a
PPI network are organised geometrically, while the PPI network that includes all
available PPI data has both STICKY and GEO structure (Figures 2.2 and 2.3). We
confirm the robustness of this modelling approach by randomly swapping node IDs,
thus conserving all topological properties of the networks (see Section 2.2.4 Testing
the robustness of the modelling approach on page 44 for details), and find that the
results are consistent across data sets: as the node IDs get increasingly permuted, the
geometricity of the functional sub-modules drops (GEO model), while the topological
randomness increases (ER and ER-DD); this is more apparent on sub-modules that
have sufficient nodes and edges to be outside of the region of instability and be
modelled with confidence (see caption under Figure A.2 for details). In contrast, we
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Figure 2.3. The fit of random graph models to yeast PPI functional sub-
networks. We present results for four different biotechnologies, as these data sets produce
functional sub-networks dense enough to be modelled with confidence (explained above):
A — acms, B — acw, C — rc, and D — y2h. Together, these four cover over 90% of all
interactions in E — BioGRID. F — the literature curated set of PPIs125 also contains
sufficient PPI data for all 14 functional sub-networks to be induced on it. On the x-axis,
label FULL denotes the complete yeast PPI network (named in the panel’s title) and labels
A, B, C, . . . , N denote sub-networks of FULL broken down according to biological functions.
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find that proteins linking functional sub-modules contribute to STICKY topology of
the PPI network. These linker proteins may or may not be functionally annotated;
if they are, then they are not physically interacting with proteins belonging to
their functional sub-module, but with proteins belonging to other functional sub-
modules (illustrated in Figure A.1; see the discussion in Section 2.3.3 for a detailed
explanation of this). This GEO-STICKY topological duality in PPI data is easily seen
by comparing degree distributions of intra- and inter- functional proteins (Figure 2.4).
The degree distribution of all proteins within the network follows a power-law (blue
circles in Figure 2.4) which indicates the presence of hubs. If we then break all
proteins into two sets — intra- and inter- functional proteins, i.e. those that interact
with proteins of the same function (green triangles in Figure 2.4) and those that
do not (red squares in Figure 2.4), respectively — we see that intra-functional
proteins have Poisson degree distribution just as GEO networks have (confirming
that functional modules are GEO), while the degree distribution of inter-functional
linker proteins follows a power-law as does the degree distribution of the entire
PPI network. This means that the majority of cross-functional linkers are of lower
degrees, i.e. make a link between single proteins in different functional modules, but
that there exists a small number of linkers that provide high connectivity between
functional modules (illustrated in Figure A.1).
In addition, we find that linkers are almost exclusively disordered proteins —
also known as intrinsically unstructured, or naturally unfolded proteins — whose
lack of a fixed tertiary structure is said to be key to their diverse binding abilities
(binding to enzymes, signalling receptors, regulators, etc.). We do this by comparing
them against databases of known disordered proteins: MobiDB, 209 IDEAL, 210 and
DisProt.211 Also, we find linkers to be significantly4 involved in:
• signal transduction (e.g. membrane trafficking, cell surface receptors).
• regulatory processes (e.g. biosynthesis, metabolism, transcriptional control).
• transport (e.g. trans-membrane, vesicle-mediated).
• organisation of membrane, chromatin, chromosomes, cytoskeleton, actin, macro-
molecular complex subunits, vesicles, mitochondrion, spindle, peroxisome and
nuclear pores.
• modification of chromatin, histones and small proteins.
Interestingly, the disordered nature and, consequently, biochemical properties of
4 p-value ≤ 0.05; all p-values were adjusted using Benjamini-Hochberg multiple-hypothesis
testing procedure
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linkers are ideal for exactly these types of biological functions — i.e. for mediat-
ing molecular interactions, for quickly initialising the signalling process, and for
orchestrating regulatory and organisational events.
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Figure 2.4. Degree distributions of intra- and inter- functional proteins. A
log-log scale shows three degree distributions: — all proteins in a network, — proteins
in functional sub-networks (intra-functional), and — linker proteins (inter-functional).
Left panel — degree distributions for the full BioGRID network. Right panel — degree
distributions for interaction data from affinity-capture coupled with mass spectrometry.
We show only two data sets here, but we verified that all PPI screening biotechnologies
(listed in Data preprocessing on page 39) yield the same degree distribution patterns..
2.3.3 PPI network topology is independent of interaction-
detection biotechnology
We showed above that the topology of functional sub-modules of PPI networks is
geometric and that communication between them is done by disordered signalling,
regulatory, or organisational proteins of relatively low connectivity. We found this
GEO-STICKY duality to be present regardless of the biotechnology used for detecting
PPIs. Surprisingly, we observe the same GEO-STICKY duality across all screening
biotechnologies. In other words, the topology of the interactome seems not to be
biotechnology-dependent.
Since the human PPI network is the second most studied, we check if similar
results hold for it as well. Indeed, we find that the human interactome largely agrees
with the above findings for yeast. However, the human PPI network seems to be
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“more sticky” than the yeast PPI network (see Section A.4 Modelling the human
interactome on page 197 for details). Additionally, we find the linkers in the human
PPI network to be enriched5 in proteins from the Rab protein family, in particu-
lar, those involved in regulation of Rab GTPase activity and regulation of
Rab protein signal transduction. Interestingly, the Rab protein family is an
umbrella term for all the GO terms that we found in yeast’s linkers. It is a mem-
ber of the Ras protein superfamily which consists of G-proteins functioning as an
“on/off” switch for cellular processes. Ras is activated by G-protein coupled receptors
(GPCRs) and regulates cell behaviour by signal transduction and is also involved in
cytoskeletal dynamics and morphology, as well as membrane trafficking. We speculate
that the reason we find linkers to be currently isolated from intra-functional proteins
could be the hydrophobic nature of GPCR proteins, which reduces the ability of
high-throughput screening to detect protein interactors of GPCRs (for more details
see Section 1.1).
2.3.4 The yeast interactome is gaining structure
The advances and benefits of molecular interaction data collection can be seen if
we look at the evolution of available yeast PPI data over the last 30 years (the
first publicly available yeast protein–protein interactions date back to 1982 46). We
embed yeast PPI data from BioGRID into 3D space using the deterministic multi-
dimensional scaling (MDS) algorithm.212–214 MDS is considered a standard approach
when embedding PPI networks and was previously shown to preserve well the rela-
tions between proteins in PPI networks, to help reduce the noise and boost interaction
prediction performance, and to produce better data dimensionality reduction while re-
vealing complex, non-linear patterns in the data compared to other approaches215–217
We perform embedding in this way for each year in the 1982–2014 time span. For
each year, we take into account only those interactions that were available at that
time (i.e. historical interaction data screened up to and including that year). This
gives us 33 embeddings of the yeast interactome which show the growth of PPI
data. Figure 2.5 shows how the yeast interactome is becoming more structured: the
growth in acquisition of PPI data is observable soon after its genome was sequenced
in 1996 and from there, as more data becomes available, the interactome — that
is, its 3D-embedded spatial representation (panels in Figure 2.5 were obtained by
5 p-value ≤ 0.05; all p-values were adjusted using Benjamini-Hochberg multiple-hypothesis
testing procedure
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3-dimensional embedding of the yeast interactome as explained above) — begins to
take on a form which is rather distinct and quite different to what could be expected
for a random a network of the same size and density (see Section A.2 on page 196 for
details). In Figure 2.5 we see that about 10 years ago groups of proteins started to
cluster together and separate from other protein clusters in this spatial representation
of the yeast interactome. Given clean data and a fully complete protein–protein inter-
action map, one would expect those clusters to be distinct functional compartments,
but functional enrichment analysis suggests otherwise: a large portion of proteins in
each cluster is indeed annotated by a single function, while surprisingly each cluster
also contains a small percentage of a few other functions. Perhaps these represent
primary biological functions interlaced with functional redundancy mechanisms, but
whether this is true remains to be seen.
201420082005
1995 1996 2002 2003 2004
Figure 2.5. The structure of the yeast PPI network over the past three dec-
ades. Each panel shows a historical snapshot of available yeast PPI data embedded
in 3-dimensional space using the multi-dimensional scaling (MDS) algorithm.212 Points
represent individual proteins and they are coloured based on their functional annotation
as in Figure 4.4.
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2.3.5 Topologically consistent growth of the human inter-
actome
After looking at the evolution of the yeast interaction data in the previous section,
next we focus on human PPI data made available over the last 10 years through
yeast two-hybrid high-throughput interaction detection technology. The first high-
throughput human PPI network data started appearing shortly after the publication
of the first reference sequence of the human genome, over a decade ago. We take three
major snapshots of the PPI data from 2005, 2011, and 2013 (see Data preprocessing
on page 39). We find that, from 2005 to 2013, the average number of neighbours
increased and both the average path length and the diameter decreased, suggesting
that the human PPI network is becoming more compact and less sparse (Table A.3).
Also, the degree distributions of HI-2005, HI-2011 and HI-2013 roughly follow a
power-law (Figure 2.6), possibly meaning that yeast two-hybrid screening of human
protein interactions has been progressing in a consistent manner. A non-quantitative
change in the degree distribution (e.g. a shift away from the power-law distribution to,
say, a random distribution) would indicate a major change in the global topological
properties of the human PPI network. As this is not the case, and the distributions
differ only in the number of proteins having a certain degree, this suggests that
new screening experiments are adding proteins and interactions to the human PPI
network in a topologically consistent way.
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Figure 2.6. Degree distributions for HI-2005, HI-2011 and HI-2013. The plot is
shown on a log-log scale. Values on the x-axis are node degrees and values on the y-axis
are the corresponding numbers of nodes with those degrees.
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2.3.6 New proteins as mediators in the human interactome
The HI-2013 data set has 2 525 newly added proteins compared to the previous
HI-2011 interactome version; (note that 460 proteins from HI-2011 are absent from
HI-2013). The degree distribution of the 2 525 newly added proteins again follows a
power-law, with 1 233 of them being linked to only one other protein in HI-2013, 473
of them being linked to two other proteins, 235 to three, etc., but there are 16 new
proteins with over 70 interacting partners in HI-2013 (four of which have over 200
interacting partners, and one of them has 313 interacting partners – KRT40 is the
most connected protein of HI-2013).
We ask what the impact of the addition of these 2 525 proteins on HI-2013 network
topology is and what are the topological patterns in which new proteins get wired
into the human PPI network. To answer this, we analyse HI-2013 using graphlets:
in Figure 2.7 (left panel) we colour red all orbits i such that when we count all
proteins in HI-2013 with non-empty ith orbit, we find that the newly added proteins
contribute over 50% to these counts.
2-node
graphlet
4-node graphlets3-node graphlets
5-node graphlets
G0 G1 G2 G3 G4 G5 G6 G7 G8
0
1
2
3
4
5 6
7
8
10
11
9
13
12
14
G9 G10 G11 G12 G13 G14 G15 G16 G17 G18 G19
G20 G21 G22 G23 G24 G25 G26 G27 G28 G29
15
16
17
18
20
21
19
22
23
25
26
24
29
30
28
27
34 36
37
38
35 39
42
40
41
43
44
46
48
47
45
50
49
52
53
51 54
55
57
58
56 59
61
60
63
64
62
65
67
66
68
69
70
71
72
32
33
31
2-node
graphlet
4-node graphlets3-node graphlets
5-node graphlets
G0 G1 G2 G3 G4 G5 G6 G7 G8
0
1
2
3
4
5 6
7
8
10
11
9
13
12
14
G9 G10 G11 G12 G13 G14 G15 G16 G17 G18 G19
G20 G21 G22 G23 G24 G25 G26 G27 G28 G29
15
16
17
18
20
21
19
22
23
25
26
24
29
30
28
27
34 36
37
38
35 39
42
40
41
43
44
46
48
47
45
50
49
52
53
51 54
55
57
58
56 59
61
60
63
64
62
65
67
66
68
69
70
71
72
32
33
31
Figure 2.7. The wiring of new proteins into the interactome. Left panel —
Orbits coloured red are the most frequent ones in the newly added proteins (i.e. in the 2 525
proteins that exist in HI-2013, but not in HI-2011). Right panel — Presence of specific
topological wirings (i.e. graphlets) in the full HI-2013 network. Circled graphlets are those
for which a large portion of their counts in HI-2013 come from proteins added to HI-2013.
To gain further insight into the wiring patterns (i.e. topology) of HI-2013 caused
by added proteins, we analyse graphlet counts (note, the higher the number of
occurrences of a graphlet, the more prominent that wiring pattern within the network)
and find several surprisingly specific topological wirings in HI-2013 caused by the 2 525
newly added proteins (Figure 2.7, right panel). We look for graphlets such that over
50% of their counts in HI-2013 come from at least one of the newly added proteins:
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in Figure 2.7 (right panel), if 50%–59% of graphlet Gi counts (i ∈ {0, 1, . . . , 29}) in
HI-2013 include at least one newly added protein, we circle graphlet Gi in blue; if
60%–69% of graphlet Gi counts in HI-2013 include at least one newly added protein,
we circle graphlet Gi in green; if over 70% of graphlet Gi counts in HI-2013 include at
least one newly added protein, we circle that graphlet in orange; finally, graphlet G22
is circled in red since 94% of its counts in HI-2013 include at least one newly added
protein. What does this mean? For instance, graphlet G22 is present 2 454 886 times
in HI-2013 and 2 302 331 of these counts include newly added proteins. This means
that the newly added proteins are responsible for 94% of HI-2013 wiring patterns
described by graphlet G22, and being able to visualise the change in wiring in this
way (i.e. by observing graphlet G22 and other prominent graphlets) facilitates the
analysis of these newly introduced topological features.
Next, in order to distinguish the precise topological position of newly added
proteins within the interactome, we look whether newly added proteins tend to touch
G22 at orbit 54 or orbit 55. This will tell us the exact orbit within graphlet G22
which describes how the new proteins interact with the rest of the network. We find
that about 94% of orbit 55 counts in HI-2013 come from the newly added proteins,
while about 58% of orbit 54 counts come from them. Hence, one of the topological
patterns by which newly added proteins got wired into HI-2013 is described by
orbit 55, indicating that the new proteins tend to link to existing proteins in the
interactome that were not interacting between themselves. Similarly, we look at
orbits of graphlet G24 and find that about 78% of orbit 61 counts in HI-2013 come
from the newly added proteins, about 64% of orbit 60 counts come from the new
proteins, and about 48% of orbit 59 counts come from the new proteins — again,
this indicates that the newly added proteins are more likely to get linked to existing
proteins that do not interact between themselves. We conclude the same when we
analyse orbits of G14. In G11, new proteins contributed 73% to the count of orbit 23
and 53% to the count of orbit 22, again confirming the above conclusion. The same
can be concluded from similar analyses of orbits of the remaining circled graphlets.
2.3.7 The human interactome is getting more complete
We have seen how newly added proteins and interactions tend to get wired into the
human PPI network. Now, we look at the topology of the entire interactome and
how it evolves as more PPI data becomes available. For each of the three human
PPI networks (HI-2005, HI-2011 and HI-2013), we generate random network models
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of their size to see which one best fits the data (see Section 2.2.2 Fitting random
network models to network data on page 41).
We see that the best fitting network model for the human interactome is the
stickiness-index based model (STICKY), followed by the geometric model (GEO).
This is consistent across all three instances of the human interactome data (Figure A.6,
left panel). However, we find that the relative rise in the fit of GEO over time (HI-
2005 → HI-2013) is 6.31% and the relative drop in the fit of ER is 2.16%, pointing
to the fact that the human interactome is getting more complete. This is because
geometric graphs have already been shown to model well higher-confidence and more
complete PPI data (Sections 2.3.1 and A.4).129,131,218 We confirm the consistency of
this result on several other model organisms (further details in Section A.5).
2.3.8 Biologically consistent growth of the human interactome
We perform a topological network alignment (see Section 2.2.5 Network alignment
on page 45) of the three human PPI networks with PPI networks of plant, worm,
yeast and fly. Since we are interested in the similarity in wiring between the human
PPI network and PPI networks of model organisms, we use a network alignment
algorithm that would align interactomes based purely on topology. Hence, we use
MI-GRAAL139 restricted to using only topological similarities to find similar nodes to
align. The results show that as the human interactome is getting more complete over
time, the correctly aligned network region with yeast and worm increase, while with
the plant and fly decrease (Figure 2.8 and Table 2.1). The aligned sub-network of HI-
2005 and YI-2 contains 783 proteins and 644 interactions with the largest connected
component (LCC) in the alignment containing 318 proteins and 318 interactions (so
it has only one cycle); the alignment of HI-2011 and YI-2 has 1 014 proteins and
866 interactions with its LCC containing 514 proteins and 514 interactions (again,
almost a tree, i.e. it contains only one cycle); and the alignment of HI-2013 and YI-2
has 1 306 proteins and 1 152 interactions with its LCC containing 844 proteins and
845 interactions (again, almost a tree, with only two cycles).
We examine the biological function of yeast–human alignments by computing the
enrichment of Gene Ontology (GO) terms in each of the three human–yeast aligned
sets of proteins and find that the enriched biological process (BP) and molecular
function (MF) terms include regulation of transcription, DNA repair, cell
cycle and apoptosis as some of the top statistically significantly enriched GO
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Figure 2.8. Alignment between human and non-human PPI networks. The
y-axis shows the percentage of aligned interactions (edges) between PPI networks (numbers
of correctly aligned interactions are given in Table 2.1).
terms6. Also, we compute GO term overlap for each human–yeast aligned protein
pair in each of the three alignments. Shared GO terms between a pair of inter-species
aligned proteins are indicative of their similar biological functions, therefore providing
a link between topological analysis and biological function. We find that in each of
the three human–yeast alignments, over 40% of aligned proteins have at least one
GO term in common (42.83% in HI-2005–yeast alignment, 44.77% in HI-2011–yeast
alignment, and 40.59% in HI-2013–yeast alignment). This indicates that, since the
alignments are obtained purely from the topology of the interactomes and since
biological function is conserved (through both enriched and shared GO terms in
the inter-species alignments), the human interactome has been growing so that its
topology is reflective of biological function. We did not analyse the alignment of the
human interactome with those of other model organisms because their interactomes
are less complete and contain more noise than interactomes of yeast and human.
2.3.9 There are no large cycles in PPI networks
To examine the change of cycle content in the human interactome over time, as well
as to compare the cycle content of human interactome and the interactomes of other
organisms, we generalise the clustering coefficient, which corresponds to triangles
(3-node cycles), to analogous coefficients that correspond to larger cycles (4-node,
5-node, 6-node cycles etc.; methodology described in Section 2.2.6 Cycle coefficient
6 p-value ≤ 0.01, all p-values were adjusted using Benjamini-Hochberg multiple hypothesis
testing procedure
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Table 2.1. Alignment between human and model organisms’ PPI networks.
Edge correctness values are given as percentages with respect to the perfect alignment of
all edges of the smaller network to the edges of the bigger network. In brackets are the
numbers of correctly aligned edges, meaning that if protein A in network 1 is aligned to
protein A’ in network 2 and protein B in network 1 is aligned to protein B’ in network 2,
then if AB is an edge in network 1, A’B’ is an edge in network 2.
A. thaliana AI-1 C. elegans WI-2 S. cerevisiae YI-2 D. melanogaster FI-2
HI-2005 29.18% (744) 24.16% (616) 25.26% (644) 38.87% (991)
HI-2011 24.79% (922) 20.60% (766) 32.01% (866) 35.55% (1 322)
HI-2013 23.53% (1 301) 35.30% (1 141) 42.59% (1 152) 18.02% (2 420)
as a measure of topology on page 45). The results are presented in Figure 2.9 (left
panel): while HI-2005 and HI-2011 had similar content of cycles, HI-2013 has many
more cycles; also, for all versions of the human interactome, there are practically no
cycles with more than 7 proteins; similar holds for PPI networks of model organisms.
This indicates that the interactomes are tightly wired in the way that forbids large
cycles. We also compare cycle coefficients of the human interactome with those
of model networks and find that the all three versions of the human interactome
are much closer to STICKY and GEO than to ER graphs with respect to cycle
coefficients (Figure 2.9, right panel). Examining causes and implications of this is a
subject of further research.
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Figure 2.9. Cycle coefficient for PPI networks. Left panel — Cycle coefficients for
PPI networks of human and model organisms. Numbers on the horizontal axis correspond
to cycle size, i.e. 3 stands for the cycle coefficient for 3-node cycles, C3 (this is the clustering
coefficient), 4 for the cycle coefficient for 4-node cycles etc. The vertical axis gives the
value of the ith cycle coefficient of a network, for i ∈ {3, 4, 5, . . . , 10}. Right panel — Cycle
coefficients for HI-2013 and model networks.
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2.4 Concluding remarks
In this chapter, we analysed the yeast and human PPI networks using random graph
models with the same number of nodes and edges as the data. We applied the
five network models for modelling biological networks to study in depth the yeast
S. cerevisiae and human PPI networks. This modelling approach shows that different
interaction screening biotechnologies produce consistent interactome topology, i.e.
that the topology of PPI networks is independent of the biotechnology that produces
them. Furthermore, it shows that functional modules contribute to the geometricity
of the topology while at the same time proteins which link those functional modules
contribute to the stickieness of the topology, creating a topological duality in the
interactome.
These proteins which link multiple network disease-modules are considered to be
effective drug-targets since, beside being independently regulated from the proteins
belonging to a single module they are mostly non-hub nodes, and targeting non-hub
nodes can be a desirable feature in mitigating unwanted side-effects of drug ther-
apy.219 Even more generally, nodes which link network modules of any kind provide
cross-talk between signalling pathways which is an especially attractive property of
putative drug targets. Hence, topological properties of functional sub-networks in
yeast and human interactomes are shown to be quite similar and linked with proteins
whose function is preserved between yeast and human, and whose further exploration
as effective drug-targets with controllable side-effects could potentially yield novel
insight for pharmaceutical drug development.
By performing a network analysis of the human PPI network made available over
the past decade to study the its topological evolution, we found that the human
PPI network is becoming more compact and less sparse. It is interesting that while
mostly the same proteins were hubs in HI-2005 and HI-2011, that is not the case
in HI-2013, where other proteins took over the role of hubs — mainly keratin-type
proteins. Note that some proteins that were hubs in HI-2011 lost edges in HI-2013.
This may be due to the fact that HI-2011 has 460 proteins that HI-2013 does not
have. So perhaps a union of HI-2011 and HI-2013 would provide a more complete
version of the interactome.
We found a topological pattern of the interactome growth process: the newly
screened proteins and interactions tend to link existing proteins in the interactome
that were not interacting between themselves; and these newly added topological
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features are contributing to the more complete topology of the interactome. For
instance, we find that the human interactome is losing the random, Erdös-Rényi-like
structure, while at the same time gaining a more geometric (GEO) structure, which
is characteristic to well-studied and more complete interactomes, such as that of
baker’s yeast. Also, by aligning the human interactome to the interactomes of
model organisms, we saw an increasing functional and topological overlap with the
yeast’s interactome, and a divergence from the plant’s interactome. Furthermore, we
introduce a new network measure, the cycle coefficient, which points to the fact that
wiring of PPI networks is not rich in large cyclic chains of protein interactions.
We conclude that the yeast and human interactomes are evolving in principled,
non-random ways. The search for mechanisms driving its data acquisition is far from
complete, however, as more data becomes available we are beginning to gain insights
into global trends which govern the growth of the protein interactome space.
In the next chapter, we complement this macro-scale analysis of the interactomes
with a micro-scale analysis, examining the hypothesis that it is the specifics of the
wiring between proteins in the PPI network that is causal to diseases.
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The core of molecular interaction
networks and complex diseases
We have seen in Chapter 2 that the structure of the human PPI network is far
from random and contains distinct wiring around specific proteins which is suit-
able for effective drug targeting; and previous studies have demonstrated that the
same wiring patterns in the network underlie the same biological processes and
diseases.12,57,59–61,119,120,142,220 Here, we ask if there exists a sub-network of the human
PPI network such that its topology is the key to disease formation and hence should
be the primary object of therapeutic intervention. We demonstrate that such a
sub-network exists and can be obtained purely computationally. In particular, by
successively pruning the entire human PPI network, we are left with a core sub-
network that is not only topologically and functionally homogeneous, but is also
enriched in disease genes, drug targets, and it contains genes that are known to drive
disease formation. We call this sub-network the core diseasome and show that its
topology is unique in the human PPI network, suggesting that it may be the wiring
of this network that governs the mutagenesis that leads to disease (Sections 3.3.1
to 3.3.5).
Motivated by the structural and functional consistency in the growth of the
human interactome from Chapter 2, in Section 3.3.6 we search for a conserved part of
the interactome. We identify a sub-region of the core structure which has remained
topologically unchanged since the first high-throughput proteome-scale human in-
teractome map, and find that it is involved in biological processes related to the
cell’s development and progression, as well as disease formation. In Section 3.3.7 we
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briefly demonstrate the effectiveness of the computational core-approach in different
biological contexts, namely to try and get insight into the core of specific complex
diseases such as cardiovascular disease, breast carcinoma, and neuro-degenerative
traits originating in the cell’s signalling machinery: even though these diseases are
major global causes of death, many of their causal genes still await discovery.
3.1 Motivation and previous studies
The systematic study of diseases through molecular interaction network data is a
decade-long, still ongoing, scientific effort. The topological patterns of these networks
have made possible the differentiation between essential and non-essential proteins,
helped in predicting and subsequently validating novel melanogenesis pathways and
brought forward the identification of key therapeutic targets for numerous cancers
and hereditary diseases (see Sections 1.2 to 1.4 for an in-depth survey of related
studies). Here, we examine the hypothesis that it is the specifics of the wiring
between proteins in the human PPI network that is causal to diseases. A method is
designed that identifies the core sub-network of the PPI network in which genes, i.e.
their protein products (we use terms gene and protein interchangeably except when
specifically referring to genetic interaction) involved in a multitude of diseases reside.
The idea is that if a sub-network that is simultaneously causal to many diseases
exists, then we may be able to exploit this compactness and concentration of disease
genes for therapeutic intervention and link previously seemingly unrelated diseases.
Indeed, not only do we computationally identify this core diseasome sub-network,
but also show that its way of interconnectedness is unique in the PPI network and
different from that of the rest of the network.
This is the first study that purely from the topology of the human PPI network
identifies a topologically and functionally compact and homogeneous sub-network
that may drive disease formation and be a key to therapeutics. Specifically, without
any a priori knowledge of the involvement of genes in diseases, by using k-core
decomposition (described in Section 3.2.2 below) and applying it to the PPI network
of Homo sapiens, we effectively captured the genes present in the above described
core diseasome network. In addition, the proteins in the core diseasome network are
statistically significantly similar in their wiring in the PPI network, demonstrating a
link between network topology and involvement in disease. Furthermore, when we
searched for sub-networks with the wiring (i.e. topology) similar to that of the core
64
3.1 Motivation and previous studies
diseasome sub-network, we found that all similar sub-networks agree with the core
diseasome in less than 11% of edges; hence, the topology of the core diseasome is
truly unique in the PPI network. Also, this network has a very high concentration
and a statistically significantly enrichment of apoptosis and cell death genes, as well
as drug targets and genes involved in genetic interactions. It also contains genes that
are believed to be drivers of disease formation.
Two other studies used the k-shell decomposition of PPI data221,222, but from a
different perspective and with different goals. In particular, Wuchty and Almaas221
study the protein interaction network of Saccharomyces cerevisiae and focus on the
property of a protein to be essential and evolutionarily conserved at the same time;
they find an absence of a trend for proteins to be both nonessential and evolutionarily
conserved. They further observe that such proteins participate in a substantial
number of protein complexes and search for proteins which are simultaneously lethal
and orthologous. The other study, by Wachi et al. 222, also focuses on the PPI
network of baker’s yeast and concludes that the genes important for human cancer
cells share topological characteristics of essential genes in yeast. The focus of our
study is different. First, we build upon the claim that direct neighbourhood alone
is not a sufficient criterion to characterise a protein’s position in the network and
that the extended local neighbourhood of a protein is to be considered to examine
or predict a protein’s function. We address this by applying graphlets. Second, we
focus specifically on the human PPI network, and use data sets that are up to date
and much more complete than those used in older studies. Also, we account for
the presence of noise in the PPI data (Section 3.2.1 Data). Furthermore, the above
mentioned studies that use k-shell decomposition do not investigate the druggability
of the obtained network sub-structure, the presence of driver genes, genetic mutations,
or incorporate the similarity in the wiring of extended neighbourhood of every node
in a PPI network, while our study does. Also, we do not focus on a single disease
as do the above studies, rather, we ask the question: what is it that is common
in the PPI network wiring for a multitude of human disease proteins? Hence, the
approach in this thesis is different in that it systematically addresses many aspects
of the human PPI network sub-structure related to disease.
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3.2 Methods and data
3.2.1 Data
Protein–protein interaction data. We obtain the H. sapiens PPI network data
from BioGRID46 and HPRD45. We use the union of interactions from these two
databases to increase coverage. Also, we remove all self-interactions, as well as
all proteins that participate in fewer than four interactions. We remove these low-
connected proteins, since they may be involved in lower confidence interactions. This
is because their low connectivity may be due to the lack of experiments performed
for detecting the interactions. In this way, we remove both disease and non-disease
genes that are not well studied and hence could be involved in noisy interactions.
Genetic interaction data. We obtain the human genetic interaction data from
BioGRID. This data set is still very sparse, with under 300 interactions (data from
July 2011).
Disease–gene associations. We obtain disease–gene association data from Dis-
ease Ontology. Similar to PPI data, for disease–gene data we also filter out potentially
noisy associations: we do not consider diseases that have fewer than five genes as-
sociated with them. The reason for this is that association of genes with such
diseases may not have been fully explored yet (data from September 2011). Table 3.1
summarises the three data sets.
Table 3.1. Sizes and sources of used interaction data. The reference column
indicates the source from which the data was obtained.
Data set # of nodes # of edges Reference
Protein–protein interactions 11 100 56 708 45,46
Disease–gene associations 561 diseases / 4 004 genes 4 029 144
Genetic interactions 274 281 46
3.2.2 k-core decomposition
k-core decomposition is a process of iteratively pruning a network in search of its
sub-graph in which all nodes are of degree at least k 223,224. It works as follows:
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1. All nodes of degree one or less are removed from the network, along with all their
edges;
2. In the remaining network, all nodes of degree two or less are removed, along with
their edges;
3. This process is repeated until only nodes of degree at least k remain. The largest
k value for which k-core is not empty is called kmax, and the corresponding
sub-graph is called kmax-core.
This is illustrated in Figure 3.1. k-core decomposition has been used to analyse social
networks225, the World Wide Web and the Internet226,227, as well as to investigate
essentiality and lethality of proteins221,222. We use k-core decomposition to find a
unique sub-network within the human PPI that is thought to drive disease formation
(Sections 3.3.1 to 3.3.5), and to study how it changes as our knowledge of the
interactome topology grows (Section 3.3.6). Subsequently, we apply this principle to
gain additional insight into specific complex diseases such as cardiovascular disease,
breast carcinoma and neuro-degenerative traits (Section 3.3.7).
3-core
2-core
1-core
Figure 3.1. k-core decomposition. A three-level deep k-core decomposition of a
network. The value of kmax is 3.
Note that the obtained kmax-core of a network is not inherently biased towards
hub nodes but, rather, is a method for extracting the core of a given network. We
illustrate this through an example of a network that contains highly connected hub
nodes (say of degree 300) but on its periphery, i.e. these peripheral hubs have many
neighbours linked only to the hub node (say a hub of degree 300 has 299 of its
neighbours of degree one): such hub nodes nodes would not end up in the core (i.e.
kmax-core) of the network because the first iteration of the core-finding algorithm
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would strip away almost all of its neighbours (i.e. it would strip away the 299 degree
1 neighbours of the hub in this example) and the hub in question would be of very
low degree after the first iteration of the algorithm (i.e. it would be of degree 1 in
our example) and would itself be eliminated in the next iteration of the algorithm.
Hence, such hubs would not be in the core, even though they are of much higher
degree than the nodes that are close to the centre of the network and hence would be
in the core. This is exactly what happens to the proteins in the human PPI network
that we analysed. The core that we extract from the human PPI network contains
around 37% of the highest degree nodes, where we define the highest degree nodes
to be those that are in the top 1% of the nodes with highest degree. Furthermore,
we examine Pearson correlation between the degree of a node and its k-core index:
the resulting correlation is only 0.69 indicating that the connectivity (i.e. degree) of
a node is not strongly correlated to the node’s k-core index. This says that it is not
the hub nodes that are captured by the k-core decomposition, but the nodes which
have a specific strategic placement within the network. This is also confirmed by
Kitsak et al. 228 and Wuchty and Almaas 221 .
In addition to k-core, there exists k-shell decomposition. It is an adaptation of
the k-core algorithm and represents the sub-graph of nodes in the k-core containing
only nodes of exactly degree k, rather than nodes of degree k or more as is the case
with k-core. This allows for a layered decomposition of a network. In Chapter 4 we
use k-shell decomposition to compare the functional organisation of different types
of molecular interaction networks.
3.2.3 Extracting four sub-networks from the human PPI net-
work
Here, we explain how we transformed the PPI data described in Section 3.2.1 to
obtain the four networks which will be used in this study. The entire human PPI
network, which we will call H-ALL, contains 11 100 nodes and 56 708 edges, after
removing self-loops and filtering noise as described above. First, we find the sub-
network of H-ALL that contains topologically similar disease proteins: we test for
topological similarity of all pairs of disease proteins using graphlet degree vectors
(GDVs) (described in Section 1.4.2 Graphlets and graphlet-based heuristics on page
27) using a statistically significant threshold (p-value ≤ 0.01). A similarity value is
attributed to a statistical significance cutoff in the following way. We place pairs of
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proteins into bins of similarity ranging from 0% to 100%. Once we have the number
of protein pairs in each of the similarity bins, we apply a statistical hypergeometric
model to find what is the random chance of each bin containing at least the number
of protein pairs that it does contain. By doing this, we assign a p-value to each
similarity bin. Hence, the p-value of 0.01 corresponds to proteins that, in this case,
have wirings around them which are at least 87% similar. We form an induced
sub-graph of H-ALL on these statistically significantly similar disease proteins and
call that sub-graph H-SIM. This gives us a much smaller PPI network of 8 655
interactions amongst 1 706 nodes. We form this network searching for a relationship
between network topology of disease proteins and the role of topology in linking
seemingly different diseases. An induced sub-graph of H-ALL with nodes that are
not in H-SIM is called REST. It is clear that REST is free of any disease proteins
that are statistically significantly topologically similar with respect to GDV. Note
that REST still contains many disease proteins, but not those with similar wiring
around them. However, we show in Section 3.3.3 below that REST does not enrich
the same Gene Ontology (GO) terms as H-SIM, hence strengthening the hypothesis
that not all disease proteins are equal.
To further refine our H-SIM network in search of the key network topology that
would explain the source and cause of many different diseases, we find the k-core
decomposition (described in Section 3.2.2) of H-SIM; it contains exactly 100 proteins.
Our hypothesis is that by taking all disease proteins with highly similar topology
around them (H-SIM) and looking at the core, should give insight into a “central”
structure specific to disease, quite possibly the one that is driving the formation
of disease. After finding the core proteins, we then ask if we could have obtained
these 100 proteins directly from the topology of the entire PPI network, without
any a priori knowledge about disease proteins or their topological similarity. Indeed,
we find that when we perform the k-core decomposition of H-ALL, we obtain 105
proteins amongst which 88 overlap with the 100 proteins from k-core decomposition
of H-SIM; we call the PPI network induced on these 88 proteins CORE. Note that
CORE is not biased towards hub nodes, i.e. nodes of high degree, as explained in
Section 3.2.2.
Table 3.2 summarises the basic statistics of H-ALL, H-SIM, REST and the CORE
networks. The three sub-networks were extracted from H-ALL, and the statistics
were computed on those extracted sub-networks rather than on the networks as
part of H-ALL. For example, this table shows that the CORE network has the most
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compact topology (the smallest e¯); note that e¯ of CORE is computed on CORE
network itself and not on CORE as a part of H-ALL. Hence, low e¯ is not an artefact
of the construction process of this network, but it is a property of CORE itself. The
highest possible value of e¯ is 2, as d = 2 × r, and thus, REST has this maximum
(and H-ALL and H-SIM almost achieve it), which implies that it is as far “stretched”
as it possibly can be. So, even with these simple statistics, we see a difference in
structural organisation between CORE and all other networks: CORE has the largest
clustering coefficient and average degree, and the smallest diameter, radius, e¯, and
average path length of all four networks. This means that it is compact and densely
clustered, while the other three networks are not: they are rather uniform in the
values of the measured network properties and are far spread and low clustered.
Table 3.2. Basic network properties for our four networks.
H-ALL CORE H-SIM REST
number of nodes 11 100 88 1 706 8 227
number of edges 56 807 865 8 655 24 730
clustering coefficient 0.125 0.462 0.173 0.102
diameter 13 3 9 16
radius 7 2 5 8
compactness, e¯ 1.85 1.5 1.8 2
average degree 10.23 19.65 10.14 4.53
average path length 3.69 1.87 3.48 4.53
3.3 Results and discussion
We analyse the entire human PPI network, H-ALL, as well as its three different
sub-networks: the first, CORE, consists of disease-annotated proteins involved in
very tightly knit interactions; the second, H-SIM, also contains only disease-related
proteins, but they are more loosely intertwined; and the third, REST, is also loosely
intertwined and contains some disease-related proteins, as well as all proteins that
are currently not known to be related to disease (see Data and Extracting four
sub-networks from the human PPI network for details on used PPI data sets).
In Section 3.3.1 we examine the topology of CORE and show that it substantially
differs from the topology of the other three sub-networks. We then show that the
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internal wiring of CORE is unique in the entire human PPI network (Section 3.3.2),
and we examine the functional annotation and pathway enrichment of CORE and
show that it also differs from those of the other three sub-networks (Section 3.3.3).
Since CORE has a distinct topology and biological function, in search of an explan-
ation for this difference, we further test it for enrichment in genetic interactions
and drug targets (Section 3.3.4). We offer a biological explanation for the observed
uniqueness of CORE with respect to its topological and functional characteristics.
3.3.1 Topological homogeneity of the core diseasome
We examine in detail the topology of the four PPI networks by using GDV similarity
described in Section 1.4.2. In particular, we compare the topology around nodes
within each of the four networks (Figure 3.2) and show that the internal wiring of
CORE differs from those of the other three networks. We also compare nodes across
networks (Figure 3.3) and highlight which networks have similar wiring and which
ones differ.
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Figure 3.2. Distributions of GDV similarities of proteins within each of the
four PPI networks. x-axis represents GDV similarities of nodes in the network in bins
of 1%. y-axis represents percentages of protein pairs that have a particular GDV similarity.
The four networks are H-ALL (black line), H-SIM (red line), CORE (green line), and
REST (dashed line).
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Figure 3.2 presents GDV similarities between all pairs of nodes within each of the
four networks. It shows that while H-ALL, H-SIM, and REST have heterogeneous
node wiring patterns (black, red, and dotted lines, respectively), that is not the
case with CORE (green line in Figure 3.2). In particular, GDV similarity of nodes
within CORE is distinctly higher that that of the other networks, starting at about
75% and peaking at about 95% GDV similarity, while in the other three networks
the distribution is fairly flat and uniform. Note that this is not expected from
the construction of these sub-networks (H-SIM is an induced sub-graph on disease
proteins with statistically significantly higher GDV similarity then expected at
random in the entire PPI network, i.e. p-value = 0.01 which corresponds to GDV
similarity of 87% — see Extracting four sub-networks from the human PPI network
on page 68), since GDV similarities are computed only within sub-graphs induced
on the nodes belonging to the sub-networks, rather than in the context of the entire
PPI network. Hence, we conclude that the topology of CORE is homogeneous in the
sense that all of its nodes have very similar wiring, while the topology of the other
three networks is not. It is particularly surprising that H-SIM has heterogeneous
node wiring, since it is constructed only on disease proteins whose GDV vectors are
statistically significantly similar in the entire PPI network. In the next two sections,
we explore the biology behind this phenomenon. Our hypothesis is that such compact
topology (in the sense of small e¯ and large clustering described in Section 3.2.3) and
homogeneous node wiring contribute to the recently proposed existence of driver
genes whose mutations trigger mutation of other genes that collectively lead to
various types of cancer phenotypes85,229–231 (details in Section 3.3.4).
Figure 3.3 also presents GDV similarities between nodes, but now across different
PPI networks. In particular, we compute GDV similarities between all pairs of nodes
across the four PPI networks, resulting in six comparisons represented by six lines in
each of the two figure panels. Both panels represent the same comparisons, the only
difference is that in panel A, GDV similarities are in bins of 1% , while in panel B
they are in bins of 10%; we do this to emphasise the trends that may be difficult
to observe from any panel alone. As expected, the figure shows differences in node
wirings of CORE and the entire PPI network, H-ALL (red line), as well as in node
wirings of CORE and REST (black line). Also, CORE and H-SIM have similar node
wirings (dark blue line), which is expected since CORE is a sub-graph of H-SIM.
The remaining three comparisons, H-ALL versus REST (green line), H-ALL versus
H-SIM (light blue line), and H-SIM versus REST (purple line), demonstrate neither
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Figure 3.3. Distributions of GDV similarities of proteins across the four PPI
networks. x-axes represent GDV similarities of nodes across the networks: A) in bins of
1%; B) in bins of 10%. y-axes represent percentages of gene pairs that have a particular
GDV similarity. The four networks are H-ALL, H-SIM, CORE and REST, and their
comparisons are: H-ALL versus REST (green line), H-ALL versus CORE (red line), H-
ALL versus H-SIM (light blue line), H-SIM versus CORE (dark blue line), H-SIM versus
REST (purple line), and CORE versus REST (black line).
similarity nor dissimilarity node wiring patters across these networks. It is surprising
that the latter two exhibit no dissimilarity, since H-SIM is constructed on the nodes
that have statistically significantly high GDV similarity; however, this is due to
GDV similarities being computed in the induced sub-graph itself rather that in it
as a part of the entire PPI network. Interestingly, neither proteins in H-SIM nor
in REST differ in wiring from the proteins in H-ALL, which is not expected since
proteins in H-SIM should differ from H-ALL as they are disease proteins with similar
network wiring; again, this is because GDV similarities are computed within H-SIM
only. These observations point to detailed structural differences across the four
networks, over and above those mentioned in Section 3.2.3. Since proteins in H-ALL
and H-SIM have no topological dissimilarities, which are expected, and since CORE
proteins are topologically similar to H-SIM and dissimilar to H-ALL, we further
examine if CORE proteins can somehow make a topological connection between the
other two sets. Indeed, this is the case (Section 3.3.5). The structure of CORE is
illustrated in Figure 3.4; as mentioned above, we hypothesise that it contains the
driver genes whose mutations lead to various types of cancer85,229–231 and henceforth
we call proteins in CORE network the core diseasome (Section 3.3.4).
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Figure 3.4. The core diseasome of H. sapiens. Known and predicted disease driver
genes are coloured red.
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3.3.2 Topological uniqueness of the core diseasome
We ask if the above described distinct topology of the core diseasome is unique in the
PPI network. Hence, we search in H-ALL for sub-networks with the structure similar
to that of CORE. To do that, we perform 4 000 alignments of CORE with H-ALL
using MI-GRAAL algorithm described in Section 2.2.5. We perform 4 000 alignments,
since by doing so we cover 97% (i.e. the entire largest connected component) of
the entire human PPI network as it matches each node in CORE with a node that
has not just a similar degree but the entire 4-level-deep neighbourhood similar to
it. Interestingly, the average edge correctness of aligning CORE to other regions
of H-ALL obtained by the 4 000 alignments is 9.47% with the standard deviation
of 0.25%, while the maximum obtained edge correctness value for this alignment is
10.52% (Figure 3.5). There is no universal edge correctness threshold for establishing
similarity between two networks. Clearly, in theory, a perfect match is 100%. How-
ever, it is unrealistic to expect such high edge correctness in alignment in complex
biological networks. Hence, as a reference point, we use a study by Kuchaiev and
Pržulj 139 which aligns two different PPI networks (human and baker’s yeast) using
the same configuration of MI-GRAAL and purely topological alignment that we use
here. In that study, the maximum achieved edge correctness between PPI networks
of yeast and human is 23.26% with an average of 19.73% and a standard deviation of
1.39%. This falls 6.62 standard deviations away from our maximal (best case) score,
making our maximal score small enough not to be considered a clone with extremely
high statistical significance. As mentioned, the MI-GRAAL algorithm, which works
by matching the topological environment of a node, includes the degree measure as
just one of 73 constraints it is based on. Therefore, it is much more stringent and
precise in detecting topological similarity than just searching for a structure with
similar or exact same degree distribution as CORE. This indicates that the topology
of the core diseasome is unique, i.e. the topological copy of CORE does not exist
anywhere else in the human PPI network.
3.3.3 Functional annotation of the core diseasome
We have seen that CORE proteins have a topology distinct from the topology of
disease proteins that are not in CORE. To examine biological properties of CORE, we
investigate their functional annotation described in Gene Ontology (GO), along with
the implicated pathway enrichments. GO consists of three main domains — cellular
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Figure 3.5. The distribution of edge correctness scores across 4 000 different
runs of MI-GRAAL network alignment algorithm applied to CORE and H-
ALL networks. The x-axis represents the 4 000 runs of MI-GRAAL, while the y-axis
represents the achieved edge correctness for each of them. We ordered the runs on x-axis
in descending order of edge correctness.
component (CC), molecular function (MF) and biological process (BP) — which
indicate where the gene product is located in the cell, what molecular functions it
performs, and in which biological processes it participates, respectively. We analyse
enrichment across all levels of GO hierarchy.
Using H-ALL as the background model and performing hypergeometric statistical
testing with Benjamini-Hochberg False Discovery Rate (FDR) correction to obtain
relevant p-values, we find that proteins in CORE are enriched in 104 MF terms, 549
BP terms and 59 CC terms. The terms that have the highest statistical signific-
ance in the MF category are all related to transcription and binding, in particular:
enzyme binding (p-value = 2.9×10−24), transcription factor binding (p-value
= 3.7× 10−22), transcription regulator activity (p-value = 2.3× 10−20), DNA
binding (p-value = 2.5 × 10−12), and promoter binding (p-value = 3.2 × 10−12).
In the BP category, terms with the highest statistical significance are mostly
related to regulation, in particular: positive regulation of macromolecule
metabolic process (p-value = 2.1× 10−32), positive regulation of cellular
biosynthetic process (p-value = 5.0×10−29), response to organic substance
(p-value = 5.6 × 10−27), regulation of cell proliferation (p-value = 2.5 ×
10−23), and positive regulation of gene expression (p-value = 3.5 × 10−23).
76
3.3 Results and discussion
A CC term with a high statistical significance is nucleus (p-value = 1.7× 10−18),
where 78% of the CORE’s genes are. All of these GO category enrichments indicate
that the core diseasome plays a critical role in transcriptional regulation. We notice
that regulation of cell death and apoptosis (GO terms GO:10941 and GO:42981,
respectively) are highly and statistically significantly enriched in H-SIM and CORE,
but not in REST (Table 3.3). Note that H-SIM contains about half of all disease
genes, so REST contains the other half of them. However, while H-SIM has about
20% enrichment in the above GO terms, REST has no enrichment in them. To
rule out the possibility of this result being a feature of higher connectedness of
proteins involved in these processes, we check for their presence in the top 1% of hub
nodes. We find that only 9 nodes (out of 185) apoptosis proteins fall in this category.
Even more, these 9 are evenly split between H-SIM and REST, so that 5 are in
H-SIM and 4 in REST. Cell death has no proteins in the top 1% of hubs. Hence
the achieved enrichment is not a feature of higher connectedness of these proteins.
Interestingly, CORE has an even higher (and statistically significant) enrichment
in these GO terms of about 30%. This indicates that the core diseasome subset of
H-SIM may capture genes causal to diseases for which we generally have no effective
cure, including cancer, hematologic diseases, neurodegenerative diseases, progression
of viral and HIV infection. Indeed, we verify that CORE genes are enriched in the
following pathways: (a) pathways in cancer (p-value = 2.2 × 10−29); (b) acute
myeloid leukemia (p-value = 1.7× 10−10); (c) Wnt signalling pathway (p-value
= 3.0× 10−5); (d) ErbB signalling pathway (p-value = 2.5× 10−13); (e) T cell
receptor signalling pathway (p-value = 1.5× 10−6).
Table 3.3. Enrichment in regulation of cell death and apoptosis. Enrichment of
GO terms corresponding to regulation of cell death and apoptosis (GO:10941 and GO:42981,
respectively) in the four PPI networks (H-ALL, H-SIM, CORE, and REST).
regulation of cell death regulation of apoptosis
(GO:10941) (GO:42981)
H-ALL 8.9% 8.8%
H-SIM 19.9% (p-value = 8.59× 10−60) 19.8% (p-value = 1.13× 10−59)
REST no enrichment no enrichment
CORE 32.1% (p-value = 6.93× 10−10) 29.8% (p-value = 1.1× 10−8)
In addition to asserting the topological uniqueness of CORE in Section 3.3.2,
to account for the possibility of existence of other sub-networks inside the human
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PPI which are not only structurally but also functionally alike CORE we perform
statistical significance testing. Enumerating and testing for enrichment all possible
combinations of genes, including those that have a degree distribution like CORE, is
computationally infeasible as it would require an unreasonably long time (years of
processing time). For this reason the statistical significance of our obtained results
was computed using the model of hypergeometric distribution that computes the
probability of observing a given result over all possible random permutations of
proteins within the network.
To control for the percentage of disease genes in a network affecting the enrichment
of that network with disease related GO terms, we test for GO term overlaps under
different conditions. We find that the overlap in GO terms between REST and
H-SIM (when specifically compared against a same background model to rule out
any bias) is almost non-existent. Hence, we effectively achieved an almost perfect
functional separation of the disease genes using only topological difference. To test
this, we observe the overlap between enriched GO terms in two sets — H-SIM as
the first, and a set of only disease genes in REST as the second. As both these sets
contain a similar portion of all disease genes (roughly 50% each), to exclude any
biases we compare them against the same background model comprised of the entire
H-ALL network. The chosen p-value is 0.01 and the results are as follows. H-SIM
enriches 3 299 GO terms, while disease genes in REST enrich 1 186 GO terms. To
account for all overlaps and achieve the maximal possible overlap, we use GO terms
from all three classifications – cellular component (CC), biological process (BP) and
molecular function (MF). The intersection of these two GO sets is only 61 GO terms
(13 CCs, 14 MFs and 34 BPs), none of which are related to apoptosis or cell death
and they all appear to be related to fairly widespread organismal functionalities.
Hence, we conclude that it is possible to obtain a functional separation of disease
genes through pure topology.
3.3.4 Driver mutations in the core diseaseome
To further explore the functional space of the core diseasome, first we examine the
enrichment of genetic interactions in CORE and then examine druggability of proteins
participating in them. This is because it has been proposed that genetic interactions
can lead to development of new therapeutic approaches:85 as cancer genomes are
gaining momentum in unveiling key genetic principles in cancer, genetic interactions
are increasingly starting to show that a very small number of genetic changes may
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trigger disease onset. These mutations are usually called driver mutations. CORE
captures 15 of these driver genes (both known and predicted). It contains 32 genes
participating in genetic interactions. There are 21 genetic interactions amongst 22
genes in CORE (depicted as green nodes in Figure 3.6, left panel) and the remaining
10 of the 32 genes participate in genetic interactions with 59 genes (depicted as
white nodes in Figure 3.6, left panel) outside of CORE; the total number of genetic
interactions in Figure 3.6 (left panel) is 100. This enrichment of genetic interactions
in CORE is statistically significant (p-value = 1.1× 10−16).
We examine the 32 CORE genes which take part in genetic interactions in more
detail. Two of them, EP300 and CREBBP (pink nodes in Figure 3.6, left panel), are
hubs (i.e. highly connected) both in the entire human genetic interaction network and
in the entire human PPI network, with 22 and 18 interacting partners, respectively;
they are also hubs in CORE genetic interaction network presented in Figure 3.6 (left
panel). CREBBP, a nuclear-based transcription activating protein, has a critical role in
embryonic development, growth control, and homeostasis232. Its domains, KIX, TAZ1
and TAZ2, bind to a sequence present in transactivation domains of transcription
factor p53232,233. It shares high sequence similarity with the other hub gene, EP300,
which is used for effectively restraining cells’ growth and division233. Additional genes
with at least three genetic interactions in the CORE genetic interaction network
are: RELA, CTNNB1, AR, MYOD1, CEBPA, and BRCA1. The meaning of this epistasis is a
subject of future research.
Amongst the 22 genes participating in genetic interactions within CORE, there
are 11 drug targets linked to 116 distinct drugs (p-value = 8.64× 10−5). Three of
these eleven drug targets are targeted by 23 or more drugs. In particular, ESR1
is targeted by 61 different drugs, AR by 40, and NCOA2 by 23 (Figure 3.6, right
panel). The p-value of any target being hit by more than 22 drugs is 0.0017. Fur-
thermore, two known driver genes, RB1 and CTNNB1, are drug targets and are in
CORE. This may indicate that the topological compactness and homogeneity of
the core diseasome (Sections 3.3.1 and 3.2.3) and its enrichment in druggable driver
genes genetically interacting with many other genes, may facilitate discovery of new
therapeutic approaches. Further refinement of network analysis techniques along
with experimental discovery of additional driver genes could yield insights into disease
and improvements in therapeutics.
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Figure 3.6. Genetic interactions and drug targets in the core diseasome. Right
panel — Green nodes are genes in CORE, pink nodes are the two hubs (highly connected
genes), and white nodes are outside of CORE which participate in genetic interactions
with genes in CORE. Left panel — An illustration of the drug-target network of CORE.
Blue nodes are drugs and green nodes are genes.
3.3.5 Computing the core diseasome
Recall that CORE was obtained by intersecting the kmax-core decompositions of
H-ALL and H-SIM. Since H-SIM was constructed from topologically similar disease
genes, the knowledge of disease genes was used to construct CORE. Now we ask
whether we could obtain the core diseasome purely computationally and without any
knowledge of disease genes.
To do that we focus on the subset of H-ALL containing only proteins obtained
from the kmax-core decomposition of H-ALL. Hence, no knowledge of disease genes
was used to construct this subset. We call this subset ALL-CORE. ALL-CORE
contains 105 proteins, 88 of which are in CORE. When we examine the 17 proteins
of ALL-CORE that are not in CORE, we find that five of these 17 proteins are
known drug targets, each targeted by at least two drugs; thep-value of having such
enrichment of drug targets in these 17 proteins is 0.048. One of them, MAPK14, is
targeted by 50 different drugs (p-value = 0.026).
Next we examine if there is any relationship between proteins in ALL-CORE
and those in SIM-CORE, which we obtain by the kmax-core decomposition of H-SIM.
SIM-CORE has 100 proteins out of which 88 are in CORE. Interestingly, 11 of the
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12 SIM-CORE proteins that are not in CORE (i.e. all but NCK1; they are coloured
green and listed in Figure B.1) are related with the 17 proteins from ALL-CORE
that are also not in CORE (coloured blue and listed in Figure B.1): they together
cause the same disease. The list of diseases that they jointly cause is presented in
Figure B.1. Additionally, they do not have direct physical interactions between them,
but are linked via 57 proteins in 175 out of the maximum possible 204 different ways
(12× 17 = 204). 30 out of these 57 connecting proteins are in CORE.
This illustrates the topological compactness and functional relatedness of proteins
in ALL-CORE with those in CORE and SIM-CORE, suggesting that the notion of
the core diseasome could be enlarged and purely computationally obtained from the
human PPI network. That is, by simply computing the kmax-core decomposition of
the entire human PPI network, we can obtain the set of topologically and functionally
unique proteins that we term the core diseasome.
3.3.6 Topologically conserved core of the human interactome
We have seen in previous sections that by k-core decomposition of the human PPI
network a unique topological structure emerges — namely, the core sub-network
of the human interactome — which is enriched in disease genes, drug targets and
contains genes that are known to drive disease formation. Here, we examine how the
core structure changed through the three versions of the human interaction networks,
HI-2005, HI-2011, and HI-2013 (data as in Section 2.3.5).
We find that the core of the interactome gets larger and denser with time
(Table 3.4), and that a part of it remains topologically conserved (i.e. not altered
by addition of new proteins and interactions over time) across all three networks:
it consists of 20 proteins and 59 interactions (Tables 3.4 and 3.5 and Figure 3.7).
This set of 20 proteins is statistically significantly enriched with GO terms of cellu-
lar localisation, in particular, with non-membrane-bounded organelles, which are
known to govern cellular structure and morphology and include organelles such as
ribosomes, the cytoskeleton and chromosomes. The 20 proteins are also enriched in
coiled coil domains, which are usually present on transcription factors, proteins
involved in cell proliferation and growth, regulation of gene expression,
and HIV related proteins. Many of them are, indeed, involved in regulation of
transcription and cancer development (Table 3.5). For example, keratin protein
family is statistically significantly enriched in the core of HI-2013: tumor tissues have
been shown to strongly express keratines,234,235 and also solid epithelial tumors (both
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primary carcinomas and their metastases) have been shown to exclusively contain
keratin intermediate-sized filaments.236,237
- regulation of cell survival and apoptosis
- regulation of transcription 
- regulation of cytokinesis 
- cancer development
- Wnt signaling
- role in HIV
- signal transduction
- cytoskeleton organization
- regulation of gene expression
- cell growth, proliferation and diﬀerentiation
HI-2013 PPI
Topologically conserved core
HI-2005 PPI
HI-2011 PPI
Core of the Human Interactome
Figure 3.7. Topologically conserved core of the human interactome. The wiring
of the conserved core of the human interactome remains topologically unchanged as the
interactome grows.
Table 3.4. Network properties of the topological conserved core. Network prop-
erties of core sub-networks of HI-2005, HI-2011, HI-2013, and the intersection of the core
sub-networks (i.e. the conserved core sub-graph). The column labels are as follows: |N |,
number of nodes; |E|, number of edges; CC, clustering coefficient; APL, average path
length; ANN , average number of neighbours; d, diameter; and r, radius.
|N | |E| CC APL ANN d r
HI-2005-Core 62 284 0.109 2.14 9.16 4 3
HI-2011-Core 91 449 0.105 2.26 9.86 4 3
HI-2013-Core 138 1 722 0.210 1.94 24.95 3 2
Intersection 20 59 0.240 1.80 5.90 3 2
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Table 3.5. Biological function of proteins in the topologically conserved core.
The 20 listed proteins form the conserved core which has remained topologically unchanged
across the three versions of the human interactome.
Gene name Function
1 PSMA1 proteasome subunit
2 LZTS2 regulation of cytokinesis and Wnt signaling
3 MDFI regulation of transcription and Wnt signaling
4 ZNF250 potential regulator of transcription
5 TRAF2 regulation of cell survival and apoptosis
6 LNX1 signal transduction and potential role in tumorgenesis
7 CALCOCO2 cytoskeleton organization
8 PLSCR1 cell proliferation and differentiation
9 ZNF581 regulation of transcription
10 KRT15 keratin (intermediate filament) protein family (KAP)
11 KRTAP4-12 keratin (intermediate filament) protein family (KAP)
12 CCDC33 coiled-coil domain protein
13 FBF1 keratin cell polarity
14 CEP70 mitotic spindle organization
15 LDOC1 role in cancer development
16 CCDC85B repressor of transcription; cell growth
17 KIAA1267 regulation of transcription
18 NECAB2 binding partner of adenosine A2A receptor
19 USHBP1 unknown
20 C16ORF48 unknown
83
3 The core of molecular interaction networks and complex diseases
3.3.7 Application to complex diseases
In this section, we briefly explore ways to utilise the core structure of the human
PPI network to find key genes, that could potentially be targeted by drugs; the hope
is to use the properties of such important genes to predict new ones, which would in
turn improve a choice of therapy since discovery of novel therapeutic targets that
will allow patient-tailored treatment of these diseases is an emerging area of scientific
interest. The following sections are short summaries of three collaborative studies.
3.3.7.1 Breast cancer
Breast cancer accounts for more than 1 300 000 new cases and 450 000 deaths yearly
worldwide.238 As such, it is the most common female neoplasm. Heterogeneity of
breast cancer is reflected in the fact that there are at least seven distinct molecular
subtypes of the common estrogen receptor- positive disease239 and six distinct groups
of triple-negative (estrogen-, progesterone-, and HER2- receptor-negative) breast can-
cers.240 Such molecular complexity highlights the need for the discovery of novel
therapeutic targets that are oncogenic drivers which are overexpressed and/or amp-
lified in individual tumors, allowing for a precision medicine approach and patient
tailored treatment. Biologically, clinically, and functionally relevant targets in cancer
often undergo high-level DNA amplification, conferring cancer cells with survival
advantage. In solid malignancies, such as breast cancer, some specific regions in the
genome harbour amplicons such as the HER2-related amplicon on chromosome 17,241
as well as the chromosome 1 quantitative anomalies present in 50–60% of breast
tumors.242
Recently, nicastrin has been identified as a novel therapeutic target.243,244 Its
overexpression is indicative of worse overall survival in the estrogen-receptor-negative
breast cancer patient population. Guided by the example of the anti-HER2 antibody
therapy, in this study we1 investigated nicastrin gene amplification status in a large
patient cohort available on the cBio Cancer Genome Portal,246 with the notion that
detection of nicastrin gene amplification in patients’ tumors would help stratify
those who would be candidates for anti-nicastrin therapy. We analysed data from
this large invasive breast carcinoma study and confirmed nicastrin amplification.
1 This study is a result of collaborative work and was published in Sarajlić, A., Filipović, A.,
Janjić, V., Coombes, R. and Pržulj, N. The role of genes co-amplified with nicastrin in breast
invasive carcinoma. Breast Cancer Res. Treat., 143(2):393–401, 2014.245
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In search for genes that are co-amplified with nicastrin, we identified a potential
novel breast cancer related amplicon located on chromosome 1. The study showed
that it is the core diseasome that “glues together” into a cohesive network these
genes co-amplified with nicastrin (i.e. links them all into a single connected network),
and helps form a pathway that may play a role in nicastrin’s amplification process.
Based on this finding, our collaborators experimentally confirmed the downstream
signalling mechanism of nicastrin in breast cancer cells. Relevant details of the full
study are given in Section B.2 Application to complex diseases: breast cancer study
on page 204.
3.3.7.2 Cardiovascular diseases
Another major global cause of death are cardiovascular diseases (CVDs). They are
a group of heart and blood vessel related diseases, with more people dying every
year from CVDs than from any other cause:247 with one in three deaths in the
United States being caused by CVDs, controlling and preventing CVDs and their
complex pathogenesis — which is influenced by genetic, environmental and lifestyle
factors — has gained considerable attention.247 CVDs are studied in mechanistic,
genetic and biochemical contexts that include genomic,248 gene expression249 and
proteomic studies.250 In cardiovascular research, proteomics is used in two ways:
for investigating protein function in different physiological and disease processes
(mechanistic studies) and for investigating difference in protein levels and function
in a diseased state of an organism (biomarker studies).250,251 Proteomics research
includes sample pre-processing or sample pre-fractionation, mass spectrometry and
data analysis.252
We2 explored the predictive power of similarity in PPI network wiring around
proteins (see Chapter 1 and references12,57,59–61,119,120,142,220) to find those genes which
are important for CVDs. More specifically, we used GDV similarity to find clusters
of proteins with wiring similar to that of proteins already known to be involved
in CVDs. From the obtained clusters we identified a consensus subset of CVD-
related genes that are enriched in drug targets and driver genes found in the core
diseaseome. We validate a substantial portion of our predictions in the literature.
Since these are known to drive onset and progression of a disease, this indicates that
2 This study is a result of collaborative work and was published in Sarajlić†, A., Janjić†, V.,
Stojković, N., Radak, D. and Pržulj, N. Network topology reveals key cardiovascular disease genes.
PLoS One, 8(8):e71537, 2013.253
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the identified core CVD genes may potentially be therapeutically exploited. Given
the importance of CVDs to human health, even a small step in this direction may
have substantial healthcare benefits. Relevant details of the full study are given in
Section B.3 Application to complex diseases: cardiovascular disease study on page
216.
3.3.7.3 The new human G-protein-coupled receptor interactome
In September 2012 we received from our collaborators3 a data set with the first
comprehensive interactome map of the human G-protein-coupled receptors (GP-
CRs). These are seven-transmembrane (7TM) proteins involved in many signal
transduction pathways and are implicated in numerous human diseases. Our collab-
orators produced the data using a modified Membrane Yeast Two-Hybrid (MYTH)
approach,38,41–44 specifically tailored to identify interactors of full-length integral
membrane proteins, thereby creating the annotated interactome of 50 selected full-
length, clinically relevant human GPCRs in their ligand-unoccupied state, localised to
their native plasma membrane. We use these data to build a network representation
of the GPCR interactome. The resulting network connects 699 proteins by 997
unique interactions, including 368 membrane proteins.
Due to their involvement in signal transmission, GPCRs are highly druggable bio-
logical targets for numerous pharmaceutical compounds used for various clinical indic-
ations.254 These 7TM proteins are associated with diseases such as schizophrenia,255
Parkinson’s disease,256–258 hypertension,259 obesity,260 and multiple cancers.261 In
order to design successful treatments for these diseases, it is essential to increase our
detailed understanding of the molecular events occurring during GPCR-mediated
signal transduction, and to identify all of the proteins associated with a particular
GPCR relevant for human health. Therefore, the reason why we study the new
GPCR interactome lies in the fact that analysing these data presents new possibilities
for increasing our fundamental understanding of the cellular role and regulation of
this important family of integral membrane proteins, and may facilitate development
of new treatments and a more accurate understanding of drug mechanisms of action.
We found that the analysed GPCR network constitutes the basis for a wiring
sub-structure within the PPI network whose purpose is to quickly and efficiently
relay signals throughout the whole PPI network. In other words, a signalling cascade
originating in such a sub-network is very few interactions removed from any other pro-
3 Stagljar Lab, Donnelly Centre, Dept. of Molecular Genetics, University of Toronto, Canada
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tein or signal receptor in the entire PPI network. It acts as a signalling “spine” which
is topologically elongated along the interactome and whose functional enrichment is
completely distinct (i.e. no functional overlap) from the proteins in the rest of the PPI
network: as expected, it is primarily involved in the cell’s signalling machinery and
its related processes. Also, we found that its topological structure is best modelled
by the STICKY random network model, while the rest of the network is GEO. This
is in agreement with the findings from Section 2.3.2 on page 48 and Section 2.3.3
on page 52, which showed that the GEO-STICKY topological duality in the human
and yeast interactomes is caused by the presence of both function-performing and
communication-relaying proteins. As a final part of our computational analysis of
this new GPCR interactome, we looked at the core of the human GPCR interactome
and found it to be enriched in neuro-developmental disorders, diseases of the nervous
system, and mental disorders, with most of the involved proteins being expressed in
the brain. Relevant details of the full study are in Section B.4 Network analysis of
the new G-protein-coupled receptor interactome on page 227.
3.4 Concluding remarks
This chapter demonstrates that we can computationally isolate a sub-network of
the human PPI network that is topologically and functionally homogeneous and
enriched in disease genes and drug targets. Also, this sub-network contains genes
that are known to drive disease formation. Furthermore, we show that it’s topology
is unique in the human PPI network. We call this network the core diseasome and
demonstrate its applicability in three case studies involving complex diseases. Since
this network has a very specific structure that varies from the remainder of the
human interactome, and since it is also enriched with genes involved in key disease
mechanisms, this leads to a speculation that driver topology indeed exists within our
interactome and we hypothesise that it may be the wiring of the core diseasome that
leads to disease formation.
In this chapter and in Chapter 2 we looked at what biological insights about the
functional modularity of the interactome and the disease wiring patterns within it can
be obtained through computational analysis of protein–protein interaction networks.
In the next chapter, we expand on these topics by exploiting additional sources
of molecular interaction data to propose the first unified model of the functional
organisation and functional cross-communication of the cell, and to find new links
87
3 The core of molecular interaction networks and complex diseases
between previously unrelated diseases through the integration of a large number of
molecular interaction data sets.
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The advent of genome-scale genetic and genomic studies allows new insight into
disease classification. Recently, a shift was made from linking diseases simply based on
their shared genes towards systems-level integration of molecular data. In Chapters 2
and 3 we mainly analysed diseases through one type of molecular interaction data,
namely the PPI network. In this chapter, we show that different molecular interaction
data (such as co-expression, protein–protein, and genetic interaction data) offer
slightly different, yet complementary, perspectives into disease causes and onset. We
further use this fact to study the functional organisation of the cell, as well as to
find new relationships between diseases and between biological functions based on
evidence from fusing all currently available molecular interaction and ontology data.
In Section 4.3.1, we explore the notion that different molecular data encode
different information about the same underlying system, i.e. about the cell, and find
that different molecular data have different functional dimensionality.1 We compare
the protein–protein, genetic and co-expression data, and analyse specific differences in
biological information carried by these three molecular data sets. A new framework is
proposed for “untangling” the functional space to exploit this data complementarity,
and use it to create the first integrated model of the cell’s functional organisation, as
well as to capture and describe the lines of cross-functional communication.
1 We thank Prof. Charlie Boone, Prof. Chad L. Myers, and Dr. Noël Malod-Dognin for help
with this work.
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In Section 4.3.2, we2 build and examine a multi-level hierarchy of disease classes
that significantly overlaps with the existing disease classification. In it, we find 14
disease–disease associations currently not present in Disease Ontology and provide
evidence for their relationships through comorbidity data and literature curation.
Interestingly, even though the number of known human genetic interactions is cur-
rently very small, we find they are the most important predictor of a link between
diseases. Furthermore, we show that omission of any one of the included data sources
reduces prediction quality, further highlighting the importance in the paradigm shift
towards systems-level data fusion. Analogously to this use of data integration to
predict new relationships between diseases, in Section 4.3.3 we3 show that almost all
functional relationships between genes currently present in Gene Ontology can be
reconstructed solely from molecular interaction data, as opposed to being manually
curated an maintained by domain experts and members of research and annotation
communities, as was the case until recently.
4.1 Motivation and previous studies
In April 1996 the whole yeast genome sequence came under the limelight264 shortly
followed by a complete set of deletions of every open reading frame,265,266 promising
a revolution in drug discovery and a leap-forward in understanding life on a systems
level. Today, almost 20 years later, we still struggle to fully understand and explain
even the most straightforward monogenic Mendelian disorders and the much anticip-
ated revolution in disease therapy has yet to make its appearance. Due to ease of
experimental manipulation, yeast remains the de facto model in system biology.267,268
Approximately 90% of yeast’s genes have some functional annotations268,269 and
linking proteins to their cellular functions has possibly been the most important
contribution of yeast as a model organism.270 Yet, despite the abundance of biological
and functional data, the functional organisation of the cell remains largely unknown.
Different molecular data are known to carry different information about a bio-
logical system,86,271 offering multiple views into the system.272,273 Because a single
data type is likely to reveal a small number of insights into the cell’s functional
organisation, which would equate to a one-dimensional view of the biological system,
2 The work described was done in collaboration with Dr. Chris G. Larminie from GlaxoSmithK-
line and Marinka Žitnik from the Bioinformatics Lab of Prof. Blaž Zupan.262
3 The work described was done in collaboration with Vladimir Gligorijević.263
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combining multiple data types has the potential to yield a more complete insight
than those obtained from individual sources of data in isolation.273,274 Recently,
data integration methods were applied to predict protein function,275 to identify
common genetic phenotypes,276 and to predict the missing links in Gene Ontology.277
These motivated us not only to study the cell’s functional organisation from each
molecular interaction data set alone, but also to devise a new computational frame-
work to integrate them and propose a unified functional organisation model of the
cell. In Section 4.3.1 of this chapter, we make several steps towards describing and
understanding the functional organisation of the yeast’s cell, using the three most
comprehensive molecular interaction data sets: protein–protein interaction (PPI),
co-expression (COEX) and genetic interaction (GI) networks.
Section 1.2.1 introduced Disease Ontology (DO), a well established classification
of the human disease, which relates and classifies diseases based on pathological
analyses and clinical symptoms. Currently, the growing number of heterogeneous
genomic, proteomic, transcriptomic and metabolic data do not contribute to this
classification; and our understanding of even the most straightforward monogenic
classic Mendelian disorders is limited without considering interactions between muta-
tions and biochemical and physiological characteristics. Hence, redefining human
disease classification to include evidence from heterogeneous data is expected to
improve prognosis and response to therapy.278
A challenge in relating diseases and molecular data is in the multitude of in-
formation sources. Disease profiling may include data from genetics, genomics,
transcriptomics, metabolomics or any other omics, all potentially related to suscept-
ibility, progress and manifestation of disease. Such data may be related on their
own: for example, information on transcription factor binding sites, gene and protein
interactions, drug-target associations, various ontologies and other less-structured
knowledge bases, such as literature repositories, are all inter-dependent and it is not
trivial to integrate them in a way that will yield new information about diseases.
This stresses the need for an integrated approach of current models to exploit all
these heterogeneous data simultaneously when inferring new associations between
diseases.279 In Section 4.3.2 of this chapter we demonstrate the usefulness of molecular
data integration by applying it to the open problem of disease reclassification, and
examining how fusing together modern molecular-level interaction data can improve
current knowledge of relationships between diseases.
Similarly to DO, in Section 1.2.1 we introduced Gene Ontology (GO), a major
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source of biological information regarding functional annotation of proteins across
various species. Since its foundation, GO has been growing in size and complexity
containing today vast amounts of annotated biological data. Initially, GO was
manually curated by domain experts and members of the research and annotation
communities. However, due to their inconsistency in translation to GO terms and
relations, manual curations have encountered many difficulties.280 Additionally, rapid
development of technologies for biological data acquisition has resulted in an accu-
mulation of biological data exceeding our ability to interpret.156 To overcome these
problems, many computational tools for automatic gene and protein annotation have
been devised. Much effort has been invested in assessing the accuracy of such an-
notation predictions.281 Methods for gene annotation prediction have either followed
approaches that transfer annotations from well-observed to partially observed genes
based solely on sequence similarity282 or approaches that directly predict function
of unknown genes using machine learning methods. 283 Recent methodologies focus
more on integration of distinct biological data sources which contribute to more
accurate predictions of gene annotation. In Section 4.3.3 of this chapter we use data
integration as an approach to show that large parts of GO can be reconstructed
purely from the topology of molecular interaction networks.
4.2 Methods and data
4.2.1 Data preparation
4.2.1.1 Data preparation for the cross-functional communication links
study
For the computational experiments described in Sections 4.2.2 to 4.2.6 and their
biological results presented in Section 4.3.1, we use the following three large-scale
yeast molecular interaction data sets.
Protein–protein interactions (PPIs). Like in previous chapters, we use a com-
bination of high-confidence PPI data from several studies.17,18,74,284 The corresponding
PPI network has 4 038 nodes and 16 615 interactions. Since we will be embedding the
interaction data, we need a measure of distance/similarity between proteins. We use
Jaccard Index as a standard metric for measuring similarity between proteins in PPI
networks. It measures the similarity of the two proteins’ neighbourhoods in the PPI
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network, and is defined as J(i, j) = |ni
⋂
nj|
|ni ⋃nj| (where ni is the set of the neighbours
of protein i and nj is the set of neighbours of protein j in the PPI network).
Gene co-expression data (COEX). We use the large, integrated data set from
Huttenhower et al. 88 (explained in Section 1.2.1). We model COEX as a network
by connecting two genes with an edge if their co-expression z-score is greater than
1.0 (the value is suggested by the original authors in Huttenhower et al. 88). The
corresponding COEX network has 5 712 nodes and 997 701 interactions. We also use
the co-expression z-score between two genes as a measure of their distance in the
COEX network.
Genetic interactions (GIs). We use the latest, largest, unpublished set of yeast
GIs that we received from our collaborators4,5,6. We create the genetic interaction
(GI) network in the following standardised way (Section 1.2.1). The corresponding
GI network has 2 718 nodes and 16 374 interactions. We use the Pearson’s correlation
coefficient between genetic profiles of two gens as their similarity/distance in the GI
network.
We use Gene Ontology (GO) as a benchmark model of the cell’s functional
organisation, against which we compare PPI, COEX and GI data. We measure the
similarity between the GO annotations of two genes by using the semantic similarity.
There exist two types of semantic similarities:
• Node-based semantic similarity defines the information content of a term as a
function of its frequency of appearance in the annotated data set and measures
the similarity between two terms according to their most informative ancestor in
the ontology.285,286
• Edge-based semantic similarity only uses the ontology, directed acyclic graph, and
measures the similarity between two terms based on the shortest path between
them, or based on the depth in the ontology of their common ancestors.287
We use the node-based semantic similarity from Resnik 286 because it achieves higher
and more consistent correlations with molecular interaction data than other ap-
proaches.288–290
4 Boone Lab, Donnelly Centre, Department of Molecular Genetics, University of Toronto, Canada
5 Computational Biology and Functional Genomics Lab, University of Minnesota, USA
6 Baryshnikova Lab, Lewis-Sigler Institute for Integrative Genomics, Princeton University, USA
93
4 Integrating molecular interaction data
4.2.1.2 Data preparation for the disease reclassification study
For the computational experiments described in Section 4.2.8 and their biological
results presented in Section 4.3.2, we integrate biological data on objects of four
different types (nodes in Figure 4.1): genes, diseases (Disease Ontology terms),
drugs, and Gene Ontology (GO) terms. We observe these four through 11 sources
of information (edges in Figure 4.1). Every source of information is represented
by a distinct data matrix that either relates objects of two different types (such
as drugs and their associated target proteins) or objects of the same type (such
as genetic interactions between genes): relations between objects of types i and j
are represented by a binary boolean relation matrix, Rij, and relations between
objects of the same type i are represented by a binary boolean constraint matrix, Θi.
Table 4.1 summarises all 11 data sets.
Table 4.1. Data for the disease reclassification study. The table lists data types,
their size, edge density, and reference source from where it was obtained. Constraint
matrices Θi relate objects of same type. Relation matrices Rij relate objects of two
different types and their numbers are reported separately (delimited by a forward slash).
Matrix Data description # Nodes # Edges Reference
Θ(1)1 Protein–protein interactions 10 360 55 787 BioGRID46
Θ(2)1 Gene co-expression 539 869 Prieto et al. 291
Θ(3)1 Cell signalling data 1 217 7 517 KEGG292
Θ(4)1 Genetic interactions 542 511 BioGRID46
Θ(5)1 Metabolic network 5 908 1 505 831 KEGG292
Θ4 Drug interaction data 4 477 21 821 DrugBank293
Θ3 GO semantic structure 11 853 43 924 GO94
Θ2 DO semantic structure 1 536 1 098 DO95
R13 Gene annotations 17 428/11 853 100 685 GO94
R14 Drug–target relationships 1 978/4 477 7 977 DrugBank293
R12 Gene–disease relationships 5 267/1 536 22 084 GeneRIF294
Disease data. As we have seen in Section 1.2.1, the principal source of inform-
ation on human disease associations is Disease Ontology (DO).95 It semantically
combines medical and disease vocabularies and addresses the complexity of dis-
ease nomenclature through extensive cross-mapping of DO terms to standard
clinical and medical terminologies of MeSH, ICD, NCI’s thesaurus, SNOMED
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Figure 4.1. System-level data fusion approach to disease reclassification. The
relationships between data sources: nodes represent four types of objects, i.e. sources that
relate objects of different types (relation matrices,Rij , i ̸= j), or objects of the same type
(constraints, Θi).
and OMIM. It is designed to reflect the current knowledge of human diseases
and their associations with phenotype, environment and genetics. We extract
1 536 DO terms from the latest version of the database and construct a binary
matrix R12 from 22 084 associations between genes and diseases. DO leverages
the semantic richness through linking terms by computable relationships in the
hierarchy (e.g. mediastinum ganglioneuroblastoma is_a peripheral nervous
system ganglioneuroblastoma, which is_a ganglioneuroblastoma and then in
turn is_a neuroblastoma) first by etiology and then by the affected body system.
We use the semantic structure of DO to reason over is_a relations. Since entries
in the constraint matrices are positive for objects that are not similar and negative
for objects that are similar, the constraint between two DO terms in Θ2 is set to
−0.8hops, where hops is the length of the path between corresponding terms in DO
graph. We empirically chose 0.8 from [0, 1] range — 0 meaning that no two terms
in the DO graph are related, and 1 meaning that two DO terms are always related
(regardless of the path distance between them in the DO graph) — by performing
standardised internal cross-validation using values between 0 and 1 with a 0.1 step
(i.e. 0, 0.1, 0.2, . . . , 1). Scores of multiple parentage (multiple is_a relationships) are
summed to produce the final value of semantic association. Throughout Section 4.3.2,
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we use disease and DO term interchangeably, which both refer to a unique DO
identifier (DOID).
Gene ontology data. We use relations between 11 853 distinct genes and 100 685
gene annotations that are given by Gene Ontology (GO)94 to construct a binary
matrix of direct annotations R13. Topology of the GO graph is included by reasoning
over is_a, part_of and has_part relations between GO terms to populate Θ3 in the
same way as Θ2 with the constraint between two GO terms set to −0.9hops.
Drug data. We obtain drug data from DrugCard entries in the DrugBank293 data-
base that contains chemical, pharmacological and pharmaceutical drug information
with comprehensive drug target details. Our model contains 4 477 distinct drugs,
each identified by a DrugBank accession number. Drugs are related to their target
proteins in R14, which is populated by 7 977 binary drug-target relationships from
DrugBank. We use reported side-effects of drug combinations from DrugBank as
21 821 binary indicators of interactions between drugs in Θ4 (i.e. 1 if there is a
reported side-effect, 0 otherwise).
Gene interaction data. We obtain the relationships between genes from five
sources of interaction data (top five rows in Table 4.1). Genes are identified by their
NCBI gene IDs. We first map the approved gene symbols and Uniprot IDs to Entrez
gene IDs using the index files from HGNC database,295 downloaded in November
2012. This is done to convert all gene annotations, drug-target, and co-expression
data into NCBI IDs. To increase coverage of gene and protein interaction data, we
include all genes (or equivalently, proteins) for which at least two supporting pieces
of information were available in any of the data sources listed in Table 4.1. In total,
these sources include: 55 787 protein–protein interactions (PPIs) between 10 360
proteins (Θ(1)1 , 869 pairs of co-expressed genes (Θ
(2)
1 ), 7 517 cell signalling interactions
(Θ(3)1 ), 511 human and interspecies genetic interactions (Θ
(4)
1 ), and 1 505 831 pairs of
genes involved in metabolic pathways (Θ(5)1 ).
4.2.1.3 Data preparation for the gene–function prediction study
To make our gene–function prediction study directly comparable to the latest, most
comprehensive study to date for reconstructing GO from network data, we run
the computational experiments described in Section 4.2.9 (results presented in Sec-
tion 4.3.3) on the same Saccharomyces cerevisiae data as Dutkowski et al. 277 : PPI
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network from BioGRID, 46 genetic interaction (GI) network from DRYGIN, 86 gene
co-expression (COEX) network from SMD296 and integrated function network, Yeast-
Net.297 For each of the these networks we construct Laplacian constraint matrices,
L(1)1 , L(2)1 , L(3)1 , and L(4)1 , respectively. In addition to that, we include the information
about the similarity in wiring around genes. We measure this by using the distance
between graphlet degree vectors (GDVs, Section 1.4.2) of all node pairs. By adding
GDVs, we incorporate a purely topological measure of similarity into the integration
process and improve accuracy of predictions. We label these matrices Λ(1)1 , Λ
(2)
1 , Λ
(3)
1
and Λ(4)1 . Graphlet-based similarity has not been exploited in any of the previous
network integration approaches. We make all data matrices of the same dimension
Table 4.2. Data for the gene–function prediction study. Matrix dimensions are
given before creating a union of genes across all data sets to obtain matrices of the same
dimensions. GDV matrices (Λ(i)) are of different dimension than L matrices because they
contain only genes that are statistically significantly similar (see Section 4.2.9). NNZ
denotes the number of non-zero entries in the corresponding matrix.
Matrix Data description Matrix dimension NNZ
L(1)1 Protein–protein integrations (PPIs) 3 401× 3 401 26 596
L(2)1 Genetic interactions (GIs) 3 090× 3 090 22 480
L(3)1 Gene co-expression (COEX) 228× 228 3 410
L(4)1 YeastNet 3 351× 3 351 21 146
L2 GO semantic structure 3 993× 3 993 15 872
R12 Gene annotation 5 051× 3 993 45 782
Λ(1)1 GDV similarity (PPI) 1 609× 1 609 93 536
Λ(2)1 GDV similarity (GI) 1 550× 1 550 89 434
Λ(3)1 GDV similarity (COEX) 122× 122 2 524
Λ(4)1 GDV similarity (YeastNet) 1 453× 1 453 88 986
by constructing them over the union of genes presented in all four data sources. The
semantic structure of Gene Ontology is also taken into account in our integration
algorithm. We extract all GO terms for S. cerevisiae and create L2 constraint matrix
as follows. First, we construct a directed, acyclic, ontology graph using the four basic
semantic types of GO relations: is_a, part_of , regulates and has_part. Then, we
assign value 0.9hops to each pair of GO terms as a measure of association strength,
where hops is the length of directed shortest path between terms in the ontology
graph. This allows us to also take into account mutual influence of hierarchically
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distant non-adjacent GO terms.298 The value of 0.9 is chosen from empirical observa-
tions, like in Section 4.2.1.2. Finally, we construct the Laplacian constraint matrix,
L2, by using these values of association strengths.
Annotation files from GO are used to construct the binary relation matrix,R12,
with entries R12(i, j) = 1 if gene i is annotated by GO term j and 0 otherwise. For
each of the above mentioned biological networks, we also compute GDV similarity
constraint matrices: {Λ(1)1 ,Λ(2)1 ,Λ(3)1 ,Λ(4)1 }. As we shall describe in Section 4.2.9,
we only consider gene pairs with statistically significant GDV similarity. All these
network data are given in Table 4.2 and schematically represented in Figure 4.2.
Figure 4.2. Schematic representation of data sets used in this study. Two types
of objects are represented: 1) genes, interconnected via four types of interaction networks:
protein–protein interaction (PPI), genetic interaction (GI), gene co-expression (COEX)
and YeasNet); and 2) GO terms, interconnected via directed, semantic relations from GO
hierarchy.
4.2.2 Measuring the complexity of different molecular interac-
tion data
To see how well COEX, GI and PPI correspond to the complete set of known GO
relations, we compare the distances between genes in each data set to the semantic
similarity between the GO functional annotations of those genes as follows (definitions
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of all distance measures described above in Data preparation for the cross-functional
communication links study).
First, we measure the raw fit between data distances and GO distances using
polynomial regression (a linear fitting regression is equivalent to computing the
Pearson’s correlation). We find that the simple linear regression is never the best
fitting when comparing COEX, GI and PPI data with GO. Since a higher order
polynomial fit between interaction data and the functional organisation represented
in GO indicates a higher functional dimensionality of data, for each data set we find
the highest order polynomial after which the fit does not further improve and call
that the functional dimensionality of the data set. The results show that the three
interaction data sets only weakly correlate with GO: COEX achieves the highest
correlation coefficient (0.162), followed by GI (0.102) and PPI (0.094), with all
correlations being statistically significant, as measured by using the F-test (p-values
≤ 10−20; top three panels in Figure 4.3). Similar low correlations have been observed
for COEX and PPI data in the past288 and are expected because the data are both
noisy and incomplete.
To get a cleaner view of the relationships between the interaction data and GO,
we adapt the discretized fitting methodology of Sevilla et al. 288 ; all three network
distances are binned into 100 intervals, then, for each bin, we consider the average
semantic similarity value of all the elements in it, and finally, we perform the same
regression fitting as in the previous, undiscretized raw, experiment. Note that the
discretized fits do not have any predictive abilities, but rather highlight trends. Again,
COEX achieves the highest correlation coefficient with GO (0.997), followed by GI
(0.985) and PPI (0.835), and again, all p-values ≤ 10−20 (bottom three panels in
Figure 4.3).
4.2.3 Embedding molecular interaction data
We hypothesise that all biological entities exist in a multi-dimensional functional
space. 299 To make this study feasible, we approximate this high dimensional space
with three-dimensional Euclidean space and embed the interaction data into this
space using spring embedding.300 We then approximate the functional distances
between genes with their Euclidean distances in the embedding. Since spring embed-
ding is stochastic, we perform 100 embeddings for each interaction network in order to
increase the robustness of the experiments and get stable results with corresponding
intervals of confidence.
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Figure 4.3. Polynomial fitting of interaction data to GO semantic similarity.
Top — Raw correlations between the three data sets and GO semantic similarity. GI data
(top-left) is best fit to GO with a regression fit of a 5th order polynomial function. COEX
data (top-middle) is best fit to GO with a cubic function, and PPI data (top-right) is best
fit to GO with a quadratic function. The heat maps are based on the number of protein
pairs in the corresponding region: red areas contain more protein pairs than blue areas;
white areas contain no pairs. Bottom — Discretized fitting. GI data (bottom-left) uses
regression fit with a 5th order polynomial function, COEX data (bottom-middle) uses cubic
fit, and PPI data (bottom-right) uses quadratic fit. Each point corresponds to a single
bin (there are 100 bins in each of the three panels) and represents an average semantic
similarity of all protein pairs in that bin. For all raw and discretized correlations,ρ is the
correlation coefficient of the fit and p-value is its statistical significance obtained using the
F-test.
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4.2.4 Creating functional organisation maps
Here, we introduce and describe a new computational framework for mapping out
the functional layouts of various interaction data (illustrated in Figure 4.4). It works
as follows. For each functional group of genes in an embedded space, we compute its
volumetric spread in space, the centre of mass of that volume, and its overlap and
separation from each of the remaining embedded functional groups.
  1       Cell cycle progression/meiosis
  2       Cell polarity/morphogenesis
  3       Chrom. seg./kinetoch./spindle/microtub.
  4       Chromatin/transcription
  5       DNA replication & repair/HR/cohesion
  6       ER-Golgi trac
  7       Golgi/endosome/vacuole sorting
  8       Metabolism/mitochondria
  9       Nuclear-cytoplasmic transport
10       Protein degredation/proteosome
11       Protein folding & glycosylation/cell wall
12       RNA processing
13       Ribosome/translation
14       Signalling/stress response
1                                             2
3 4 5
Figure 4.4. Illustration of our approach for constructing functional organisa-
tion maps from molecular interaction data. 1 — “clouds” of embedded functionally
colour-coded genes. 2 — convex hulls (also colour coded) encompassing each functional
“cloud”. 3 — centres of volumetric mass for each function’s convex hull. 4 — centres of
volumetric mass scaled according to the number of genes annotated with a certain function
and linked via edges weighted using the closeness between functions (for visualisation
purposes, we show only those edges that make up the top 50% of the weight of all edges,
that is, we excluded weak links between distant functions). 5 — the functional organisation
map (heat map) with hierarchically clustered functions.
We define the volumetric spread of a function as the convex hull301 7 encompassing
all genes annotated with that function. The centre of mass for each convex hull is
7 A convex hull for a given set of points, S, is the smallest polygonal shape that contains all the
points from S, such that for any two points, p and q, inside the shape, the line segment connecting
p and q does not cross the boundaries of the shape.
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located in space by taking the mean of embedded coordinates of all genes belonging
to it. The pairwise distance between two convex hulls, f and g, denoted by df,g,
is the Euclidean distance between their centres of mass. Given the computational
hardness of the problem of finding the spatial overlap between f and g,302,303 we
approximate the solution by diving the space into voxels304 of the same size and
separating the genes according to the non-empty voxels they belong to: if Tf are the
genes from f that fall into voxels containing only f , and if Tg are the genes from g
that fall into voxels containing only g, then the separation between the two convex
hulls is Sf,g =
|Tf |+ |Tg|
|f |+ |g| (where | · | denotes the number of genes in each set) and
their spatial closeness is Cf,g = Sf,g×df,g. We apply non-linear scaling and normalise
all Cf,g values into the [0, 1] range by using C ′f,g =
√
Cf,g−C
C−C , where C and C are
the minimum and maximum values of C over all pairs of functions, respectively,
to produce visually cleaner clusters without affecting the results. This gives us a
matrix of distances between convex hulls that can be viewed as the communication
distance matrix between biological functions (illustrated in Figure 4.4 step 5; smaller
values, in blue, indicate closer communication between functions, and each function
has self-communication C ′f,f = 0). We cluster this matrix to observe the lines of
communication between biological functions. Deciding which clustering method is
best for a given data set with no a priori knowledge of what the answer should be is
a hard problem with no right or wrong answers. We chose hierarchical clustering as
it yields groups of inter-functional links in descending order of their communication
strength, from strongest to weakest (the heat map and dendrogram in Figure 4.4,
panel 5).
4.2.5 Comparing functional organisation maps against Gene
Ontology
We embed the genes into Euclidean space according to the pairwise semantic sim-
ilarities of their GO terms, and using the same approach that we used for COEX,
GI and PPI, we create the GO-based functional organisation map of the cell. To
formally compare functional maps of COEX, GI and PPI with that of GO, we
apply four statistical tests: two that consider the pairwise communication distances
between functions (i.e. they compare every entry from a functional organisation map
obtained from interaction data to its corresponding entry in the GO reference map),
Pearson’s ρ correlation test and Kendall-Tau test;305 and two that compare only the
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distributions of communication distance values between the functional organisation
map of an interaction data set and the reference functional organisation map of GO,
2-sample Kolmogorov-Smirnov test and Mann-Whitney U test.
Since the spring embedding algorithm, which we use for constructing the func-
tional organisation maps, is non-deterministic (as explained in Section 4.2.3), we
repeat the embedding procedure 100 times for each of the 4 data sets (COEX, GI,
PPI and GO) to get stable results and confidence intervals. We apply the four stat-
istical tests to all 30 000 data-vs-GO functional organisation maps combinations (100
functional organisation maps per interaction data set ×100 functional organisation
maps for GO gives 10 000 comparisons for each of the three interaction data sets).
All four statistical tests give consistent results, but we report only the results of
Pearson’s correlations, as they are the strongest test since Pearson’s correlation
uses the actual values of compared elements, while the other tests use ranks and
distributions.
4.2.6 Integrating functional organisation maps from multiple
molecular interaction sources
To test whether combining multiple data sources produces a functional map of the
yeast’s cell that is in higher agreement with GO than those offered by each data set
individually, we propose an integration model that can easily scale to accommodate
an arbitrary number of input data types. It works by solving the multiple linear
regression, GO ≃ α × COEX + β × GI + γ × PPI + δ, and finding (α, β, γ, δ)
coefficients for the quadruplet of functional organisation maps derived from GO,
COEX, GI and PPI data. This approach is useful as it allows for easy inclusion or
omission of data sets, enabling us to determine the exact contribution of individual
data sources and their combinations to the integrated model.
4.2.7 Matrix tri-factorisation approach to data integration
Here we explain the co-clustering algorithm based on penalised non-negative matrix
tri-factorisation (PNMTF) for heterogeneous data clustering (introduced in Wang
et al. 306,307) used in Sections 4.3.2 and 4.3.3 to integrate heterogeneous biological
data. Clustering analysis is used to infer new relations between data objects that
were not previously present in the data. Such a technique makes use of all available
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information presented in network form, including both inter-type relations and intra-
type constraints.306,308 The algorithm aims to simultaneously cluster data using the
interrelatedness between data types under the guidance of some prior knowledge given
in the form of intra-type pairwise constraints. These constraints often indicate simil-
arity or dissimilarity relationships between data objects of the same type, which guide
the clustering procedure so that similar objects can belong to the same cluster while
dissimilar cannot. PNMTF has been used for prediction of disease associations,262
identification of cancer subtypes, 309 predicting protein–protein interactions, 160 and
detecting phenotype–gene associations.310
The simplest co-clustering problem involves only two types of objects (e.g. genes
and Disease Ontology terms) with size n1 and n2. If there are n1 objects of the
first type and n2 objects of the second type, then we have an inter-type relationship
matrix R12 ∈ Rn1×n2 with an entry R12(i, j) representing the relationship between
ith data point in the first data set and the jth data point in the second data set.
Simultaneous clustering of these data sets can be seen as a solution of the non-
negative matrix tri-factorisation (NMTF) problem where a given relation matrix,
R12 ∈ Rn1×n2 can be approximated as the product of three low-rank matrix factors
R12 ≈ G1S12GT2 , where non-negative G1 ∈ Rn1×k1+ and G2 ∈ Rk2×n2+ correspond to
the cluster indicator matrix of the first and the second data set, and S12 ∈ Rk1×k2
corresponds to compressed low-dimensional version of the initial relation matrix.
Rank factors, k1 and k2, are often chosen to be much smaller than the corresponding
matrix dimensions (k1 ≪ n1, k2 ≪ n2; see Section C.1 Rank parameter selection
on page 237 for details). The NMTF algorithm minimises the following objective
function:
min
G1≥0,G2≥0
J =∥ R12 −G1S12GT2 ∥2 (4.1)
This objective function can be further used to incorporate intra-type constraints
whose violation causes penalties. Constraints that relate data points, i and j, in
two different data sets are represented via two constraint matrices, Θ1 ∈ Rn1×n1 and
Θ2 ∈ Rn2×n2 . Entries of the constraint matrix are positive for dissimilar data objects
because they impose penalties on the current approximation given in equation (4.1).
Entries of the constraint matrix are negative for similar objects because they are
rewards which reduce the objective function. Therefore, the constraint matrices can
be included as additional penalty terms in the objective function in the following
way:
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min
G1≥0,G2≥0
J =∥ R12 −G1S12GT2 ∥2 +tr(GT1Θ1G1) + tr(GT2Θ2G2) (4.2)
where || · || and tr(·) denote Frobenius norm and the trace of a matrix, respectively
(they are commonly used in matrix approximation tasks). This optimisation problem
is known as penalised non-negative matrix tri-factorisation (PNMTF). Its solution
produces two matrix factors, G1 and G2, that can be interpreted as the cluster
indicator matrices for the first and the second data set. Specifically, factor G1 is
used to assign data objects from the first data set to clusters so that data object j is
placed in the cluster i if G1(i, j) is the largest entry in column j.311 This assignment
procedure results in a binary connectivity matrix, C, of size n1 × n1 with entry
C(p, q) = 1 if objects p and q belong to the same cluster and C(p, q) = 0 otherwise.
Hence, integration of two data sources is achieved by clustering the first and the
second data sets simultaneously using R12, Θ1 and Θ2 which encode the relevant
data. The block matrices representing inter-type relations (R), intra-type constraints
(Θ), cluster indicators (G), and low-dimensional factors (S) encode the data in the
following manner:
R =

0 R12 . . . R1n
RT12 0 . . . 0
... ... . . . ...
RT1n 0 . . . 0

Θ =

Θ1 0 . . . 0
0 Θ2 . . . 0
... ... . . . 0
0 0 . . . Θn

S =

0 S12 . . . S1n
ST12 0 . . . 0
... ... . . . ...
ST1n 0 . . . 0

G =

G1 0 . . . 0
0 G2 . . . 0
... ... . . . 0
0 0 . . . Gn

To avoid data redundancy we encode only explicit relations between objects. Such
representation leads to zero off-diagonal blocks in R (instead of relation matrices R23,
R24, . . . , R2n, R34, . . . , R3n, . . . ) and to symmetry of relation matrices Ri,j = RTj,i,
Si,j = STj,i.
A limitation to the approach in equation (4.2) comes in the form of low coverage
and sparsity of molecular interaction data.310 The density of constraint matrices (i.e.
adjacency matrices) for almost all currently available molecular interaction networks
is only around 1%. To address this problem, we incorporate additional knowledge
about network connectivity by implementing these constrains into the objective
function in form of network Laplacians (see Wang et al. 307 , Hwang et al. 310 for
details). That is, we are now minimising:
min
G1≥0,G2≥0
J =∥ R12 −G1S12GT2 ∥2 +tr(GT1L1G1) + tr(GT2L2G2) (4.3)
where Lα = Dα −Aα represents the network Laplacian of the molecular network of
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the α data type; Aα is the network adjacency matrix and Dα is the diagonal degree
matrix with entries being row summation of the matrix Aα: Dα(i, i) =
∑
jAα(i, j).
These additional, Laplacian-based terms encourage the connected elements in the
network (e.g. genes, drugs, ontology terms) to be assigned to the same cluster. For
example, to integrate network data and predict GO term relationships along with
new gene annotations, the term tr(GT1L1G1) imposes that interacting genes get
placed into the same cluster while tr(GT2L2G2) simultaneously imposes that linked
GO terms get placed into the same cluster.
Multiple constrains on the same object. The above described approach is
taken when integrating only two types of objects. However, many biological data
include multiple types of interactions (i.e. constraints) over the same set of entities.
For instance, genes might interact via genetic interactions and they also might be
related based on the correlation of their expression profiles (i.e. GI and COEX
networks, respectively). To properly integrate this information into the clustering
procedure, Žitnik and Zupan 312 make an improvement to the regularised PNMTF
optimisation problem — they extend it to take into account multiple constraints
over the objects of the same type. Suppose we have a set of N adjacency matrices:
{A11,A21, . . . ,AN1 }, representing N data sources relating objects of the first type. By
adding these constraints in the Laplacian form as penalty terms into our objective
function (equation (4.3)), we end up with the following:
min
G1≥0,G2≥0
J =∥ R12 −G1S12GT2 ∥2 +
N∑
β=1
tr(GT1Lβ1G1) + tr(GT2L2G2) (4.4)
4.2.8 Integrating molecular data to predict new disease–
disease links
The intermediate data fusion approach explained in Section 4.2.7 above is chosen
for for its accuracy of inferring prediction models (i.e. how well a model can learn
to predict disease–disease associations) and the ability to explicitly measure the
contribution of each data set to the extracted knowledge.159,163 Kernel-based fusion
can only use data sources expressed in the “disease space”, i.e. all data sources
have to be expressed as kernel matrices encoding relationships between diseases,
which may incur loss of information when transforming circumstantial data sources
into appropriate feature space. Since most of the molecular data sources used in
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this study are only indirectly related to diseases, we employ the above-described
intermediate data fusion by matrix factorisation approach, which has an accuracy
comparable to kernel-based fusion approaches but can treat all data sources directly
(i.e. no transformation of data into “disease space” is necessary). The key idea of
that approach lies in the sharing of low-rank matrix factors between data sources
that describe biological data of the same type. For instance, genes are one data
type which can be linked to other data types such as Gene Ontology (GO) terms or
diseases through two distinct data sources, namely GO annotations and disease–gene
mapping. The fused factorised system contains matrix rank factors that are specific
to every molecular data type, as well as matrix factors that are specific to every data
source. Thus, low-rank matrix factors can simultaneously capture both source- and
object type-specific patterns.
We combine 11 data sources for four different types of objects described in
Section 4.2.1.2 Data preparation for the disease reclassification study on page 94.
Figure 4.5 illustrates how these data are encoded in two types of matrices: constraint
matrices, which relate objects of the same type (such as drugs if they have common
adverse effects) and are placed on the main diagonal (illustrated by matrices with blue
entries in Figure 4.5); and relation matrices, which relate objects of different types
and are placed off the main diagonal (illustrated by matrices with grey entries in
Figure 4.5). The data fusion approach involves three main steps. First, we construct
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Figure 4.5. Graphical representation of the PNMTF data fusion approach. We
use this approach for discovering new disease–disease associations. The shown block-based
matrix representation exactly corresponds to the data fusion schema in Figure 4.1.
a block-based matrix representation of all data sources used in our study (left panel
in Figure 4.5). The molecular data encoded in these matrices are sparse, incomplete
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and noisy (depicted by different shades of blue and grey) and some matrices are
completely missing because associated data sources are not available (e.g. no link
between GO terms and drugs). In the second step, we simultaneously decompose all
relation matrices as products of low-rank matrix factors and use constraint matrices
to regularise low-rank approximations of relation matrices. As stated above, the key
idea of this data fusion approach is sharing low-rank matrix factors between relation
matrices that describe objects of common type. The resulting factorised system
(middle panel in Figure 4.5) contains matrix factors that are specific to every type of
objects (four matrices in left part; e.g. GDrug), and matrix factors that are specific
to every data source (six matrix factors in right part; e.g. SGene, DO Term). Finally, we
use matrix factors to reconstruct relation matrices and complete their unobserved
entries (right panel in Figure 4.5).
Disease class assignment. Each factorisation run produces a set of matrix factors
that reconstruct the three relation matrices in our model. For disease association
discovery, we are interested in approximating R12 ≈ G1S12GT2 , specifically factor G2
that contains meta profiles of DO terms and is used to identify classes of diseases.
Class membership of a disease is determined by maximum column-coefficient in
the corresponding row of G2. This is a well-known approach in applications of
non-negative matrix factorisation.311,313 A binary connectivity matrix C is then
obtained from class assignments with Cij set to 1 if disease i and disease j belong
to the same class (see algorithm in Table 4.3). Repeating the factorisation process
15 times with different initial random conditions and factorisation ranks gives a
collection of connectivity matrices, C(i), i ∈ {1, 2, . . . , 15}. These are averaged to
obtain the consensus matrix C¯ that is then used to assess reliability and robustness
of disease associations. The entries in the consensus matrix range from 0 to 1 and
indicate the probability that diseases i and j cluster together. If the assignment of
diseases into classes is stable, we would expect that the connectivity matrix does not
vary among runs and that the entries in the consensus matrix tend to be close to 0
(no association) or to 1 (full consensus for association). To recover informative and
relevant disease associations, we are interested in diseases with high values in the
consensus matrix. The process is outlined in the algorithm given in Table 4.3.
Disease associations scoring. Disease associations are scored by permuting the
entries in gene-disease relation matrix R12 and inferring the prediction model from
the permuted matrix. Matrix R12 encodes relations between genes and diseases,
108
4.2 Methods and data
Table 4.3. Disease class assignment. The algorithm for assigning diseases to classes
and obtaining disease–disease association predictions.
• Input: A sequence of matrix factors from 15 repetitions of factorisation G(i)2 for 1 ≤ i ≤ 15.
• Output: Consensus matrix, C¯, and a set, D, of disease classes, D.
1. Repeat the following for each matrix factor G(i)2 for 1 ≤ i ≤ 15.
1. For each disease j compute its class as argmaxmG(i)2 (m, j).
2. Compute connectivity matrix C(i) from class assignment such that C(i)(r, s) is set to 1 if
disease r and s were assigned the same class in step 1.
2. Compute consensus matrix as C¯ = 115
∑
iC(i).
3. Extract new disease classes, D = {D | D ⊂ {Disease Ontology IDs} ∧ ∀i, j ∈ D ∧ i ≠ j :
C¯(i, j) = 1}.
and via genes to the rest of the fusion model, so permuting its entries is sufficient
for a complete rewiring of associations. To compute the p-values for the disease
associations observed in our inferred model, we generate 70 consensus matrices (each
one is averaged over 15 permutations of a disease–gene connectivity matrix, giving
70 × 15 = 1 050 unique matrices) and express the p-value of a particular disease
association as the fraction of factorisation runs in which it was observed.
4.2.9 Integrating molecular data to predict new gene function
links
Analogous to the approach from Section 4.2.8 for predicting new links in the Disease
Ontology, here we also use the PNMTF method described in Section 4.2.7 to take
multiple types of molecular network data and utilise them to reconstruct and update
Gene Ontology with new information. We apply our method to Saccharomyces
cerevisiae data described in Section 4.2.1.3 Data preparation for the gene–function
prediction study on page 96.
Unlike previous studies where only network connections were considered as con-
straints,160,309,310,314 the approach presented here takes a step further by incorporating
additional constraints in the form of topological similarity between nodes in a net-
work that are not necessarily linked. Here, we use the topological similarity measure
based on graphlet degree vectors (GDV) (explained in Section 1.4.2 Graphlets and
graphlet-based heuristics on page 27). We include the GDV similarity measure
into our objective function (equation (4.4)) as follows. For each of the given data
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source β (i.e. biological network) we construct a similarity matrix Sβ ∈ Rn×n. Then,
by computing a statistically significant threshold for topological similarity of two
nodes in each of the GDV similarity matrices (significance threshold computed as in
Section 3.2.3 on page 68), we consider only data objects (genes/proteins) with GDV
similarity higher than the computed threshold:
σβ(u, v) =

1, if Sβ(u, v) ≥ Sthresholdβ
0, if Sβ(u, v) < Sthresholdβ
These topological similarity constraints are again implemented into the objective
function through Laplacian regularisation:
min
G1≥0,G2≥0
J =∥ R12 −G1S12GT2 ∥2 +
N∑
β=1
tr(GT1Lβ1G1)
+
N∑
β=1
tr(GT1Λ
β
1G1) + tr(GT2L2G2)
(4.5)
where, Λ = D − σ is a Laplacian of σ matrix and D is the diagonal matrix with
entries equal to the row summation of σ matrix.
Multiplicative update algorithm. To solve the optimisation problem in equa-
tion (4.5), we need to follow the multiplicative update rules for matrix factors G1,
G2 and S12:306
S12 ← (GT1G−11 GT1R12G2(GT2G−12 ) (4.6)
G1(i, j)← G1(i, j)
√√√√√(R12G2ST12)+ij + [G1(ST12GT2G2S12)−]ij + [∑β (Lβ1 +Λβ1 )−G1]ij
(R12G2ST12)−ij + [G1(ST12GT2G2S12)
+]ij + [
∑
β (Lβ1 +Λβ1 )
+G1]ij
(4.7)
G2(i, j)← G2(i, j)
√√√√√(R12G1S12)+ij + [G2(S12GT1G1ST12)−]ij + [L−2G2]ij
(R12G1S12)−ij + [G2(S12GT1G1ST12)
+]ij + [L+2G2]ij
(4.8)
where we use + and − sign in superscripts to denote non-negative matrices M+ and
M− of a matrix M defined as: M+ = |M|+M2 and M− =
|M|−M
2 . The algorithm
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starts by randomly initialising matrices G1 and G2, which are iteratively updated to
minimise objective function in equation (4.5). The rigorous proof of the correctness
and convergence of these update rules can be found in Wang et al.306 . Under these
update rules, the objective function J in equation (4.5) is guaranteed not to increase.
Hence, we look at the change in the objective function between two consecutive
iterations and define the stopping criterion as: |Jn − Jn−1| < ϵ. In all our runs,
parameter ϵ is set to 10−5 which was shown to be significant to minimise the objective
function. Compared to the probabilistic clustering approach for GO reconstruction
presented by Dutkowski et al. 277 , our approach is computationally more demanding
due to slow convergence of multiplicative update rules. However, our approach is
more general, since it can integrate any number and type of heterogeneous data, that
could lead to more accurate predictions.
Function class assignment. Each factorisation run produces matrix factors: G1
related to the set of genes, and G2 related to the set of GO terms. We use G2 factor
to construct connectivity matrix C as described in Section 4.2.7. Clusters of mutually
related GO terms are obtained from the connectivity matrix. To assess reliability
and robustness of GO term associations prediction, we use the stochastic property
of our algorithm. We perform multiple runs with the same rank parameters and
different initial random initialisations and construct a set of 20 different connectivity
matrices: {C(1), . . . ,C(20)}. Then, we compute the consensus matrix, C, defined as
the average over all connectivity matrices. Thereby entries in the consensus matrix
range from 0 to 1 and they can be interpreted as probabilities that two GO terms,
GOi and GOj , belong to the same cluster. To predict new GO term associations, we
are only interested in values of probability equal to one, because they correspond to
the case of hard clustering, in which there is no overlap between clusters and hence,
there is no ambiguity in predicted GO term associations. The complete algorithm
for prediction of new GO term association is summarised in Algorithm 4.1.
Function association scoring. To assess the statistical significance of GO term
associations, we compute the p-value in the following way. First, we remove any
prior knowledge on GO term relations (i.e. we remove matrix L2). Then, we run
our algorithm 100 times, each time with different relations matrix obtained by
permuting the entries of the original relations matrix, R12. In total, we obtain
100×20 = 2 000 different connectivity matrices. We define the p-value of a particular
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Algorithm 4.1. GO term associations prediction
Input: Relation matrix: R12; constraint matrices: Lβ1 and Λβ1 for networks β ∈ {1, 2, 3, 4}; Λβ2 for
Gene Ontology; rank parameters k1 and k2
Output: Consensus matrix C.
for i ∈ [1, 20] do
Initialise G1 and G2 with random values
while not |Jn − Jn−1| < ϵ do
Update S12 using equation (4.6) while keeping G1 and G2 fixed
Update G1 using equation (4.7) while keeping fixed G2 and S12
Update G2 using equation (4.8) while keeping fixed G1 and S12
end while
Compute connectivity matrix C(i) for GO terms using G2 for class assignment
end for
Compute the average connectivity matrix as: C = 120C(i)
Extract new GO term relations:
G = {(GOi, GOj) | ∀GOi,∀GOj ∈ {all GO terms} ∧C(i, j) = 1}
GO term association as the fraction of connectivity matrices in which that particular
association is observed.
4.2.10 Summary of the computational approach
Below we give a brief step-by-step summary of the work done, in order to make the
results presented in Sections 4.3.1 to 4.3.3 easier to follow.
First, we explore the relationships between the above-described interaction net-
works and the Gene Ontology (GO) annotations of the genes, and quantify the
complexities of these relationships using polynomial fittings. We observe that PPIs,
which capture the most direct interactions (physical binding between proteins) have
the relationship with GO of the smallest complexity of the three (quadratic) while
GIs, which capture very indirect interactions often along alternative pathways,86
have the relationship with GO that is the most complex of the three (5th order
polynomial). These functional complexities suggest that the macromolecules are
operating in a high-dimensional space (Section 4.3.1.1).
Second, for computational feasibility purposes, we approximate the functional
space of the cell by Euclidean space and embed the three data sets into it, seeking
insights into the cell’s functional organisation, i.e. the clustering of genes of sim-
ilar function close in space. We use the Receiver Operating Characteristic (ROC)
curve analysis to quantify the spatial separations of biological functions in each of
COEX, GI and PPI data, and the low areas under the ROC curves that we ob-
tained suggest that biological functions are never well separated in “biological space”,
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but rather are interlaced, posing a question of identification of lines of functional
cross-communication (Section 4.3.1.2).
Hence, we build upon this observation and propose a new model of the cell’s
functional organisation. We embed the data sets into Euclidean space and use spatial
overlaps between regions containing different biological function to measure the
strength of the communication lines with the spatial overlaps. This results in a
square matrix encoding all of the cell’s functional cross communication lines, which
we term the functional organisation map . We compute the functional organisation
maps for COEX, PPI and GI data, and compare them to the reference functional
organisation map computed from the semantic similarities between the genes’ GO
annotations. We observe that the functional map of COEX best fits the reference
GO-based one, followed by the GI and by the PPI maps (Section 4.3.1.3).
Because each of the three interaction data sets capture different aspect of the
cell’s functional organisation, we integrate the functional organisation maps of COEX,
GI and PPI network data into a single, unified, functional organisation map of yeast,
which best correlates with the reference GO-based map, validating the approach and
indicating the complementarity of different biological data sets in capturing cellular
functioning (Section 4.3.1.4).
To better understand differences in the functional information captured by differ-
ent molecular interaction data sets, we devise a method based on k-shell decomposition
to locate the biological functions on the biological networks, from their peripheries
to their network cores. We observe that the functional decompositions of all three
networks are biologically relevant even though they are very different from each
other. This means that in addition to producing topologically unbiased data (as we
have discussed extensively in Chapter 2), different biotechnologies producing these
heterogeneous data sets capture different, but complementary aspects of the cell’s
functional organisation that have strong biological underpinnings (Section 4.3.1.5).
Finally, in Sections 4.3.2 and 4.3.3 we demonstrate the usefulness of combining
multiple sources of biological information by applying an integration approach based
on penalised non-negative matrix tri-factorisation (PNMTF)306,307 of heterogeneous
molecular interaction data to mine new disease–disease associations, and to mine
new gene–function relationships. Starting from Disease Ontology, we revise the
links between diseases using related H. sapiens systems-level data, including protein–
protein and genetic interactions, gene co-expressions, metabolic data, drug-target
relations, and other. By fusing these data we identify several disease–disease asso-
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ciations that were not present in Disease Ontology and validate their existence by
finding strong support in the literature and significant comorbidity effects in associ-
ated diseases. We also quantify the contribution of each molecular data source to
the integrated disease–disease association model. In addition, we apply this method
to multiple Saccharomyces cerevisiae molecular interaction data with the goal of
predicting GO term annotations of unannotated genes and finding new relations
between existing GO terms.
4.3 Results and discussion
4.3.1 Data integration reveals lines of cross-functional commu-
nication in yeast
4.3.1.1 Complexity of different molecular interaction data
Both experiments described in Section 4.2.2 (i.e. raw and discretized polynomial
fits) show that PPI data have the simplest quadratic relationship with GO, while
COEX data have a cubic relationship with GO and GI data have the most complex
relationship with GO corresponding to a 5th order polynomial. Surprisingly, the
complexity of the relationships with GO relate to the “directness” of the interactions
captured by the data types. The PPI data capture direct physical bindings between
proteins and interestingly, we find that they have the simplest relationship with
GO. The COEX data capture molecular interactions that are more complex, as
they involve proteins, genes and RNAs related with gene expression, which support
our finding that these data have a more complex relationship with GO than PPI
data. Finally, GI data captures interactions between a gene and all other genes,
and many other molecules in the cell play a role that leads to phenotypical fitness
effects; and we find that GI data have the most complex relationship with GO. Also,
these functional complexities suggest that the macromolecules are operating in a
highly dimensional functional space and motivate us to study the separation of the
biological functions in the functional space.
4.3.1.2 Biological functions are interlaced in space
To measure the quality of the spatial separation of the biological functions, we
compute the Area Under the Curve (AUC) of the Receiver Operating Characteristic
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(ROC)315 by comparing the Euclidean distances between genes in the embedded
space (embedding procedure described in Section 4.2.3) against a gold-standard
classification of the genes into 14 functional groups.86 The obtained AUCs represent
the probability that in the embedded space, two randomly chosen genes belonging to
the same functional group will have a smaller pairwise distance than two randomly
chosen genes belonging to different functional groups. A large AUC value would
indicate that the functional groups are well separated in space, while a low AUC
value means that functional groups are interlaced (AUC = 0.5 is the expected result
of a random classifier).
Although AUCs detect some functional separation, with AUC = 0.591 for COEX,
AUC = 0.576 for GI, and AUC = 0.550 for PPI, the fact that they re all close to
0.5 indicates a lack of functional separation in the interaction space of all three
data sets. (Figure 4.6). This means that biological functions are interlaced in space,
and that the existing clustering methods based solely on distances between genes
in space cannot discern the cell’s functional organisation. This interlacing of the
biological functions also suggests the presence of strong communication lines between
the functions and supports our approach to characterise the functional organisation
of the cell.
 0.0  0.2  0.4  0.6  0.8  1.0
PPI
AUC = 0.5498
 0.0  0.2  0.4  0.6  0.8  1.0
COEX
AUC = 0.5944
 0
 0.2
 0.4
 0.6
 0.8
 1
 0.0  0.4  0.6  0.8  1.0
GI
AUC = 0.5763
False positive rate
Tr
ue
 p
os
iti
ve
 ra
te
 0.2
Figure 4.6. ROC curves indicate a weak separation of biological functions in
embedded space of GI, COEX and PPI networks. Area under the curve (AUC) is
given in the bottom right corner of each panel.
4.3.1.3 Mapping the functional organisation of a cell
To try to “untangle” this interlaced functional space we use the computational frame-
work introduced in Section 4.2.4. The functional communication lines that we obtain
in this way have a structured organisation, as shown by the clusters in the functional
organisation maps of PPI, COEX and GO data (blue clusters in Figure 4.7-A).
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We find that the strongest functional links in the COEX data are between DNA
replication and repair, chromosome segregation, and Golgi/endosome/vacuole sorting
functions, while the GI data show the strongest links between mitochondrial, meta-
bolic, stress response and ER-Golgi related functions. In the PPI data, the strongest
connections are signalling and stress response, mitochondrial and metabolic function,
and DNA/RNA replication and repair. All these are in agreement with known biology.
For example, in the cell’s anti-viral response, fast action involving rapid exchange of
information between the PPI network’s strongest connected functions, signalling and
stress response, mitochondrial and metabolic function, and DNA/RNA replication
and repair, is required.316 Here, the immune system relies on RIG-I-like receptor
(RLR) protein complexes (a family of intracellular pattern recognition receptors)
to recognise RNA viruses and viral replication events that take place in the cell’s
cytoplasm and to switch on an anti-viral response, thus heavily relying on PPIs
related to signalling, stress response, metabolism and RNA repair. Similarly, when
mitochondrial DNA sustains damage, it is released into the cytoplasm and is able to
trigger stress-response signalling cascade to counteract the source of damage, thereby
recruiting PPIs related to signalling, stress response, mitochondrial function and
DNA repair.
To see how well the functional organisation maps obtained from COEX, GI
and PPI data reflect the current knowledge of the cell’s functional organisation,
we compare them to the gold-standard of functional organisation, the GO, using
the approach described in Section 4.2.5 Comparing functional organisation maps
against Gene Ontology on page 102. The results suggest that the functional organ-
isation of COEX data correlates best with that of GO, with the maximum Pearson’s
correlation coefficient (PCC) of 0.72 over the 10 000 functional organisation map
comparisons, followed by that of GI, which has the maximum PCC of 0.57 over the
10 000 comparisons, and then followed by that of PPI data, which has the maximum
PCC of 0.26 over the 10 000 comparisons (the top bars of box plots in Figure 4.7-A).
When considering the average Pearson’s correlations of all statistically significant
comparisons (those with p-values ≤ 0.05), we get the same ranking (Figure 4.7-A,
median lines in box plots), which demonstrates the robustness of our approach.
These results are in good agreement with the characterisation of the complexity
of the relationship between interaction data and GO presented in Section 4.2.2: both
approaches yield the same ranking of the agreement of the interaction data with
GO, with COEX data having the best correlation with GO, followed by GI data and
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then by PPI data. The fact that the functional organisation of COEX data is in best
agreement with the functional organisation of GO is perhaps surprising, since less
than 0.5% of functional annotations in GO are inferred from co-expression patterns;
this high agreement of COEX with GO may be due to the larger size of COEX data
compared to PPI and GI data.
A                                                                                                                       B
G
I
Pe
ar
so
n’
s 
co
rr
el
at
io
n 
w
ith
 G
O
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
  PPI                   GI                   COEX      Integrated                                                                        model
In
te
gr
at
ed
 m
od
el
 ~
 α
 C
O
EX
 +
 β
 G
I +
 γ
 P
PI
 +
 δ
0.88
0.
05
   
   
   
   
   
   
   
   
   
   
   
   
 p
-v
al
ue
   
   
   
   
   
   
   
   
   
   
   
   
 5
e-
16
Figure 4.7. Summary of the functional organisation and integration results.
A — The fit of the functional organisation maps obtained from COEX, GI and PPI data to
the reference model of functional organisation obtained from GO. y-axis is the value of the
Pearson’s correlation coefficient between the functional organisation maps of the interaction
data and GO: box plots with minimum, median and maximum Pearson’s correlation values
between the 100 functional organisation maps obtained from each of the three data sets
(PPI, GI and COEX, x-axis) and the 100 reference functional maps of GO. Above each
box plot is the functional organisation map which best correlate with that of GO. The
highest correlations for the three data sets are: COEX 72% (p-value 5× 10−16), GI 57%
(p-value 5 × 10−9 and PPI 26% (p-value 1 × 10−2). The last point on x-axis shows the
fit of the Integrated Model of functional organisation maps of the interaction data with
the functional organisation map of GO (88%, p-value ≤ 10−33). B — The functional
organisation map of the Integrated Model. The functions are colour-coded as in Figure 4.4.
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4.3.1.4 Complementarity of biological data
Using the integration approach described in Section 4.2.6, we find that combining
the functional maps obtained from COEX, GI and PPI data results in the model
that is in best functional agreement with GO, achieving the Pearson’s correlation
coefficient of 0.88 (and p-value ≤ 10−20), a 15% increase over the highest-agreeing
single data source (Figure 4.7-A). That is, the best model is obtained by using all
molecular data, showing that each data set captures a complementary functional
aspect of the cell. In the integrated map, the strongest functional link is between
cell cycle progression/meiosis and signalling/stress response functions, which are
also strongly linked in the functional organisation map of COEX, but not in the
ones of GI and PPI. This association is biologically meaningful, since filamentation,
osmolarity growth, cell integrity, spore wall assembly and pheromone stress response
pathways in yeast are regulated by overlapping MAP kinase pathways.317 Surprisingly,
the integrated map strongly separates RNA processing from all other functions
except for nuclear-cytoplasmic transport, but such separations are not present in
the functional organisation maps of the three interaction data sets. While we lack
a molecular evidence for these separations, the link between RNA processing and
nuclear cytoplasmic transport is expected, since the CAP protein that protects the
5-end of a primary transcript during the RNA processing also aids in transporting
RNAs out of the nucleus.318 We further explore these functional differences in the
three omics data types in the next section.
4.3.1.5 Functional differences between molecular data
As highlighted above, the three molecular interaction data sets capture different, but
complementary functional aspects of the cell. Here, we seek to better understand
how functional organisations of the data sets differ.
A straightforward measure of similarity between two interaction data sets is
measuring the number of interactions they have in common. That is, how many
connected pairs of proteins from one network are present in another. Using our three
interaction data sets, we find that GI and PPI share only 6% of interactions, while
COEX shares 29% of interactions with GI and 60% of interactions with PPI. As only
a portion of the interactions is shared between the data sets, this means that there
is a unique informational value within each data set, which explains why combining
the data sets like in Section 4.3.1.4 gives a greater biological insight than any single
data set alone.86,262,263,271,273
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To help unveil the functional differences in the three yeast omics data sets, we
“peel” the COEX, GI, and PPI networks by performing k-shell decomposition of these
networks (see Section 3.2.2); this is done through successive pruning of a network
by first removing all nodes of degree at most one (i.e. proteins that interact with at
most one other protein in the network) and assigning them to the first layer, then
removing all nodes of degree at most two in the remaining network and assigning
them to the second layer, and so on until only nodes of degree ≥ k remain. For
the largest k for which it is not possible to continue this process and which yields a
non-empty remaining sub-network, that sub-network is called the core. We examine
the functional enrichment8 in each of these layers and in the core, and associate a
biological function to the k-shell layer that is the most enriched in it (illustrated in
Figure 4.8). We find that PPI, GI, and COEX interactions carry different, almost
complementary functional information, as evidenced by complementarity of the
functional enrichment of k-shell layers in the three data sets. Similar was observed by
Baryshnikova et al. 271 and Ryan et al. 319 , as well as by our functional organisation
maps presented in Sections 4.3.1.3 and 4.3.1.4.
Close to the core of the PPI network, where proteins densely interact, PPI
network’s layers are enriched in chromosome segmentation and protein degradation,
which occur during a short mitotic phase of the cell cycle. Close to the core of the
GI network, layers are enriched in Golgi mechanism and ER-Golgi traffic, while
the layers close to the core of the COEX network are enriched in RNA processing
and translation. In the peripheral layers, where proteins sparsely interact, PPI
network is enriched in Nuclear-cytoplasmic transport functions, while GI periphery
handles meiosis, transcription and metabolic processes. Furthermore, if we look
at the placement of specific functions in each of the three networks, such as the
ER and Golgi machinery, we find it to be peripheral in the PPI network, central
in the GI network, and placed somewhere in-between in the COEX network. A
somewhat similar pattern of functional layering in the interaction data has already
been noticed,320,321 but unlike the previously reported core-periphery functional
polarity, where only the core and the outer-most peripheral layers are functionally
enriched and where there is a large functional gap between them, our analysis shows
a full spectrum of layers, each with a unique primary function, spanning uniformly
from the core to the periphery of each interaction network.
8 p-values ≤ 0.01 after the adjustment by using Benjamini-Hochberg multiple-hypothesis testing
procedure
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Figure 4.8. Illustration of different functional layering in different molecular
interaction networks. The three networks are GI, PPI, and COEX. Each coloured arc
represents a layer of distinct biological functionality in a network, and is obtained by
k-shell decomposition of that network. The layers are colour-coded and numbered like in
Figure 4.4.
Differences in the k-shell functional layering of COEX, PPI and GI data have
biological underpinnings. For example, co-expressions are a result of gene regulatory
processes, that do not necessarily involve protein-protein bindings, e.g. the transcrip-
tional control where regulatory proteins bind to the promoting regions of genes on
the DNA. Thus, the strongly co-expressed genes located close to the core of the
COEX network (e.g. Ribosome and translation) may not correspond to proteins that
physically bind to each other, which explains why their functions appear on the
periphery of the PPI network. Similarly, genetic interactions capture genes belonging
to alternative pathways86 and such pathways may not be physically connected by
proteins binding to each other, or may not be regulated by the same regulatory
processes. Further biological explanations and implications of these diverse functional
layering in COEX, GI and PPI data are subject of future research and may become
more evident with the collection of more and better quality molecular interaction
data.
In the next two section, we study ways in which integrating molecular inter-
action data can give us new into disease–disease relationships and the functional
relationships between genes.
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4.3.2 Data integration reveals new disease–disease associations
We fuse systems-level molecular data by using the matrix-factorisation approach
described in Section 4.2.8 on page 106 to gain new insight into the current state-
of-the-art human disease classification. This large-scale data integration results in
108 highly reliable disease classes (each corresponding to a clique in the consensus
matrix, C¯; see Algorithm in Table 4.3). Size distribution of the 108 disease classes
is as follows: 60 disease classes contain 2 diseases; 31 disease classes contain 3 or 4
diseases; 9 disease classes contain 5, 6 or 7 diseases; 5 disease classes contain 8, 9 or 10
diseases; 2 disease classes contain 11 or 17 diseases; and 1 disease class contains 146
diseases. For each class we examine the associations between its member diseases to
inspect how the obtained classes align with currently accepted disease classification.
Using Disease Ontology (DO) and literature curation, we find that the 107 smaller
classes successfully capture closely-related diseases that are also placed near each
other in DO (see below for details). Also, we find that in the largest identified disease
class (i.e. the one containing 146 diseases), the most represented major disease is
cancer (31.5%), followed by nervous system diseases (14.4%), inherited metabolic
disorders (9.6%) and immune system diseases (5.5%). This class primarily contains
diseases of anatomical entity (45.2%), cellular proliferation (25.4%) and metabolic
diseases (14.3%), with other major concepts of DO being rarely represented. The
large size of this class may reflect the following underlying biases in various data
sources — its constituents represent either larger majority groups in DO, or minority
groups at a lower level of ontology:
• diseases of anatomical entity, because diseases are often described based on
tissue/organ;
• cellular proliferation, because of the heavy enrichment of cancers and the sub-
classification of these into many variant diseases, also possibly driven by rich
gene/pathway annotation around cell cycle and proliferation;
• metabolic diseases, because of significant representation of metabolic diseases and
significant understanding of metabolic pathways. Metabolic disease is a primary
focus for systems modelling and simulation, as much is known from pathways
and a wealth of omics data available.
Since the obtained distribution appears unbalanced due to one large class contain-
ing 146 disease, we further decompose that class by repeating data fusion analysis on
its disease members. This effectively gives us a multi-layer hierarchical breakdown of
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disease classes (see Figure 4.9). The large class is broken down into 10 classes (only
those observed in all 15 inferred models are taken into account; see Section 4.2.8).
The distribution of disease class sizes is: 9 disease classes with 2 or 3 diseases, and 1
disease class with 51 diseases. The diseases captured by the 9 smaller classes are:
two classes consist of cancer diseases, three consist of inherited metabolic disorders,
one contains nervous system diseases, two contain respiratory system diseases, and
the last one has cardiovascular system diseases. The largest disease class (containing
51 disease members) is further decomposed into 8 disease classes. The distribution of
disease class sizes at this level of hierarchy is: 7 disease classes with 2 or 3 diseases,
and 1 disease class with 18 diseases. The diseases captured by the 7 smaller classes
. . . 6
abetalipoproteinemia, 
lung metastasis
dysgerminoma
serous cystadenoma
factor XIII de!ciency
Plasmodium falciparum malaria
Level 3
immune system diseases
cognitive disorders
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cancer
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Figure 4.9. Multi-layered hierarchical decomposition of disease classes. Our
analysis yields 108 disease classes using the most stringent threshold for predicting disease–
disease associations. Identified classes are rather small and each class contains at most 17
diseases with the exception of the largest disease class that consists of 146 diseases (at root
layer). We further decompose the largest class by re-running the data fusion process on
set of diseases that are in the largest class in order to identify its fine-grained structure
(level one). We repeat data fusion analysis using this top-down strategy two more times
(levels two and three), which results in a hierarchical decomposition of most reliable disease
classes (as defined in Section 4.2.8 and in the algorithm given in Table 4.3).
are: two classes with immune system diseases, one class with cognitive disorders,
one class with acquired metabolic diseases, one with cancer, and the last three
were split between cognitive disorders and metabolic diseases. The largest class
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(containing 18 disease members; again, under the most stringent agreement threshold;
see Section 4.2.8) is finally decomposed into six conserved diseases (the remaining
12 diseases grouped less reliably under our stringent threshold): lung metastasis,
dysgerminoma, serous cystadenoma (cellular proliferation and cancer), abetalipo-
proteinemia (metabolic disorder), related factor XIII deficiency and plasmodium
falciparum malaria.
4.3.2.1 Evaluating disease classes through co-morbidity
A comorbidity relationship exists between diseases whenever they affect the same
individual substantially more than expected by chance. We want to know whether
diseases assigned to the same disease class by our data fusion method exhibit higher
comorbidity than diseases assigned to different classes. Hidalgo et al. 322 proposed
two comorbidity measures to quantify the distance between two diseases: a relative
risk (defined below) and Pearson’s correlation between prevalences of two diseases
(φ). A relative risk (RR) of two diseases is defined as the fraction between the
number of patients diagnosed with both diseases and random expectation based
on disease prevalence. Expressing the strength of comorbidity is difficult because
different statistical distance measures are biased to under- or over-estimating the
relationships between rare and prevalent diseases. The RR overestimates associations
between rare diseases and underestimates associations involving highly prevalent
diseases, whereas φ has low values for diseases with extremely different prevalence,
but is good at recognising comorbidities between disease pairs of similar prevalence.
We find that 66 (out of 107) disease classes have a significantly higher comorbidity
than what would be expected by chance (p-value < 0.001 with Bonferroni multiple
comparison correction applied to all p-values). We assess the statistical significance
by randomly sampling disease sets of the same size as the disease class in question,
and computing the comorbidity enrichment scores of the sampled sets according
to the two comorbidity measures, RR and φ, as proposed by Hidalgo et al. 322 The
enrichment score is then computed as the mean of comorbidity values between all
disease pairs in a disease class. For subsequent layers of hierarchical decomposition
of the largest disease class (i.e. the one containing 146 diseases), we find that: 7 out
of 10 first level disease classes have a significantly higher comorbidity (measured by
both RR and φ) than what would be expected by chance; comorbidity data was
available for only 3 out of 8 second-level disease classes, and 2 of them exhibited
significantly higher comorbidity than what would be expected by chance.
123
4 Integrating molecular interaction data
4.3.2.2 Evaluating disease classes through Disease Ontology
To see how well our fusion approach captures disease–disease associations already
present in the semantic structure of DO, we look at the overlap between 107 disease
classes (again, we perform enrichment analysis of the largest above-described class
separately, see below) and find that 79 classes have at least 80% of disease members
directly connected in DO via is_a relationship; an example of one such disease class
is given in Figure 4.10. We assess the statistical significance of such a high number
of classes being enriched in known relations from DO by computing the p-value as
follows. First, we remove all DO-related information (i.e. we remove the constraint
matrix Θ2) and then we perform the data fusion again without any prior information
on relationships between diseases. We find that such a high number of classes is
unlikely to be enriched in known relations from DO by chance (p-value < 0.001).
This result is very interesting as it indicates that DO could, in principle, be
reconstructed from molecular data only. Our findings suggest that disease clas-
sification derived from pathological analysis and clinical symptoms (DO) can be
largely reproduced by considering only molecular data. In other words, data fusion
of different types of evidence could be used to infer a hierarchy of disease relations
whose coverage and power might be very similar to those of the manually curated
DO.
The decomposition of the largest disease class yields similar results: 5 out of 9
first-level classes have their members directly linked in DO via is_a relationships; 4
out of 7 second-level disease classes have their members directly linked in DO via
is_a relationships; the third-level class of size six does not significantly overlap with
the DO graph, but is partially supported by literature.323
4.3.2.3 Finding new links between diseases
In addition to examining classes of multiple diseases, we can use our fused model to
rank individual disease–disease associations based on supporting molecular evidence,
and make novel predictions linking previously seemingly unrelated diseases. Among
all the highest-ranked disease–disease associations in the fused model (i.e. disease
pairs from the most stable classes — obtained in step 3 of Algorithm in Table 4.3 —
with less than 6 disease members), we find 14 associations not recorded in Disease
Ontology. We perform literature curation and find evidence for all 14 of the predicted
disease associations (Table C.1). Such high accuracy is due to our choice to take a
highly stringent approach that requests the association to be observed in all 15 of the
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inferred models. Comorbidity data were available for 4 out of 14 predicted disease
associations and all 4 of these disease–disease associations were found to have sig-
nificantly high comorbidity: (DOID:11198, DOID:12336), (DOID:12252, DOID:8543),
(DOID:423, DOID:13166), and (DOID:11202, DOID:11335).
crescentic glomerulonephritis
acute prolifer. glomerulonephr.
glomerulonephritis
nephritis
interstitial nephritis
kidney diseasekidney failure
urinary system disease
Figure 4.10. Example of a disease class predicted by data fusion overlaid with
the DO graph. Members of the disease class are outlined. This illustrates the ability of
data fusion to successfully capture real disease classes: diseases associated with crescentic
glomerulonephritis are presented.
4.3.2.4 Contribution of each data source to the integration model
We have seen that data fusion can successfully retrieve existing and uncover new
associations between diseases. Now we examine the contribution of each individual
data source to the final disease–disease association model. We estimate the relative
importance of each of the fused data sources in predicting disease associations by
comparing the quality of the inferred model that includes the data source, to the
quality of the model that excludes it. The measured quality is represented by a tuple
of residual sum of squares (RSS; lower values are better) and explained variance
(Evar; higher values are better; see Žitnik and Zupan 312 for details) of gene-disease
relationship matrix R12. So an increase in RSS and a decrease in Evar hinder the
quality of the inferred model, and conversely, a decrease in RSS and an increase in
Evar improve the quality of the inferred model. We find that omission of each of
the five data sources that specify interactions between genes (Θ(1)1 , . . . ,Θ
(5)
1 ) reduces
the overall quality of the model. Surprisingly, the largest model degradation is
observed in the absence of genetic interactions when Evar drops by 9.5% and RSS
increases by 13.3%. This result is unexpected, because the number of available
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genetic interactions is small (511). This may confirm the proposed importance of
genetic interactions and functional redundancy as being critical for understanding
disease evolution and for design of new therapeutic approaches.85 Although the data
set of genetic interactions is currently small, the observed interactions are more
likely to be causative as opposed to correlative and may therefore have less noise
associated, hence they appear to be more informative and have a larger importance
on relationships between diseases than other data sources. Exclusion of other sources
results in a smaller decrease in quality (Table 4.4), but nevertheless, these results
confirm that all of the fused data sources contribute to the quality of the model.
Table 4.4. Relative contribution of each data source to the fused model. Start-
ing from the configuration given in Figure 4.1, we remove individual data sources, re-run
the data fusion algorithm, and compute residual sum of squares (RSS) and explained
variance (Evar) changes for the resulting model. For example, if we remove protein–protein
interaction data (column labelled “Θ(1)1 ”), the quality of the resulting fused model drops
by 2.0% (i.e. RSS increases by 2.0% and Evar decreases by 2.0%). The column labelled
“Θ4 +R14” corresponds to the configuration in which we remove all drug-related inform-
ation from the system, while the one labelled “Θ4” indicates that only drug side-effects
information was removed.
Data source Θ(4)1 Θ
(2)
1 Θ
(3)
1 Θ
(5)
1 Θ
(1)
1 Θ4 Θ4 +R14 Θ3 Θ3 +R13
RSS increase 13.3% 6.3% 2.0% 2.0% 2.0% 2.2% 3.8% 1.0% 1.9%
Evar decrease 9.5% 4.5% 2.5% 2.0% 2.0% 1.3% 4.6% 1.8% 3.2%
4.3.3 Data integration reveals new functional relations between
genes
We apply the data fusion approach described in Section 4.2.9 to identify new GO
term relations and annotate proteins with existing GO terms by integrating multiple
independent network sources described in Section 4.2.1.3 and summarised in Table 4.2.
We find that the optimal rank parameters k1 and k2 are 58, 56, respectively (see
Section C.1 on page 237 for choice of rank parameters). We examine the contribution
of each data source to the integration model.
Our integration of the biological networks and their corresponding GDV simil-
arities results in a set of highly reliable GO term classes, represented as clusters in
a block diagonal form of the consensus matrix. In addition to this experiment, we
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also perform the same analysis on the data consisting only of biological networks
(excluding GDV similarities from our integration procedure). This allows us to
compare the clustering results of different integration models and to estimate the
importance of additional topological constraints.
To evaluate the performance of the methodology in reproducing GO term rela-
tions, we look at the overlap between cluster members and the existing GO hierarchy
and find that on average 92% of cluster members are directly connected via semantic
relations in GO. These cluster-induced GO-term relations are confirmed to be stat-
istically significant (p ≤ 0.01, computed as explained in Section 4.2.9). A slightly
lower score of 90% is achieved when considering only the network data without
GDV similarity matrices, indicating that graphlet similarity matrices contribute to
capturing relations which would otherwise be missed.
Furthermore, we examine the robustness of this result to the removal of particular
data sets. Surprisingly, we find that omission of the GDV similarity matrix of
the gene co-expression network contributes most to the predictive performance of
our algorithm, leading to the maximum of 96% of recovered GO terms. Hence,
inclusion of GDV similarity of the gene co-expression network introduces noise into
the integration procedure, wrongly guiding the clustering process which in turn results
in lower prediction performance. This is a consequence of the random GDV similarity
distribution over all genes in the gene COEX network. Given that inclusion of the
GDV similarity matrix of the COEX network impairs the predictive performance of
our algorithm and since we have shown that its exclusion has minimal effect on the
quality of the model we discard that data source from further analysis.
Surprisingly, recovering 96% of GO terms that are directly related in GO (this
is not a percentage of recovered relations between GO terms) by is_a, part_of ,
regulates, and has_part associations, indicates that the entire Gene Ontology could, in
principle, be reconstructed solely from topologies of molecular interaction networks.
Reporting this statistic is consistent with what previous studies using a similar
methodology reported.262 When we say that “96% of GO terms is recovered”, we
mean that our methodology correctly identifies a set of 96% of GO terms that contain
relations between them. This does not mean that this set is fully connected (i.e. that
each pair of GO terms in it is related). Our set of 96% of GO terms contains 78% of
all relations currently present in GO. To our knowledge, since a large part of GO is
sequence derived, this is the first confirmation that network topology and sequence
carry very similar biological information.
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To further validate the performance of the methodology in reconstruction of
GO terms, we use the gene-GO term relation matrix, reconstructed from matrix
factors: R̂12 = G1S12GT2 . Its entries indicate the annotation strength of a gene, i,
related to a GO term j, with R̂12(i, j) = 0 denoting absence of annotation, while
R̂12(i, j) = 1 denoting the highest confidence of annotation. We define GO term j∗
as a candidate to annotate gene i if the association score R̂12(i, j∗) is larger that the
mean of association scores over all known annotations of gene i. To identify only high
confidence gene-GO term predictions we pick j∗ that are in the top 5% of largest
association scores between GO term j∗ and all other genes. As before, we run our
algorithm with and without GDV similarities (we exclude GDV similarities of COEX
network, for reasons presented above). We compute the percentage of reproduced,
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Figure 4.11. Left panel — The fraction of GO terms in each of CC (cellular com-
ponent) BP (biological process) and MF (molecular function) obtained from entries of
the reconstructed gene–GO term relationship matrix obtained with and without GDV
similarities (denoted in red and yellow colour respectively). Right panel — Distribution
of correlations of genetic interaction profiles among predicted genes associated to GO
terms plotted against distributions of randomly selected gene pairs. Value of correlation,
presented here, is shifted into the positive range [0,2].
high confidence GO terms for cellular component (CC), biological process (BF)
and molecular function (MF) separately. The results are shown in Figure 4.11 (left
panel). Better results are achieved when GDV similarity matrices are included in the
prediction model. Specifically, we capture 41% of BP terms, 41% of MF terms and
48% of CC terms. The BP and MF results outperforms those of Dutkowski et al. 277 ,
while they achieve a higher percentage of reproduced GO terms in CC.
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4.3.3.1 Finding new links between GO terms
Among all the statistically significant (p ≤ 0.01) GO term association predictions,
we find 132 not presented in GO. To further increase confidence, we extract these
associations from clusters with fewer than three GO terms that are stable over
multiple factorisation runs. We find that 14 out of the 132 associations are between
GO terms that have high semantic similarity and also confirm that additional
31 associations agree with predictions of Dutkowski et al. 277. For example, term
GO:0035267 (NuA4 histone acetyltransferase complex) is predicted as a par-
ent of GO:0032777 (Piccolo NuA4 histone acetyltransferase complex), which
was also reported by Dutkowski et al. 277 and submitted to the GO Consortium for
inclusion into the ontology. Further literature curation is performed to validate the
remaining predicted GO associations, and we find literature support for another 13
of them. Hence, we validate 58 out of 132 of our predictions.
4.3.3.2 Finding new annotations for genes
The approach presented here not only identifies novel GO term association, but it also
makes highly reliable predictions for new gene–GO term relations. We predict new
functional annotation of 972 genes. Highly reliable predictions are those with associ-
ation strength in the top 5%, as described above. For instance, we predict three genes,
YDR101C, YDR49C and YNL132W, to be involved in ribosomal subunit biogenesis
(GO:0042273) and find that the same functional prediction was previously reported
through different approaches by Chen and Xu 156 and Joshi et al. 324 To validate the
972 predicted annotations we use the new, unpublished, full set of yeast’s genetic
interaction profiles from Boone Lab.325 The data consist of Pearson’s correlation
coefficients of genetic profiles between gene pairs. We create the distribution of these
correlations between newly annotated gene pairs for which we predict GO annotations.
We compare this distribution of genetic profile correlations between the same number
of randomly sampled pairs of genes (we sampled multiple times and got consistent
results). We observe higher correlations for predicted gene pairs than for random
pairs (Figure 4.11, right panel). Moreover, using two-sample Kolmogorov-Smirnov
(KS) test we show that these two distributions significantly differ (KS statistics,
D = 0.2 and p-value = 1.5×10−6). Thus, these results are highly consistent with our
predictions of new annotations. This validate our predicted GO annotations. Even
though genetic interaction profiling analysis provides evidence that our algorithm
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is able to successfully predict new gene functions, additional biological validation
would be needed for better understanding of these newly assigned functions.
4.3.3.3 Contribution of each data source to the integration model
We estimate the influence of each network on our integration model by compar-
ing the quality of the initial model (consisting of four networks and their corres-
ponding GDV similarity matrices) with the quality of the model with one data
source removed from the initial set. Models are evaluated through residual sum
of squares (RSS), RSS(R12) =
∑
ij[R12(i, j) − (G1S12GT2 )(i, j)]2, and explained
variance, Evar(R12) = 1−RSS(R12)/∑ij [R12(i, j)]2, that measure the performance
of the matrix factorisation algorithm and its ability to accurately reproduce the
gene-GO term relation matrix. Low values of RSS and high values of Evar indicate
better quality of the model.326 We find that with the removal of each of the four data
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Figure 4.12. Relative contribution of each data source to the integration model.
The contribution is measured by the relative change in residual sum of squares (RSS), blue,
and explained variance (Evar), red. Left panel — removal of a particular network and its
corresponding GDV similarity matrix. Right panel — removal of only the GDV similarity
matrix of a particular network.
sources (a network along with its corresponding GDV similarity matrix) the value
of RSS increases, while the value of Evar decreases, implying that each data source
contributes to the quality of the model. Relative increase of RSS and relative decrease
of Evar (with respect to the initial model containing all the data), computed by
removing a particular network along with its corresponding GDV similarity matrix,
are shown in the left panel of Figure 4.12. We find that the largest model degradation
is achieved with the removal of GI network and its corresponding GDV similarity
matrix. A similar result was reported in Section 4.3.2.4 Contribution of each data
source to the integration model on page 125 where we found GIs to be the most
informative data source in prediction of disease–disease associations. Exclusion of the
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gene co-expression network and its corresponding GDV similarity matrix results in
the smallest changes in RSS and Evar indicating that co-expression data contribute
the least to the quality of the model.
To examine the contribution of GDV similarities to our model, we conduct
the same experiment by removing only the GDV similarity matrix of each of the
biological networks from the initial data set. The results are shown in the right panel
of Figure 4.12. We see that GDV similarities contribute to the quality of the models.
The smallest contribution to the model, a relative increase of 0.32% in RSS, is that
of the gene co-expression network. Also, we examine contributions of all pairs of the
four networks. We confirm the observation of Dutkowski et al. 277 that a combination
of YeastNet and co-expression network contributes the least to the to the quality of
the model (RSS = 0.8%, Evar = 1%).
4.4 Concluding remarks
We untangled the functional space of a yeast cell captured by the three omics data
sets, protein-protein interactions, genetic interactions and gene co-expressions, and
showed that biological functions are differently organised in each of these data with
varying agreement to the cell’s functional organisation reflected by GO. By combining
the functional organisation maps of the three data sets into a unifying functional
organisation framework that is in higher agreement with GO than those of each
of the data set in isolation, we demonstrated complementarity of the functional
information carried in these omics data. Finally, we offered an explanation of the
functional complementarity of the three data sets.
We used GO as the gold standard of the cell’s functional organisation, although
GO is continuously being improved and re-evaluated. However, the methods intro-
duced here are generic and can be applied to any descriptors of the cell’s functional
organisation. Also, while our integration framework elucidates the cell’s cross-
functional communication lines produces functional organisation maps that are in
high agreement with the functional organisation of GO (Figure 4.7), we are still in
search of the model that can fully capture the functional organisation of the cell and
explain the lines of inter-functional cross-communication at a finer level of functional
granularity. Nevertheless, our results demonstrate that it is possible to tackle these
biological challenges even with currently available noisy and incomplete omics data.
In addition to this, we integrated a wide range of modern systems-level molecular
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interaction and ontology data in search for relationships between diseases previously
unrecorded in DO. The findings are validated through comorbidity data and literature
curation to demonstrated that such a systems-level integration can recover known
and successfully identify currently unrecorded relationships between diseases. We
also highlighted how data fusion can reconstruct GO based solely on the integration
of the topology of biological networks: we effectively captured 96% of the existing
GO term relations, and successfully identified new associations between GO term
and predicted functional gene annotations.
We showed that all available molecular data — regardless of their sparseness —
are important for effective integration. Surprisingly, we found that genetic interaction
data are the most predictive underlying factor of disease–disease associations despite
their current small size. Choosing a semi-supervised learning method gives a data
fusion approach which is less prone to over-fitting than supervised methods, i.e.
ones that make distinctions between objects on the basis of predefined class label
information. Additionally, in order to avoid over-fitting, we selected data fusion
parameters through internal cross-validation and used constraint matrices — which
express the notion that a pair of similar objects of the same type, such as a pair of
drugs or a pair of diseases, should be close in their latent component space — to
impose penalties on matrix factors. Thus, the observed reduction in model quality
when any one of the included data sets is omitted is caused by the exclusion of
complementary information provided by the data set rather than by the lack of
robustness of the model.
In this chapter, we have seen the role of data fusion in successful retrieval of
existing and uncovering of novel links between diseases, as well as in elucidating
lines of cross-functional communication and offering a unified model of the cell’s
functional organisation. Future improvements of such comprehensive integrations
of molecular data would allow better understanding of underlying mechanisms that
drive diseases and would, in turn, improve choice of medical therapy.
The variety of new biological insights presented in this chapter and in Chapters 2
and 3 inspired us to look at the applicability of network analysis in another scientific
domain. The field of systems economics has recently gained attention due to the in-
crease in the availability of financial and economic network data. In the next chapter,
we introduce a new computational framework for tracking the dynamics changes
in network wiring, and apply it to the world trade data to study the relationship
between countries’ trade links and their economic prosperity.
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Network science is built on the premise that we live in a world of inherently incomplete
and noisy data, and over the last decade it has consistently delivered new tools which
seem to be equally useful in fluid and particle dynamics as in cell biology.327 As
we have seen in previous chapters of this thesis, in biology and medicine networks
have enabled us to see past the “single cancer gene” mindset which revolved around
the premise that if only we better understood properties of a single gene, we would
be that much closer to understanding the entire system. Just like a single particle
does not characterise the flow of fluid through porous materials, and consciousness
does not spring from a single neuron, a typical disease is caused by mutations and
alterations in many driver genes and even more passenger genes,328 which is a
colossal combinatorial problem if we try to model it.
Representing financial systems as networks is an intuitive approach, and it is
far from novel.329–331 These are networks of links among financial agents, which can
describe individual buyers or sellers, brokers, dealers, investment vehicles, financial
institutions or even entire countries.332 The networks naturally evolve as the financial
situation in the world changes, creating and breaking links based on purposeful
decisions made by agents aiming to maximise their payoffs.333
New financial network analysis techniques, most of which found their first applic-
ations in system biology, are promising to aid the design of policies, increase global
efficiency and mitigate the risk of global failure by offering to change economic links
in a way which makes these networks more robust.333 As we shall see in this chapter,
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the analysis of complex networks can be applied in a financial setting with fruitful
results, despite the fact that there are still fairly limited financial data available.334
For example, a recent algorithmic concept of network controllability aims to identify
the drivers of a network: it turns out that network drivers are not necessarily the
largest players.335 On a conceptual level, this is remarkably similar to biological
concepts of driver genes and driver topology explained in Chapter 3. Given the fact
that the relevant data across different financial markets are hard to obtain, here
we focus specifically on the network of international commodity trade, which is the
most complete data set of economic relationships and covers the time period of the
past half-century. Since interactions between countries (either individual or grouped
into coalitions) are the ones generating and steering world trade, in this chapter we
introduce a new computational methodology that can give us detailed topological
insight into the dynamics of the trading patterns of countries on a micro-scale, but
also of the entire world on a macro-scale.
5.1 Motivation and previous studies
The recent economic crisis emphasises the need for a deeper understanding of the
static architecture and dynamic change of economy on a systems level.333 The
economy is an intricate ecosystem built on inter-dependencies between international
credit flows, investments, trade relations and other such financial markets; and just
like the collective role that genes play in complex diseases, the systemic financial
behaviour leads to chain reactions that are often hard to foresee, and which cannot
(again, just like complex diseases) be explained simply through the failure of a few
major players.333
Trade, as a fundamental pillar of economy, is considered an essential part of
human social organisation which goes beyond the basic exchange of goods and
services.331,336,337 It is an important interaction channel between countries and comes
as a mutually beneficial activity of economic competition between financial institu-
tions or countries; thus, the structure of the trade network is highly unlikely to be
random.329,338,339 The down side is that these channels can also help spread financial
crises,336 which are defined as “natural consequences of economic cycle change and
the fragility of the structure of debt”.340,341 One such example is the Asiatic crisis of
the late 90s, which illustrates how perturbations in the economy of one country can
have world-wide effects.342,343
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There is a growing body of literature which looks at world trade using networks
created based on real-world data, rather than based on synthetic or simulated
data.216,329,332,334–336,339,344–348 Up until the 1990s, that is, before the field of complex
networks emerged in its own right, most trade flow analyses focused mainly on basic
network statistics, such as node degrees or closeness and betweeness centralities, to
study countries’ positions and identify hubs of trade flows. For example, Smith and
White 349 used a distance algorithm to show that structure of the trade network is
tripartite, containing the core countries with higher average gross domestic product
(GDP) per capita than semi-peripheral and peripheral countries. Only in the last
decade have researchers shifted their focus to a more complex topological analysis of
trade networks, where they look at the behaviour of the system as a whole rather
than observing it in terms of its constituent parts.216,344 The main challenges in the
analysis of world trade networks are: 1) building a more complete relational data
set with historical (time-series) data, and 2) devising new tools for describing global
as well as local topological patterns.333 In this study, we offer a new computational
tool for analysing the topology of trade networks and use it to track the dynamics of
those patterns over the past half-century.
Recently, the world trade network (WTN) was analysed in a different study (see
Yaveroğlu et al. 216 for details) using a new graphlet-based framework for analys-
ing networks and showed that a country’s topological position as a trade broker
between non-trading countries is indicative of its economic prosperity (e.g. gross
domestic product, level of employment, consumption share of purchasing power
parity), whereas peripheral roles are associated with poverty. The study found
changes in crude oil prices to be correlated with changes in WTN topology, as well
as how the change in oil price has different effects on different commodities (with the
strongest being on the trade of food and live animals, explained by agriculture’s need
for oil, as well as by an increase in demand for bio-fuels as oil price increases350).
The study also showed that during a crisis a country becomes more peripheral and
less of a broker in the WTN than in economically stable periods, with the country’s
accession to the EU having a similar effect.
Motivated by the fact that this study showed how a graphlet-based approach
can find more refined topological features in a WTN than all previously used
methods,329,336,345 here we devise a new computational method which describes the
topology of the direct neighbourhood of each country to give us detailed topological
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insight into the trading links between countries.1 The method works by treating the
1-level deep neighbourhood of each node (in this case a node represents a country) as
a separate sub-network, and counting graphlets in this sub-network (which consists of
that country’s trading partners). To be consistent with previous naming conventions
for graphlet-based measures (e.g. graphlet degree distribution, graphlet degree vec-
tor), we call the resulting vector of graphlet counts a graphlet neighbourhood vector
(GNV).
5.2 Methods and data
5.2.1 Data preprocessing
5.2.1.1 World trade network (WTN)
Finding reliable economic data and constructing networks based on that data can be
a challenging task as some countries do not allow their economic indicators to be
reported, other countries impose restrictions and allow only for partial reports to be
made public, while yet other countries’ data get misreported in the process. A huge
benefit comes from the existence of historical, time-series, data.
We obtain the data from The United Nations Commodity Trade Statistics Data-
base (UN Comtrade),2 which contains the total annual international trade between
countries for the period from 1962 to 20133, i.e. per-year data covering a time span
of 52 years. UN Comtrade is currently the most reliable and complete world trade
database, categorising all trade data with respect to the type of commodity that
is being traded (e.g. Mineral Fuels, Chemicals, Food and Live Animals, Machinery
and Transport). It organises the trade data based on 10 different categorisation
standards: SITC (4 versions), HS (5 versions), and BEC. We use the Standard
International Trade Classification (SITC) Revision 1 standard as it covers the longest
time period (since 1962). The database also reports the total trade for each year,
i.e. the combined trade volume of all commodities traded in that year. Having 52
data sets available for analysis allows a much greater level of insight than a single-
year-snapshot approach.346 There were some discrepancies between the amount of
trade volume that country A reported as its import volume from country B, and
1 We thank Prof. Zoran Levnajić and Răzvan Marinescu for help with this work.
2 http://comtrade.un.org
3 We downloaded the data in 2014, so the last complete year was 2013.
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the amount that country B reported as export volume to country A during the
same period. This is a well known issue336,345 due to the above-described regulatory
restrictions that some countries enforce, and we use the approach from Yaveroğlu
et al. 216 to resolve these inconsistencies: namely, we rank the countries on how
reliable their reports have been throughout the years, and resolve any discrepancy
by taking the value reported by the country which is a more reliable reporter.
5.2.1.2 Economic indicators
In this study we use seven sources of economic indicators. Since these seven sources
contain over 2 000 individual economic indicators categorised into appropriate groups
(i.e. economic topics), we do not describe the economic indicators individually, but
we give a list of covered economic topics. Listed below are seven sources of economic
indicators with the economic and financial topics they cover:
•World Development Indicators (WDI) from The World Bank database4, which
comprises annual time-series data from 1960–2013. Topics covered in this data
set are: agriculture & rural development, health aid effectiveness, infrastructure,
climate change, poverty, economy & growth, private sector, education, public
sector, energy & mining, science & technology, environment, social development,
external debt, social protection & labor, financial sector, trade, gender, and urban
development.
• The Worldwide Governance Indicators (WGI) database5 provided by The World
Bank aggregates six broad dimensions of governance on an annual basis for the
period from 1996–2013, and the topics are: voice and accountability, political
stability and absence of violence/terrorism, government effectiveness, regulatory
quality, rule of law, and control of corruption.
• Fraser Institute’s annual Economic Freedom of the World (EFW) index6 measures
“the extent to which rightly acquired property is protected and individuals are
engaged in voluntary transactions” (James Gwartney and Robert Lawson et al.
Economic Freedom of the World: 1996 Annual Report). These are the five broad
categories that EFW reports for each country: size of government expenditures,
taxes, and enterprises; legal structure and security of property rights; access to
4 http://data.worldbank.org
5 http://www.govindicators.org
6 http://www.freetheworld.com
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sound money; freedom to trade internationally; and regulation of credit, labor,
and business. EFW uses 42 variables to construct a summary index.
• The Democracy Barometer7 measures: individual liberties; rule of law; freedom of
mobility and speech; openness of elections; checks and balance between executive,
legislative, and judicial powers; governments resources and stability; financial
transparency and absence of corruption; freedom of information; legal constraints
against women and minorities;
• The Index of Economic Freedom (IEF)8 has been reported annually since 1995 and
measures: trade freedom, investment freedom, financial freedom, fiscal freedom,
freedom from corruption, business freedom, labor freedom, and monetary freedom.
IEF also provides an overall score based on all of these freedom scores.
• The Freedom in the World9 country ratings, available annually for 1972–2013,
measures the degree of civil liberties and political rights for nation in the world.
• Global Conflict Trends (GCT), provided by The Centre for Systemic Peace10,
contains lists of all major episodes of political violence since 1946. It is an annual
data set with interstate, societal, and communal warfare magnitude scores, such
as independence, interstate, ethnic, and civil violent events and warfare.
When we obtained these data files, they came as large unstructured (raw) files of
various file-formats. We need to extract the economic indicators from those files and
place them in a data structure which would make them consistent and comparable
in our study. To extract the relevant economic indicator information and transform
them into a unified format, we perform command-line stream manipulation using
built-in Linux binaries: awk, sed, paste, tr, cut, and grep. This gives us uniformly
formatted economic indicator data.
5.2.2 Computing the graphlet neighbourhood vector (GNV)
To get insight into the local trading patterns of a country, we analyse WTN topology
using a new graphlet-based methodology. We call it the graphlet neighbourhood
vector (GNV) and use to to analyse 52 networks of international commodity exchange
(one for each year between 1962 and 2013). We do this by first computing graphlet
counts (see Section 1.4.2 Graphlets and graphlet-based heuristics on page 27) for
7 http://www.democracybarometer.org
8 http://www.heritage.org/index/about
9 https://freedomhouse.org
10 http://www.systemicpeace.org
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the 1-deep neighbourhood of each country to get that country’s GNV. The GNV
is a 29-dimensional vector containing the number of graphlets {G1, G2, . . . G29} in
the sub-network induced on the set of that country’s neighbours (and excluding
that country). We decided to exclude G0 from the count as that gives us just the
number of edges incident on the node which does not add informational value when
studying a node’s neighbourhood structure in isolation. Since Yaveroğlu et al. 216
shows that looking at correlations between orbits can carry a substantial amount of
novel information, we take the same approach here and compute the correlations
between GNVs. More formally, we create a matrix of N × 29, where N is the number
of nodes in the original network, and then perform Pearson’s correlation for each
pair of the 29 column vectors, thereby effectively creating a 29 × 29 correlation
matrix between all GNV dimensions. Finally, we perform hierarchical clustering
(Hierarchical clustering on page 217) on the correlation matrix to find clusters of
correlated graphlets, which give insight into the topological organisation of WTNs.
This process is illustrated in Figure 5.1.
5.3 Results and discussion
5.3.1 Tracking the dynamics in world trade network topology
We apply the new methodology to each of the 52 WTNs to obtain their corresponding
correlation matrices. Perturbations in topology are clearly visible by looking at how
the plotted heat-maps of these 52 hierarchically-clustered correlation matrices change
over the years (Figure 5.2). We hypothesise that stronger topological perturbations
correspond to more economically unstable periods, while an economically calmer
period is reflected through lesser topological changes. To formally quantify the
amount of change, we compute the Euclidean distance between each subsequent pair
of GNV correlation matrices, chronologically ordered and starting from 1962. The
plot is shown in Figure 5.3. We find evidence in the economic literature indicating
periods of dramatic economic change which align with the topological perturbations
discovered by our approach (high peaks in Figure 5.3). Below we give a few examples
to illustrate.
Organization of the Petroleum Exporting Countries (OPEC) is an inter-
governmental organisation created in 1960 (predominantly by Middle-East countries).
It is responsible for the oil crisis 1973–1974 which had both short- and long-term
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World trade netwrork 2013
ARG          29        201           0             2
GBR      5006     3034     6721    23597
GRC          60       114            6           19
EGY        105        295         18           22
LBY             7          77            0             0
SGP      1299     1399       538       2872
QAT             0         84            0             0
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Figure 5.1. Computation process for GNV and the corresponding correlation matrix.
A — The world trade network from 2013. B — Illustration of GNV computation for node 1 of a
simple toy example graph. GNV counts graphlets in the graph which is induced on nodes {2,3,4,5}
(the 4 nodes within the ellipse) since these are direct neighbours of node 1. Edges included in the
computation are drawn with solid lines, while excluded edges are drawn with dotted lines. The
resulting GNV of the neighbouring sub-graph of node 1 is (3, 0, 0, 1, 0, 0, 0, . . .). Node 6 is excluded
since it is not in the 1-level deep neighbourhood of node 1. C — Table of GNVs for 7 randomly
chosen countries from the 2013 trade network shown in panel A. We perform Pearson’s correlation
between each pair of GNV columns: in this example we correlate G2 and G4. D — The resulting
matrix, M , of GNV correlations. For each pair of column vectors i and j (e.g. G2 and G4 in
panel C), we compute the Pearson correlation coefficient ρ(i, j) and store it in position Mi,j of
the resulting correlation matrix. In this example bordered red are M2,4 and M4,2 (since it is a
symmetric matrix), which correspond to the two red-bordered columns in panel C. D — The full
correlation matrix corresponding to the input network from panel A. The matrix is hierarchically
clustered.
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effects on the global economy. In 1979, the (second) oil crisis, and subsequently
the “oil glut” of the early 80s, again had global consequences: war broke out in the
Middle East and many developed industrial nations around the world undertook the
initiative to reduce their dependency on oil and switched to coal, natural gas, or
nuclear power. This resulted in a huge drop in OPEC’s oil production and export
over the next couple of years and re-shaped the oil-trading landscape of the world.
1965              1970              1975             1978              1984
1985              1986              1988             1990              1991
1992              1993              1994             1995              1996
1997              1998              1999              2000              2003
2005              2006              2007              2008             2013
Figure 5.2. GNV correlation matrices for 25 randomly chosen years of WTNs.
Topological perturbations are clearly visible as graphlets clustering changes throughout
the years.
All throughout the 60s and early 70s, a multitude of international trading agree-
ments were established: European Free Trade Association (EFTA, 1960), Latin
American Free Trade Association (LAFTA, 1962), Economic Community of Central
African States (ECCAS, 1964), Caribbean Free Trade Association (CARIFTA, 1968),
and others. But the major topological change visible in Figure 5.3 is during late
80s and early 90s, which is the incubation period of globalisation: this was an
unprecedented time in history, which caused a torrential flood of new trade links to
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be opened. In early 2000s, China entered the World Trade Organisation and the
dot-com bubble collapsed.
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Figure 5.3. The plot of chronological change in world trade network. Years are
on the x-axis, normalised Euclidean distance is on the y-axis.
However, change in the trade is not necessarily a monotonically increasing func-
tion. For example, if a change at one point in history transforms the WTN from
some initial state A to some different state B, then a subsequent change (even a
number of years down the line) can either elevate the WTN into state C which is
different from both A and B, or it can return it to a state A′ which is very similar
to A; therefore, it is possible that topological perturbations effectively undo what
has been done before. By observing only the chronological change we would notice
that a change took place, but we do not know what the net effect of that change on
the resulting topology is. Hence, to observe this, more complex, effect of change over
the entire time frame, we compare topological changes on an all-by-all basis and get
a 52× 52 matrix of changes between all pairs of years (Figure 5.4). The matrix is
symmetric around the diagonal, and the first off-diagonal entries correspond to the
case of chronological change from Figure 5.3. This gives us a new perspective over
the same data, and while further studies are needed, the results seem reasonable
on an intuitive level. For example, this shows that the 5-year period leading to the
2007/2008 global crisis (the red cluster between 2002 and 2007) is very different to
anything seen before, especially to the period between 70s and mid-80s. Also, it
shows a distinct separation between the pre-90s and post-90s structure of trade (two
large blue clusters before and after that period, which indicate that the two periods
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are self-similar but different from one another). Indeed in the late 80s and early
90s, the globalisation was catalysed by new technological advances 336 which led to
the control of capital flow and the liberation of trade; the consequence of this was
that economies around the world started to become more intertwined.336 Up to now,
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Figure 5.4. The matrix of topological change in world trade network. Years are
on both axes.
we have looked at the trade network as a whole. Next, we focus on each country
individually and ask the same questions — how did its trade links change over the
years, and does that change coincide with important economic events? Figure 5.5
shows correlation matrices for some of the countries. We can see that some countries
have a lot more variation in their trade than others. This primarily holds true for
first-world countries such as USA, UK, France, and Italy; while countries like China,
Indonesia, Korea, Malaysia, Poland, Romania, Thailand, and South Africa show
a pattern of recent trade development. Although this is an expected result on an
intuitive level, we are now able to formally capture this concept and study it.
If we look at China in Figure 5.5, we can see it slowly transitioning to an open-
market economy in the early 80s and later its trade changing noticeably after it
entered the World Trade Organisation (WTO) in the early 2000s. Similarly, if we
look at Romania, we can see how its accession to the EU spurred changes in its trade.
Likewise, Finland joined the EU in 1995, and Denmark in 1973. Egypt has had a
stable economy over the past 25 years, but it began its industrialisation programme
in late 50s and early 60s (heavy industries such as iron and steel, chemical industries,
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and heavy machinery), where nationalisation reduced the importance of the private
sector so there was no stock trading, and foreign direct investment was almost
banned. After the public sector and economic performance being adversely affected
by the 1967–1973 Arab–Israeli war, from 1974–1982 Egypt introduced policies which
encouraged foreign investment by liberalising trade. The examples above provide
Switzerland                         China                                   Germany                            Denmark                            Egypt
Spain                                     Finland                                France                                  UK                                        Greece
Hong Kong                         Indonesia                            Italy                                      Japan                                   Korea
Malasya                                  Nederlands                     Norway                                Poland                                 Romania
Singapore                            Sweden                             Thailand                                USA                                     South Africa
Figure 5.5. Per-country correlation matrices and chronological change plots.
The white lines in each panel represent the plot of chronological change. For the matrices,
both axes are years in the 1962–2013 range, and for the overlaid chronological change plot,
the y-axis represents normalised Euclidean distance in the [0–1] range.
a high-level overview of how the results could be interpreted. Now, we focus on a
concrete example of OPEC countries to see the effects the 1973 and 1979 crises had
on their topology. We chose this example as we know that OPEC countries’ main
trade is oil, and knowing the precise timing of the oil crisis can easily be superimposed
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on the resulting heat-maps to verify the correctness of the results. In Figure 5.6 we
highlight 9 OPEC member countries (Kuwait, Iran, Iraq, Venezuela, Saudi Arabia,
Libya, Angola, Qatar, and Ecuador). Interestingly, all countries show an identical
distinct patch of red and yellow precisely at the time of the two oil crisis during
the 70s (the heat-map of Venezuela also shows the impact of political violence and
turmoil during the 60s, while Qatar and Ecuador were more affected by the recent
crisis than the oil crises, so the change in their 70s topology is still clearly visible
but dampened compared to the more recent change).
             ‘73     ’79                              ‘07                 ‘73     ’79                               ‘08                ‘73     ’79                              ‘08  
‘62         ‘73     ’79                              ‘07                 ‘73     ’79  ‘73     ’79                               ‘08
              ‘73     ’79                ‘73     ’79                             ‘07 ‘73    ’79
Kuwait                                      Iran                                            Iraq
Venezuela                               Saudi Arabia                           Libya
Angola                                     Qatar                                        Ecuador
Figure 5.6. Correlation matrices for the countries from the OPEC group. Axes
and white line plots are as in Figure 5.5. Due to the density of the plots, each panel’s
x-axis is labelled with just a few relevant years.
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5.3.2 The link between economic indicators and topology
Recently, Shutters and Muneepeerakul 351 showed that a country’s topological signa-
ture can be used to predict the development trajectory of that country. They define
this signature as triads (i.e. 13 possible combinations of directed three-node paths).
However, for the signature to work they need to compare it to the triad signature’s
expected frequencies in a random network which preserves the degree distribution
of the original data. The principal issue here is that the underlying connectivity
of a real-world trade network is not unambiguously reproducible,334 and therefore
it is difficult to know exactly what random model should be used as a baseline for
characterising WTNs in such a way (biological networks suffer the same problem as
described in Section 1.4.1 Network motifs on page 27). In contrast, our approach
does not rely on the existence of a priori knowledge about the underlying structure,
and computes the frequencies with which all 3-node, 4-node and 5-node sub-graphs
actually occur in the neighbourhood of each country (instead of just the variants of
a closed path of three nodes, i.e. graphlet G2). Also, while most of the published
literature is focused on the analysis of a single year’s WTN, we analyse a much
longer time span, meaning that detected patterns have to comply with that many
more constraints in order to be accepted as statistically significant.
As we have seen above, the change in WTN topology and the political stability
of the world are somehow linked. To get a better understanding of this two-way
relationship, we obtained a wide range of economic indicators, including those that
are reflective of political stability, to analyse if and how economic indicators relate to
the re-wiring that takes place inside the trade networks (see Data preprocessing on
page 136 for details on used economic indicators). Notice that there is some overlap
between the economic indicators reported by various data-collecting agencies. For
example, multiple agencies report on the financial freedom of a country, however the
way they compute these measures varies from one agency to the next and is based
on different factors, so we can potentially use this to strengthen our findings through
multiple sources.
We perform a Pearson’s correlation between the chronological change in WTN
(Figure 5.3) and the economic indicators. To account for the time needed for a
change in trade links to be reflected in the economic indicators, which need not be
during the same year, we use the following year shifts: {−3,−2,−1, 0,+1,+2,+3}.
Zero indicates that the effects of change are visible immediately but in that case we
cannot tell whether topological changes are causing indicator changes, or if it is the
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other way round. Conversely, with positive and negative shifts, we can hypothesise
that the correlation could be causational: positive shifts mean that it takes a period
of time for the topological changes to be reflected in the economic indicators, and
vice-versa for negative shifts.
Indeed, we find that, according to the Index of Economic Freedom (IEF), the
change in overall WTN topology is highly correlated with the the overall score of
economic freedom. The correlation is just below 75% (p-value = 8 × 10−4) with
the effects being visible next year (+1 shift). The parts which make up the overall
score are, as expected, all correlated with WTN topology changes (all are above
60% and a +1 shift): monetary freedom, property rights, financial freedom, fiscal
freedom, investment freedom, freedom from corruption, trade freedom, business
freedom. On the other hand, change in labour freedom seems to precede topological
changes by 3 years (70% correlation): when labour freedom rises, trade links change,
and when labour freedom drops, trade stagnates. This can be explained by the fact
that increase of labour can produce a surplus of goods and commodities which can
then be exported to other countries. Along the same lines, change in political rights
and civil liberties are felt a few years after change in WTN (shifts +2 and +3 with
correlations of 50% and 34%, respectively). We are still analysing the data and
performing computational experiments, but some of the preliminary results are given
in Tables 5.1 and 5.2.
Finally, we briefly analyse how individual countries trade links relate to their
internal economic and political situation using economic indicators. While this is
still work in progress, what we find is that there are some countries whose change
in economic indicators is preceded by the change in their trade (such as a positive
year shift in the political stability of Colombia, Brazil, Libya, Algeria, Oman, and
South Africa), and others where the change in economic indicators precedes the
change in their trade links (such as rule of law, control of corruption, and voice and
accountability in USA, France, Sweden, Australia, Russia, Ukraine, and Greece). As
we are currently focusing on the undirected network of world trade, it is unclear
whether the change in trade links is caused by the country itself (e.g. by choosing to
initiate new or stop existing trade as a result of the internal economic and financial
situation) or by other countries trading with it (e.g. by cutting off export to or
stopping import from that country). It is quite possible that both are true and
depend on the country in question. We hypothesise that it is the bigger countries
such as USA and France who control their own trade links, while the trade links of
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Table 5.1. Change in economic indicators precedes WTN topology change.
First column is the economic indicator; second column (negative year shift) is the time
period it takes for the change in economic indicators to be observed as changes in topology.
The third column, labelled ρ is the average correlation value for the years in column two.
All correlations are statistically significant with p-value ≤ 0.01.
Economic indicator year shift ρ
government consumption -3 0.74
reliability of police -3 0.77
arms import (inverse correlation) -3 0.34
freedom of foreign tourists -3 0.77
international tourism -10 0.53
computer & communication tech. imports -3, -4, . . . , -8 0.43
foreign direct investment -3, -4, . . . , -15 0.41
import of goods & services -5 0.39
household consumption expenditure -3, -2, -1 0.35
tax rate -3, -4, . . . , -5 0.42
smaller countries are externally dependent on the political and economic decisions
made by the bigger players.
For example, the trade links of Greece are influenced by the political and economic
situation within the country: control of corruption (-2, 81%, p-value = 7.9× 10−4);
government effectiveness (-2/-3, 61%/79%, p-values ≤ 0.01); political stability (-1/-2,
66%, p-values ≤ 0.01); rule of law (-3, 67%, p-value = 0.01); regulatory quality
(-1/-2, 66%, p-values ≤ 0.01); voice and accountability (-2/-3, 87%/62%, p-values
≤ 8.7 × 10−3). Since the economic troubles of the country are very well known,
it is probable that, in a more recent case, Greece’s trading partners altered their
trade links to Greece after seeing the unfavourable political and economic outlook of
Greece.
5.4 Concluding remarks
In this chapter, we study the topological change in local trade patterns of countries’
since the early 60s. We present a new computational method for network analysis
that gives insight into the local neighbourhood wiring of nodes. It does this using
a 29-dimensional vector of sub-graph structure frequencies to build matrices of
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Table 5.2. Change in WTN topology precedes change in economic indicators.
First column is the economic indicator; second column (positive year shift) is the time
period it takes for the change in topology to be observed as change in economic indicators.
The third column, labelled ρ is the is the average correlation value for the years in column
two. All correlations are statistically significant with p-value ≤ 0.01.
Economic indicator year shift ρ
economic/financial/investment/political freedom +1 0.73
gross capital formation
(from land purchases, machines, construction of roads) +5 0.38
number of coup d’etat 0, +1 0.42
fights for independence +1, +2, +3 0.49
political rights and civil liberties +2, +3 0.40
economic freedom (trade, property, business) +1 0.65
top marginal income tax +3 0.81
household consumption expenditure -3, -2, . . . , +4, +5 0.36
legal system and property rights +1 0.56
CO2 emissions
(from commercial and public services and manufacture) +3 0.35
health expenditure per capita +5 0.29
population in urban areas (inverse correlation) +4, +5, . . . , +15 0.33
population in rural areas +2, +3, . . . , +15 0.33
export of goods and services +5 0.30
merchandise exports to developing countries +5, +6, . . . , +10 0.53
electricity production +8 0.54
national net income +10 0.50
population of infants aged 0–14 (inverse correlation) +1, +2, . . . , +5 0.42
profit tax +4 0.30
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topological correlation. Constructing these matrices on top of the newly proposed
network metric is beneficial as these matrices are easily comparable using standard
distance measures such as the Euclidean distance, thereby facilitating the analysis of
a year-by-year time-series changes in the world trade network.
Similar to Chapters 2 and 3, where we studied the macro- and micro-scale patterns
of biological networks, here we use this new approach to observe change in world trade
networks on those two scales as well: 1) we study wiring patterns on a macro-scale
to see how the overall topology changed in the entire world trade networks; and 2)
we study wiring patterns on a micro-scale to see how the links changed for each
country individually. We find that the large topological perturbations coincide with
dramatic economic and financial historical events. We also look at the net effects of
topological change on the WTN and find distinct periods with similar (and different)
wiring patterns. Furthermore, we find that each country has its role in the global
trade: some countries’ trade changes as a result of their internal economic status,
while others’ internal political turmoils follow the change in their trading links.
In this study, we took into consideration the total trade between two countries, i.e.
we combined the export and import trade volume and disregarded any directionality
in those links. While this undirected approach has given us interesting insights, it
would be useful to devise a directed graphlet approach that could discern between a
country’s import and export trade patterns.
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Concluding remarks and future
directions
6.1 Summary of the dissertation
Genes and their corresponding proteins underlay the functioning of a cell. The
advances in interaction capturing technologies are producing vast amounts of com-
plex molecular data involving various types of interactions between genes. While
in the past dedicated studies allowed us to understand the chains of molecular
interactions that lead to specific biological functions and disease formation, we still
have incomplete structural knowledge of the way in which all of these molecules
interact within a cell, and we lack the models to capture the detailed functional
organisation of a cell, which would be instrumental to understanding its functioning
and involvement in disease. However, to mine new knowledge from molecular inter-
action data which is rapidly growing due to biotechnological advances, we need new
computational approaches that can cope with this increase in data complexity. In
this thesis, we presented new static, integrative and dynamic computational frame-
works for network analysis to get new insights and formulate new hypothesis about
the underlying principles which govern the structural and functional organisation
of molecular interactions, and their implications in disease. These questions are
addressed systematically using human and yeast molecular interaction data through
three complementary perspectives: a static and a dynamic study performed on
macro- and micro- levels of the interactome topology, and an integrative study which
further augments the knowledge-mining potential of static and dynamic studies done
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on a single molecular data type by combining a multitude of molecular interaction
data sets. Motivated by the results from mining data through network analysis
in systems biology, we look at the applicability of network analysis in the rising
field of systems economics, where we analyse the world trade network using a newly
developed computational technique for static and dynamic topological analysis.
The macro-scale study of the human and yeast interactomes. We have
seen that as biological data accumulates at an ever increasing rate, the depth of our
understanding of biological data has to keep up. Protein–protein interaction (PPI)
networks are currently among the most available and studied molecular interaction
data sets. A usual and intuitive way of representing these data is via graphs (or
networks) where nodes are proteins, and edges — detected through interaction-
detection wet-lab screening experiments14–18,21,22,72,352 — are placed between them.
The topology behind these biological interaction networks has been studied
for over a decade. Yet, there is no definite agreement on the theoretical models
which best describe PPI networks. Such models are critical to quantifying the
significance of any empirical observation regarding those networks. In Chapter 2,
we perform a comprehensive analysis of yeast and human PPI networks in order
to gain insights into their topology and its dependency on interaction-screening
technology. In Sections 2.3.1 to 2.3.3, we show that: (1) interaction-detection
technology has little effect on the topology of PPI networks; (2) topology of these
interaction networks differs in organisms with different cellular complexity (human
and yeast); (3) clear topological difference is present between PPI networks, their
functional sub-modules, and their inter-functional linkers; (4) high confidence PPI
networks have more geometrical topology compared to predicted, incomplete, or
noisy PPI networks; and (5) inter-functional linker proteins serve as mediators in
signal transduction, transport, regulation and organisational cellular processes, and
their role in providing communication and cross-talk between sub-cellular modules
makes them good drug-target candidates in the development of new therapeutics.
In Sections 2.3.4 and 2.3.5, we continue studying the interactome and look at
what global patterns can be uncovered if we simply trace back the human and
yeast interactome network over the past decade of PPI screening. We take a purely
topological approach and find that as our knowledge of the human interactome is
increasing through new interaction-detection studies, the interactome topology is
not only getting denser and gaining in structure (in terms of now being better fit by
structured network models than before), but also there are patterns in the way in
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which it is growing: (a) newly added proteins tend to get linked to existing proteins
in the interactome that are not known to interact; and (b) new proteins tend to
link to already well connected proteins. Moreover, the alignment between human
and yeast interactomes spanning over 40% of yeast’s proteins — that are involved
in regulation of transcription, RNA splicing and other cell-cycle-related processes
— suggests the existence of a part of the interactome which remains topologically
and functionally unaffected through evolution. Finally, we introduce a generalisation
of the clustering coefficient of a network as a new network topology measure called
the cycle coefficient, and use it to show that PPI networks of human and model
organisms are wired in a tight way so that the occurrence of large cycles in those
PPI networks is rare.
The micro-scale study of the human interactome. After performing a macro-
scale analysis of the interactome, we zoom into specific topological features on a
micro-level to get a more complete perspective. In Chapter 3 we demonstrate that
we can computationally isolate a sub-network of the human PPI network that is
topologically and functionally homogeneous and enriched in disease genes and drug
targets. Also, it contains genes that are known to drive disease formation. We
describe this in detail in Sections 3.3.1 to 3.3.5. We show that the topology of
this network is unique in the human PPI network. We call this network the core
diseasome. Since this network has a very specific structure that varies from the
remainder of the human interactome, and since it is also enriched with genes involved
in key disease mechanisms, this leads to a speculation that “driver topology” indeed
exists within our interactome and we hypothesise that it may be the wiring of
the core diseasome that leads to disease formation. Furthermore, in Section 3.3.6
we find a small sub-network, specific to the core of the human interactome and
involved in regulation of transcription and cancer development, whose wiring has
not changed within the human interactome over the last 10 years of interactome
data acquisition. In Section 3.3.7 we explore the multi-faceted nature of the the core
diseasome approach, and apply it in a number of different biological contexts, to
get new insights into the core of specific complex diseases such as cardiovascular
disease, breast carcinoma, and neuro-degenerative traits caused by aberrations in
cell’s signalling machinery.
The integrative study of the human and yeast interactomes. In Chapters 2
and 3 we studied the topological features of the yeast and human interactomes and
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how the wiring within their interactomes relates to gene function and disease onset.
However, we did this mainly through one source of biological data, namely the
network of protein–protein interactions. In Chapter 4, we further explore questions
about the functional organisation and diseases through the integration of a wide
range of additional sources of biological information (such as metabolic, signalling,
drug-target, disease and gene co-expression data).
In Section 4.3.1 we introduce a new computational framework for molecular data
integration and use it to produce a unified model of the functional organisation of
the cell. As a result, we present the first view of the cell’s functional space and
lines of inter-functional communication, based on integrating PPI, co-expression
(COEX), and genetic interaction (GI) data sets. Mapping the complete functional
layout of a cell and understanding the cross-talk between different processes are
fundamental challenges. They elude us because of the incompleteness and noisiness
of molecular data and because of the computational intractability of finding the
exact answer. We initiate the exploration of modelling, comparison and integration
of baker’s yeast omics data to elucidate its functional organisation and lines of
cross-functional communication. We do this because a comprehensive approach
to cell organisation modelling yields insights into the cell’s machinery as captured
through multiple molecular data types, which further leads to better functional
reconstruction, manipulation and reprogramming strategies.
In Sections 4.3.1.1 to 4.3.1.5, we examine COEX, GI, and PPI data, and explore
the complexity of the relationships between each of the three data sets and the
gold standard of the functional organisation, the Gene Ontology (GO). We find
that the relationship between PPI data and GO is the least complex of the three,
while GI data have the most complex relationship with GO. As these complexities
coincide with the complexities of biological processes captured by the data, from
direct physical interactions to phenotypical fitness effects, we hypothesise that all
biological entities, including genes and proteins exist in a high-dimensional functional
space. To untangle these complex relationships, we approximate the functional
space and work in it to elucidate the cell’s functional organisation captured by each
interaction data set. We quantify the separations of biological functions in this
space for each data set, and observe that biological functions are heavily interlaced,
suggesting the presence of functional cross-communication lines. Hence, we propose
a framework to identify these cross-communication lines and present them in our
new functional organisation maps. We compare the functional organisation maps of
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the three interaction data sets with the functional organisation map of GO and find
that COEX data fits GO the best, followed by GI and then PPI. To evaluate the
functional content of the interaction data, we integrate their functional organisation
maps into an unified model of yeast functional organisation that is it in better
agreement with GO than any single data set alone, showing the complementarity of
different data in capturing the cell’s functional organisation. Finally, we show that
biological functions are located in different topological regions in different interaction
data, explaining the biological underpinnings of the differences in the functional
organisation maps of different molecular interaction data.
Motivated by the quality of new insights that data integration can yield, in
Sections 4.3.2 and 4.3.3 we apply a more sophisticated machine learning algorithm
for data fusion based on the existing penalised non-negative matrix tri-factorisation
(PNMTF) algorithm, to uncover new links between diseases and new links between
gene functions. In Section 4.3.2, we identify several disease–disease associations that
were not present in the human Disease Ontology (DO) and validate them through
literature curation and by looking at comorbidity effects between the associated
disease. When searching for disease–disease associations not present in the DO, we
considered only those associations that are present in all of the inferred models.
This conservative approach gave us 14 disease–disease association predictions which
we validated through literature and comorbidity data. Relaxing the threshold of
association to be predicted, i.e. requiring a disease–disease association to be present
in 95%, 90%, 85% or fewer of inferred models yields a higher number of predicted
disease associations. For instance, we found 89 associations unrecorded by DO when
requiring them to be present in at least 80% of the models. Exploring the effects
of lowering this threshold remains a subject of future research, as we were able to
demonstrate our goal to find potentially useful associations using the most stringent
threshold. Specifically, two of the fourteen predicted disease–disease associations —
between gastric lymphoma and crescentic glomerulonephritis, and between Cushing’s
syndrome and Hodgkin’s lymphoma — demonstrate the ability of the approach
to find interesting novel links, but also highlight the fact that it is not possible
to determine causal from correlative relationships (which, indeed, in many cases
may not be known), given our current scientific understanding. Perhaps even more
interesting is the fact that the newly identified relations between diseases could,
in principle, be used to systematically update and extend DO, or even develop a
parallel data-driven hierarchy of disease relations. Utilising data fusion for disease
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reclassification, as well as linking these results with genome-wide association studies
(GWAS) is a subject open to future research.
The standard PNMTF algorithm works by taking all network data in a matrix
form and performs simultaneous clustering of genes and ontology terms, inducing
new relations between genes and ontology terms (functional annotations in GO,
or diseases in DO) and between the ontology terms themselves. To improve the
accuracy of our predicted relations, in Section 4.3.3 we extend the methodology
to include additional topological information represented as the GDV similarity in
wiring around non-interacting genes. Surprisingly, by integrating topologies of bakers
yeast’s protein–protein interaction, genetic interaction and co-expression networks,
the method reports as related 96% of GO terms that are directly related in GO.
The inclusion of the wiring similarity of non-interacting genes contributes 6% to
this large GO-term association capture. Furthermore, we infer new relationships
between GO terms solely from the topologies of these networks and validate 44% of
our predictions in the literature. In addition, the integration approach reproduces
48% of cellular component, 41% of molecular function and 41% of biological process
GO terms, outperforming the previous method in the former two domains of GO.
Finally, we predict new GO annotations of yeast genes and validate our predictions
through genetic interactions profiling.
The study of network dynamics in systems economics. Inspired by the
insights that network analysis methods can yield in the field of systems biology, in
Chapter 5 we develop a new graphlet-based computational method for analysing
network topology and apply it in an economic field to study the world trade network
(WTN). We use it to analyse static patterns and dynamic changes in trade topology
between 1962 and 2013. Using this approach, we are able to effectively capture
and accurately describe complex topological perturbation such as the effects which
globalisation has on trade links through increasing global-scale integration of markets,
services, goods, and capital, or the oil trade crisis of the 70s, and even the recent
crisis of 2007–2009. We also find the causational and correlational ties between
changes in the economic indicators of countries, such as political stability, government
effectiveness, and control of corruption, and changes in their trade topology.
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6.2 Future directions
Despite noise and incompleteness in PPI and other systems-level biological network
data, the structural properties of these networks have already given insight into
biological function and involvement in disease of individual proteins. As we gather
more network data and as the network data mature and become more reliable, we
need to ensure that our models keep representing the data well and that our methods
can cope with increased data complexity. Also, systems-level biological networks are
currently only static representations of all interactions that we have ever observed
under any condition and in any tissue, while cells are in fact dynamic, time- and
condition-dependent systems. Hence, our data and methods should be extended to
capture this systems-wide dynamics of biological processes. 284,353–357 Analysing the
human diseasome in such a systems-level dynamic network framework has a potential
to fully explain molecular, and environmental causes for onset and progression of
disease and substantially change therapeutic practises.
Putting into the context of biological network data other approaches for ana-
lysing molecular causes of disease may lead to further insight. For example, it
has been demonstrated that a significant number of diseases with early-life onset
result from defective enzyme-coding genes, whereas adulthood onset diseases are
caused by alterations in receptors and modifiers of protein function.358 Also, it
has been indicated that age-related diseases are a consequence of accumulation of
mitochondrial dysfunction over the life of an individual.359,360 Mitochondria perform
oxidative phosphorylation that produces adenosine triphosphate (ATP) by utilising
energy released from oxidation of nutrients. In this process, toxic side-products,
reactive oxygen species (ROS), are generated, which are molecules such as oxygen
ions and peroxides. Increased ROS levels may lead to significant aberration of cell
structure, specifically to DNA damage. Hence, many studies examine the role of
energy and in particular, energy deficiency in human disease.359–361 A direct link
between mitochondrial dysfunction and disease was established and it was shown
that mutations in mitochondrial DNA (mtDNA) alone are sufficient to generate
major clinical phenotypes.362 In particular, mtDNA is present in thousands of copies
in a cell and it mediates effects of the environment onto genes by accumulating
somatic mutations in post-mitotic tissue and resulting in delayed-onset of age-related
diseases.359 Another way in which the disruption of one gene was shown to trigger the
onset of a seemingly unrelated disease is through what is known as the neighbouring
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gene effect (NGE),363 which is also termed the uncertainty principle of genetics;364
it posits that the deletion of a genomic locus may affect the function of one or more
neighbouring loci,364 effectively disrupting events downstream of the unintentionally
affected loci. Hence, NGE may lead to erroneous gene annotation: it is estimated that
NGE erroneously affects the annotation of 10% of the human interactome.86 Due to
these effects, global changes in the currently available interaction maps may soon be
necessary. Nevertheless, combining even such relatively incomplete knowledge about
the dynamics of cellular processes and gene co-localisation with the intricacies of
molecular interaction networks, and analysing those data together in an systems-level
integrated way will certainly yield new biological insights.
6.2.1 New ways of looking at genetic data
The genetic interaction data that we utilise throughout this dissertation are de-
rived from the raw genetic interaction screening experiments by making correlations
between genes’ genetic profiles and deciding whether they have similar (positive) or
opposite (negative) effects on the entire system. This approach combines all genetic
interactions into a single interaction data set. However, if instead of correlating
genetic profiles we look at the raw (direct) values of genetic interactions (which have
positive/negative raw value rather than positive/negative correlation scores) and
further separate the full set of genetic interactions into essential and non-essential
interactions, we could potentially get interesting new insights. For example, when
we view the set of yeast’s genetic interactions in this way, we find that non-essential
genes participating in both positive and negative direct genetic interactions tend
to be between genes that have a similar effect on all other genes (i.e. genes with
positively correlated genetic interaction profiles). Interestingly, this is not true for
essential genes: a synthetically viable pair of essential genes tends to have (17.2%
overlap of interactions) an inverse effect on all other genes (i.e. the two genes have
anti-correlated genetic interaction profiles), while a synthetically lethal pair of es-
sential genes tends to have (with 48.8% overlap of interactions) the same effect on
all other genes (i.e. correlated genetic interaction profiles). Also, there is a small
percentage of direct interactions between pairs of non-essential genes appear in the
correlated genetic-interaction network. There is no a priori reason to expect that
two directly interacting genes would also be present in the correlation-based network.
Thus, deviating slightly form the well-established principles on how data should be
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viewed, and transforming it in new ways can potentially enhance its informational
value.
6.2.2 New application domains
Developing methods which can be successfully utilised across various data types
within one domain, or even better across multiple domains is a formidable challenge.
We have seen in Chapter 3 an example of a general methodology, subsequently applied
to diverse scientific questions; or in Chapter 4 how a data-integration approach
can give new insights in reconstructing existing and uncovering new functional
organisation in yeast, just as good as reconstructing existing and uncovering new
disease–disease relations in humans. Similarly, while understanding trade is an
important step towards understanding economy as a whole, it is still just one part of
the picture. The graphlet-based computational framework presented in Chapter 5
is easily transferable to any other type of network data. For instance, we obtained,
for the period between 2001–2009, securities data (specifically, portfolio investment),
which represent tradable financial assets such as debt securities (e.g. bonds) and
equity securities (e.g. stocks). In almost all developed countries, short-term and
long-term loans have a central position within the financial investment segment of
the economic system.346 Debt instruments, such as bonds, are considered to be less
risky investments for two main reasons: due to the lower volatility of their market
compared to equity instruments such as stock; and due to bondholders having priority
in receiving payment compared to shareholders. It is then quite possible that these
and other such differences might cause the wiring of equities’ and debts’ investment
networks to behave differently under the same conditions.
Figure 6.1 show the different effect the 2007/2008 sub-prime crisis had on long-
term and short-term debt securities (bottom left and bottom right panel): having a
similar low starting value, the network of short-term securities experienced a great
deal of topological change between 2005–2007, while the long-term securities stayed
fairly unshaken until 2008–2009. Also, the total debt securities (top right panel)
changed in 2002 and 2009, while remaining almost stationary between those two
changes. During the same period, the network of equity securities was fairly stable
in 2003 and 2008 while changing in between.
Interestingly, applying the same methodology to biological data also yields coher-
ent results. Figure 6.2 show the methodology applied to the yeast protein–protein
interaction (PPI) network. We collected all available yeast PPI data from 1982 to
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Figure 6.1. Change in GNV correlated matrices of portfolio investments from
2001–2009. Chronological change plots (green lines) are overlaid with the cumulative
change matrices (background heat maps). All four panels have the same axes as the top
left panel (i.e. equity securities): years from 2001–2009 are on both axes; the second y-axes
(for the chronological change plot; the green line) is the normalised Euclidean distance
between GNV correlation matrices. When looking at the matrix of change, ticks denote the
end of one year and the beginning of the next. When looking at the line plot, ticks denote
the change between the two years separated by that tick. Long-term and short-term debt
securities (bottom two panels) contribute to the total debt securities (top right panel).
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2012, and organised it into networks based on the year in which the interaction was
first screened, reported and added to the interactome. We can see that the biggest
change occurred between 1995 and 1997, just around the time the sequencing of the
yeast genome was completed causing an explosion of available yeast interaction data.
If we compare these results to Figure 2.5 from Section 2.3.4 The yeast interactome
is gaining structure on page 53, we can see that even the change in shape of yeast
PPI data over that period matches the results of GNV correlation changes shown
in Figure 6.2. While detailed interpretations of both of the above-given study case
results (international portfolio investments and the yeast interactome) are a subject
of future research, the examples nicely illustrate the versatility of the graphlet-based
computational approach that we introduce.
Change in yeast PPI topology
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Figure 6.2. Change in GNV correlation matrices of yeast from 1982–2012.
6.2.3 New challenges for data integration
The field of data integration is starting to see an increasing number of advanced
methodological newcomers, and will certainly continue to evolve in terms of both
improving the performance and quality of algorithms for manipulating heterogeneous
data, and extracting knowledge in more clever ways. Just as integration of various
biological data has given new insights and a new perspective into the cellular world,
the integration of data from a variety of financial markets, such as networks of
trade,216,329,337,345 products,351,365 credit,332,334,346,348 and stock prices,366 will clearly
give us a much more detailed comprehension of the economic ecosystem.
The ultimate goal is the analysis of global economic systems through integration
of heterogeneous fine-grained, time-series data, such as dynamic network data of
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trade, finance, transportation, and communication. This certainly presents a big
challenge for both network scientists and economists, and will undoubtedly bring
new value to assessing systemic risk. Still, the principal aim is not just to observe
the underlying patterns of economic trends, but to detect them in their early stages
or even better to predict them well in advance, regulate them and smoothly guide
them in the right direction before they ever materialise.
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Appendix to Chapter 2: Topological
evolution and interaction-detection
biases in the interactome
A.1 Supplementary Tables and Figures
Figure A.1. Illustration of GEO-STICKY duality in PPI networks. Protein
interactions inside functional modules of PPI networks are organised geometrically ( ) while
proteins and interactions that are shared among modules that link different functionalities
behave in a STICKY manner ( ).
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Table A.1. Yeast protein–protein interaction (PPI) networks. The first entry
(BioGRID) is the full network of PPIs from BioGRID (i.e. includes physical interactions
from all experimental evidence). The second entry (Literature curated) represents a
PPI network constructed from a set of literature curated PPIs given in Reguly et al. 125 .
All subsequent networks are derived from BioGRID based on the experimental evidence
supporting each interaction: a sub-network is comprised of interactions detected by one
screening technology.
Network num. of nodes num. of edges
BioGRID 5 891 74 642
Literature curated 1 533 2 839
Affinity capture luminescence 15 19
Affinity capture MS 4 804 43 972
Affinity capture RNA 3 932 6 369
Affinity capture western 2 923 8 237
Biochemical activity 2 054 5 469
Co-crystal structure 560 372
Co-fractionation 718 764
Co-localization 449 492
Co-purification 984 1 352
Far western 104 77
FRET 128 122
PCA 1 744 5 007
Protein–peptide 399 653
Protein–RNA 501 514
Reconstituted complex 2 176 4 112
Yeast two-hybrid 3 557 11 171
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Table A.2. Functional categories used for annotating S. cerevisiae proteins.
The 14 categories are based on the Costanzo et al. 86 functional annotation.
Label Function
A Cell cycle progression/meiosis
B Nuclear-cytoplasmic transport
C ER-Golgi traffic
D RNA processing
E Signaling/stress response
F Chrom. seg./kinetoch./spindle/microtub.
G Protein degredation/proteosome
H DNA replication & repair/HR/cohesion
I Chromatin/transcription
J Golgi/endosome/vacuole sorting
K Protein folding & glycosylation/cell wall
L Metabolism/mitochondria
M Ribosome/translation
N Cell polarity/morphogenesis
Table A.3. Basic network properties of the analysed PPI networks. The column
labels are as follows: |N |, number of nodes; |E|, number of edges; CC, clustering coefficient;
APL, average path length; ANN , average number of neighbours; d, diameter; and r,
radius.
PPI Network |N | |E| CC APL ANN d r
HI-2005 1 523 2 549 0.033 4.35 3.77 12 6
HI-2011 2 163 3 718 0.027 4.57 3.73 12 6
HI-2013 4 228 13 427 0.054 4.06 6.52 11 6
AI-1 2 634 5 529 0.050 4.75 4.48 16 8
WI-2 2 235 3 232 0.023 5.29 3.13 15 8
YI-2 1 966 2 705 0.056 5.61 3.05 14 8
FI-2 8 023 27 795 0.011 4.28 6.99 10 6
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Figure A.2. (From previous page.) Robustness of sub-modules’ random modelling
approach. Functional sub-modules A through N. The x-axis contains the percentage of
re-labelled nodes (0%–100% in increments of 10%, where 0% corresponds to the original
network) and y-axis contains the GDDA of the resulting network. The letter in brackets in
the title of each plot is the functional sub-module being modelled. Node re-labelling enables
the networks to preserve all topological properties, thus effectively testing the robustness of
the approach. The results are consistent across the three data sets (Affinity capture / mass
spec. in the left hand column, BioGRID in the middle, and yeast two-hybrid in the right
hand column): the geometricity of the functional sub-modules decreases (GEO model) as
the randomness increases (ER and ER-DD); this is more apparent on sub-modules that
have sufficient nodes and edges to be outside of the region of instability and be modelled
with confidence (e.g. BioGRID sub-modules C, G, H, J, K, L, N; Affinity capture / mass spec
sub-modules C, E, F, G, H, J, K, L, N; Yeast two-hybrid sub-modules C, D, F, H, I, J, M, N).
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A.2 Embedding the ER random network model
In Section 2.3.4 The yeast interactome is gaining structure on page 53 we saw
that embedding the yeast PPI network into 3D space produces a rather distinct
spatial structure. To test whether such a unique embedded shape is achieved due
to the intricacies of the yeast PPI network and not by chance or as a bias of the
embedding algorithm (recall that we used MDS embedding algorithm as explained
in Section 2.3.4), we compare it to the ER network model created based on the yeast
PPI network (i.e. the same number of nodes and edges). We use ER to make sure
that no topological features in the model network, other than node size and edge
density, resemble the original yeast PPI network. We take the yeast PPI network
from 2014 and generate its corresponding ER network to compare against. To
increase confidence we generate 10 ER network instances. We find that using MDS
on the network of the same size and edge density as the yeast PPI network produces
an almost perfect spherical shape in the embedded space (Figure A.3). This spatial
organisation is obtained since in purely random networks, such as ER, edges are
placed with the same probability between any two nodes (see Section 1.5.1 Random
network models on page 31), creating virtually no topological variation (e.g. hubs,
clusters, peripheral nodes), and therefore a spherical embedding shape indicates
absence of any meaningful structure.
Figure A.3. Embedded ER network models based on the yeast PPI network.
Each panel corresponds to the 3D embedding of one of ten generated ER model network
instances as explained in the main text above. Since these are model networks, points
correspond to individual nodes which we colour uniformly, unlike in Figure 2.5 where points
correspond to proteins and are coloured based on their functional annotation.
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A.3 Functional annotation of human proteins
If we want to model the functional sub-modules of the human interactome and
compare their structure with those of yeast, we first need to find an appropriate
protein-function annotation which is comparable to that given by Costanzo et al.86
for the yeast interactome. Gene Ontology (GO)94 offers a directed acyclic graph of
biological functions along with a functional annotation for the human interactome.
However, it contains hundreds of functional categories, which are based on a many-
to-many annotation scheme: many proteins have multiple functional annotations,
some proteins hundreds, or even thousands of annotations. The somewhat condensed
version of GO functional annotation, GO Slim, was still too broad for our purposes,
having around 100 functional groups and still being a many-to-many annotation
scheme. Hence, we used GO Slim categories from Mouse Genome Informatics (MGI)1
which are specifically built to be consistent with the human GO annotation, and are
much more concise than human GO Slim: there are 14 functional categories similar
to those we use for yeast. We consider this annotation to be sufficiently compact for
the purposes of modelling the human interactome and comparing the results to those
obtained when modelling the yeast interactome (see Table A.4 for a list of functional
categories).
A.4 Modelling the human interactome
As a source of human PPI data, we used Interlogous Interaction Database (I2D) 53.
The data set version is 2.0 and was obtained in October 2012. We included in the
analysis the three variants of the I2D database:
• The network containing the complete set of all experimental and predicted inter-
actions from I2D; it has 171 580 interactions between 14 745 proteins; we denote
it by I2D-FULL.
• The network containing only the high-confidence experimental interactions, where
we consider high confidence to be all interactions verified by at least two sources
from which I2D got the data (so, this excludes orthology-based predicted in-
teractions that exist in I2D-FULL, as well as low confidence interactions which
come from a single source). This network, denoted by I2D-HC, contains 41 143
1 http://www.informatics.jax.org/gotools/data/input/map2MGIslim.txt
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Table A.4. Functional categories used for annotatingH. sapiens proteins. These
14 categories are based on the functional annotation categories from MGI.
Label Function
A death
B protein metabolism
C signal transduction
D other metabolic processes
G developmental processes
I DNA metabolism
J cell-cell signalling
H cell adhesion
K other biological processes
M RNA metabolism
F stress response
N transport
L cell organization and biogenesis
E cell cycle and proliferation
interactions between 9 647 proteins. Note that each publication is considered a
unique interaction-supporting source, but in some cases it might be possible that
two publications with different PubMed367 identifiers and with a number of years
between them refer to a similar or updated version of the same initial data set
— in this case it could be argued that the detected interaction is supported by
only one rather than two sources and thus introduces a slight mismatch between
the expected and actual HC data set; however since tracking such database
changes cannot be automated, the community standardly defines high-confidence
interactions as we do here.
• The third network (denoted by I2D-PRED) contains only predicted interactions;
it has 59 898 interactions between 6 704 proteins.
Specifically, the full network of human PPIs that includes predicted interaction (I2D-
FULL) is best modelled by STICKY model followed by ER-DD and SF. Interestingly,
the fit of STICKY to the network containing predicted interactions only (I2D-
PRED) is as good as to the entire human PPI network (I2D-FULL) that contains
predicted interactions, while if we exclude predicted and low confidence interactions
from the network (I2D-HC), the fit of GEO improves (Figure A.4). Hence, the
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topology of the full human PPI network seems to be dominated by predicted and low
confidence interactions. Furthermore, analogous to the breakdown-by-function that
we performed for yeast data, we model the functional sub-networks in I2D-FULL
and I2D-HC human PPI networks. In total, this gives us 30 networks to analyse: 2
full PPI networks (I2D-FULL and I2D-HC) and 14 functional sub-networks for each
of those two full PPI networks (see Section A.3 Functional annotation of human
proteins on page 197 for details on 14 functional categories for annotating human
proteins). Unlike for yeast, we find that the full human PPI network (I2D-FULL) has
mostly STICKY functional sub-modules: 11 out of 14 functional sub-networks are
STICKY, while the remaining 3 are split between GEO and STICKY (see Figure A.5).
Interestingly, for the high confidence part of the human PPI network, the topology
of the functional sub-networks is, just like in yeast, “more geometric”: 5 out of
14 were split between GEO and STICKY, while the remaining 9 had a marginal
difference between GEO and STICKY. Hence, while the experimentally derived
human PPI network has the topology of functional sub-modules very resemblant
of that in yeast PPI network, these results may indicate that low confidence and
interlogously predicted human PPIs may need to be re-examined.
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Figure A.4. Random graph models of human PPI networks. The fit of five
random graph models to human PPI networks. The three data sets are: 1) I2D-FULL (all
interactions from I2D), 2) I2D-HC (only the high confidence subset of I2D interactions),
and 3) I2D-PRED (only predicted interactions from I2D). Data explained in the main text.
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Figure A.5. The fit of random graph models to functional sub-networks of two
human PPI networks. Top panel — full I2D network (I2D-FULL). Bottom panel —
high confidence part of the I2D network (I2D-HC). The plot for I2D-PRED is almost
identical to that of I2D-FULL, hence we do not include it.
A.5 Random network models applied to interactomes
of model organisms
We also examine the fit of random network models to the interactomes of model
organisms worm, plant, yeast and fly (Figure A.6, right panel): yeast (YI-2) is
best modelled by GEO (yeast is currently considered to have the most complete
interactome), Arabidopsis thaliana (AT-1) by GEO and STICKY, and we have seen
in Figure A.6 (left panel) that the topology of the human interactome has been
approaching GEO over the years as well. The interactomes of worm and fly are
currently best modelled by STICKY, with GEO being the second best fitting model.
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Figure A.6. Random graph models of human and model organisms’ inter-
actomes. Left panel — The fit of random network models (ER, ER-DD, GEO, SF, and
STICKY) to the three versions of the human PPI networks. Right panel — The fit of
random network models to PPI networks of model organisms and human.
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Appendix to Chapter 3: The core
of the interactome
B.1 Supplementary Figures
Figure B.1. Alternative approach to computing the core diseasome. An illus-
tration of CORE, which is obtained by intersecting kmax-core decompositions of H-ALL
(labelled as ALL-CORE and coloured blue) and H-SIM (labelled SIM-CORE and coloured
green). The 17 proteins that are in ALL-CORE but not in CORE are presented in blue
circles, and the 12 proteins that are in SIM-CORE but not in core are presented in green
circles; they do not directly physically interact, but via 57 other proteins illustrated in the
orange bubble.
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B.2 Application to complex diseases: breast cancer
study
We look into the network of human PPIs to find proteins which interact with a stat-
istically significantly high number of proteins encoded by genes that are co-amplified
with nicastrin (we call these influential interactors), and we corroborate their relation
to breast cancer. The motivation behind the neighbourhood analysis comes from
earlier successes in extracting new biological knowledge from different biological
networks using graph theoretic approaches. It has been shown that proteins which are
closer in a PPI network are more likely to perform the same function.55 In particular,
guilt-by-association approach was used to infer functions of functionally unannotated
proteins: the direct neighbourhoods of proteins in the network were examined in
search for the most common functions among annotated direct neighbours.56 Simil-
arly, the n-neighbourhood of proteins 368 and shared neighbours of proteins 369 were
used to assign functions to functionally unannotated proteins. When it comes to
exploring the connection between topology around protein and its involvement in
disease, it has been shown that directly linked proteins in the human PPI network
are more likely to cause similar diseases.12,120 Goldenberg et al. 220 used gene and
protein interaction network to identify genes which are important for initiation
and progression of lung cancer. They identified a small set of influential genes by
examining genes whose neighbours show high expression change in cancerous tissue
versus normal tissue, regardless of their own expression.
We also ask whether any of the influential interactors has a key role in the onset
of breast cancer by examining their presence in the core diseasome.370 Proteins in
this sub-network are postulated to be the key to disease onset and progression and
hence should be the primary object of therapeutic intervention. The relation between
core diseasome and breast cancer has not been examined before, and this study offers
a new perspective on that subject.
This study is a result of collaborative work and was published in Sarajlić, A.,
Filipović, A., Janjić, V., Coombes, R. and Pržulj, N. The role of genes co-amplified
with nicastrin in breast invasive carcinoma. Breast Cancer Res. Treat., 143(2):
393–401, 2014.245
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B.2.1 Methods and data
B.2.1.1 Data
We obtain the human PPI network from BioGRID 46 (data downloaded in January
2013). It contains 13 953 proteins and 97 954 interactions. We download the drug–
target data from DrugBank293 (data downloaded in January 2013). To find genes
that are co-amplified with nicastrin in breast cancer, we obtain data from breast
cancer study from cBio Cancer Genomics Portal246 (data downloaded in January
2013): “Breast Invasive Carcinoma (TCGA, Nature 2012)” study.371 The study
contains data for 825 tumor cases, out of which we took all genes that were amplified
in cases when nicastrin is amplified. Out of the 825 tumor cases in this study, there
are 40 where nicastrin is amplified.
We further analyse the following two sets of genes, which we label and define as:
• The “AMPL-stringent” set — this set contains 22 genes, including nicastrin,
that are amplified in 95% of “Breast Invasive Carcinoma (TCGA, Nature 2012)”
cases in which nicastrin is amplified: ARHGAP30, CD244, CD48, DEDD, F11R, ITLN1,
ITLN2, KLHDC9, LY9, NIT1, PFDN2, PVRL4, SLAMF6, SLAMF7, TSTD1, USF1, PEX19,
COPA, NCSTN, NHLH1, SUMO1P3, VANGL2. 16 out of these 22 genes are present in
our PPI network.
• The “AMPL-extended” set — this set contains 472 genes obtained as follows.
For each of the 10 047 amplified genes in the 40 cases when nicastrin is amplified
in the study, we ask in how many of the 40 cases it appears. 472 genes appear in
at least 19 cases, which is just under 5% of the 10 047 genes. 308 out of these
472 genes are present in our PPI network.
B.2.1.2 Finding influential interactors of amplified genes
In order to find proteins whose direct neighbourhoods are enriched in proteins
encoded by genes that are co-amplified with nicastrin, we perform the following
computation for AMPL-stringent and AMPL-extended sets separately.
First, we denote the number of proteins in our entire human PPI network as
M , and the size of AMPL-stringent (or AMPL-extended) set as K. Then, for each
protein in our PPI network, we count: 1) the number of its direct neighbours in the
PPI network, and denote it as N ; and 2) how many genes from AMPL-stringent
(or AMPL-extended) set are among its direct neighbours, and denote that by X.
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Finally, the p-value, or the probability that X or more amplified genes are found
among neighbours of the gene in question, is computed as:
p = 1−
X−1∑
i=0
(
K
i
)(
M−K
N−i
)
(
M
N
) .
We use 0.05 as a cut-off p-value to find genes in the PPI network that have among their
neighbours a statistically significantly high number of genes from AMPL-stringent (or
AMPL-extended) set. Henceforth, we refer to these genes as influential interactors.
B.2.1.3 Assessing validity of the neighbourhood analyses in an in vivo
experimental model system of nicastrin inhibition
The wet-lab validation experiments presented here were performed by out collab-
orators from the research group of Professor R. C. Coombes from the Faculty of
Medicine at Imperial College London. We include them for completeness, since they
are part of the original published article which corresponds to this section.
In order to explore whether modulation of nicastrin signaling would affect gene
expression levels of the genes revealed in the neighbourhood analyses as members
of potential pathway associated with nicastrin amplification, we analyse metastatic
tumour deposits from the in vivo xenograft model treated with anti-nicastrin mono-
clonal antibodies. After having received 5 doses of the anti-nicastrin monoclonal
antibody treatment and the control isotype IgG antibody, mice were sacrificed and
lungs were harvested for further analyses. mRNA was extracted from lung metastatic
deposits and subjected to reverse transcription to produce cDNA and subsequently
to RT-qPCR for assessment of annotated gene expression levels (Figure B.3).
Experimental metastasis model. MDA-MB-231-luc-D3H2LN cells (1 × 106)
were injected into the tail vein of female nude mice (n = 8/group). Mice were imaged
weekly from dorsal and ventral views for 5 weeks to monitor development of meta-
stasis. Anti-NCSTN monoclonal antibodies and control rat IgG were administered i.v.
at 50 mg/kg in 5-daily intervals. At termination, lungs were harvested by dissection.
Half of the lung tissue was paraffin embedded and processed for hematoxilin and
eosin, as well as Ki67 immunohistochemistry staining. The other half was snap frozen
and consequently processed for mRNA extraction and RT-qPCR assessment of the
chosen target genes.
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RNA isolation and quantitative RT-PCR. Isolation of total RNA was per-
formed using the RNeasy kit (Qiagen, UK). RNA (1g was reverse transcribed using
oligo dT and Transcriptor First Strand cDNA Synthesis Kit (Roche, UK). Quantitat-
ive PCR was performed using the SYBR Green PCR mastermix (Applied Biosystems,
UK) on a 7900HT Thermocycler (Applied Biosystems, Warrington, UK). The PCR
cycle number that generated the first fluorescence signal above a threshold (threshold
cycle, CT; 10 standard deviations above the mean fluorescence generated during the
baseline cycles) was determined, and a comparative CT method was then used to
measure relative gene expression. Primer sequences used are shown in Table B.1.
Table B.1. Primer sequences of tested genes.
Gene Forward primer Reverse primer
GAPHD 5-TGAAGGTCGGAGTCAACGGATTT-3 5-GCCATGGAATTTGCCATGGGTGG-3
S100A8 5-ATGCCGTCTACAGGGATGAC-3 5-ACGCCCATCTTTATCACCAG-3
S100A9 5-CAGCTGGAACGCAACATAGA-3 5-TCSGCTGCTTGTCTGCATTT-3
CXCL1 5-AGGGAATTCACCCCAAGAAC-3 5-CACCAGTGAGCTTCCTCCTC-3
CXCL2 5-CTCAAGAATGGGCAGAAAGC-3 5-AAACACATTAGGCGCAATCC-3
B.2.2 Results and discussion
For each of the two sets of genes described in above — namely, AMPL-stringent
and AMPL-extended — we perform functional enrichment analysis to inspect their
role in breast cancer. We check enrichment in Gene Ontology (GO) terms using
0.05 as a cut-off p-value after applying Benjamini-Hochberg correction for multiple
hypothesis testing.372 We also look at their influential interactors (described above in
Finding influential interactors of amplified genes) to try to find those which belong
to key pathways in breast cancer onset, or which might be causal to the process of
amplification. We check if any of the influential interactors are in the core diseasome
which is postulated to be the key to disease onset and progression.
B.2.2.1 AMPL-stringent: a novel amplicon in breast cancer?
We check the cytogenetic location of genes from AMPL-stringent set and find that
all of them are mapped to the q arm of chromosome 1, framing a potential novel
amplicon relevant in breast cancer patients. This finding is in line with previous
observations of relevant genes amplified and overexpressed including 6 genes on
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1q21.373 Additionally, it has already been observed in cancer studies that recurrent
gene amplifications may be required for the survival of cancer cells, and as such
constitute novel therapeutic targets. Interestingly, more than 50% of genes from the
AMPL-stringent set are localised in the cell membrane, which is a property desirable
for human drug targets.374
Since neighbourhood analysis has previously been used for predicting functions
of proteins and establishing their association with diseases, we look for proteins —
i.e. influential interactors described above — whose neighbourhoods are enriched in
genes from AMPL-stringent (i.e. genes which are co-amplified with nicastrin). Then,
based on the guilt by association principle, we hypothesise that influential interactors
might be implicated in breast cancer due to a strong presence of amplified genes in
their neighbourhoods. We identify 8 influential interactors (listed in Table B.2) and
further inspect their biological functionality:
• The protein encoded by PTPN11 gene is a member of the protein tyrosine phos-
phatase (PTP) family and we find it in the core diseasome. PTPs are known to
be signaling molecules that regulate a variety of cellular processes including cell
growth,375 cell cycle progression,376 and oncogenic transformation.377
• SH2D1A has only 9 interacting partners in the human PPI network, 3 of which are
present in AMPL-stringent. It encodes a protein that plays a major role in the
bidirectional stimulation of T- and B- cells and can modify signal transduction
pathways on activated T, B and NK cells. It is well known that cancer cells
avoid immunosurveillance, and the contribution of T-cells, B-cells and NK-cells is
significant in the progression of cancer. Signalling of cancer related immune cells
and their cross-talk with tumor cells themselves, as well as with tumor-associated
stroma, has an important role in suppressing tumor-specific immunity.378–380 This
is the reason why much effort is being invested into immune therapy of tumors, as
well as development of bi-specific monoclonal antibodies that would be directed
both at tumor-specific antigens and tumor-related immune cells.
• GTF3C1 is required for RNA polymerase III-mediated transcription.381
• SMARCA5 is involved in transcriptional regulation.382
• TOP2B gene encodes an enzyme which controls topological states of DNA during
transcription.383
• FBXO6 is part of the of a family of human F-box proteins384 which are critical for
the controlled degradation of cellular regulatory proteins.385 FBXO6 has previously
been mentioned as a cancer marker.386
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• XRCC6 is involved in the DNA double-strand break repair pathway, which is
important for genomic stability and cancer prevention. Genetic variations of this
gene are associated with increased risk of cancer, including breast cancer.387
• ELAVL1 is involved in a variety of biological processes and has been previously
linked to cancer as a highly expressed gene.388,389 It has a high potential for
diagnosing cancer, its prognosis, and therapy.390
Influential interactors PTPN11 and SH2D1A have common neighbours among the
following genes from the AMPL-stringent set: CD244, SLAMF6 and LY9 (see Table B.2).
These three genes are members of the signaling lymphocyte activation molecule
(SLAM) family. This family forms a subset of the larger CD2 cell-surface receptor
immunoglobulin superfamily which is involved in cellular activation.391 This indicates
that influential interactors PTPN11 and SH2D1A might, through these three genes,
play a role in activation of amplification process. Whether this holds true is a subject
of future research. On the other hand, influential interactors GTF3C1, SMARCA5 and
TOP2B have two common amplified neighbours: NSCTS and a transcription factor
USF1. Having in mind importance of GTF3C1, SMARCA5 and TOP2B in the transcription
process, as described above, we suggest exploring their role in co-amplification with
nicastrin through regulation of transcription.
Table B.2. Influential interactors for AMPL-stringent set. First column: influ-
ential interactors (defined in Section B.2.1.2), i.e. genes in the human PPI network that
interact with a statistically significantly high number from AMPL-stringent set. Second
column: genes from the AMPL-stringent set that are neighbours to the particular influential
interactor. Third column: p-value which denotes the probability that an influential inter-
actor would interact with the same or higher number of genes from the AMPL-stringent
set purely by chance.
Influential interactors Neighbouring proteins from AMPL-stringent p-value
PTPN11 SLAMF6, LY9 0.003878
SH2D1A CD244, SLAMF6, LY9 ≈0
GTF3C1 USF1, NCSTN 0.001520
SMARCA5 USF1, NCSTN 0.002532
TOP2B USF1, NCSTN 0.000937
FBXO6 COPA, NCSTN 0.012470
XRCC6 NIT1, USF1 0.015468
ELAVL1 PFDN2, NCSTN, PEX19, USF1, NHLH1, F11R 0.009032
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B.2.2.2 Involvement of AMPL-extended in breast cancer
In order to assess the biological significance of the genes in the AMPL-extended set,
we check its enrichment in GO terms and find it to be enriched in functions which
represent features closely related to cancer development and progression: epithelial
cell differentiation (p-value = 5.5 × 10−23), cell differentiation (p-value
= 1.9 × 10−3) and immune response (p-value = 4.6 × 10−2). Also, 117 of AMPL-
extended genes are localised on the plasma membrane (p-value = 5.4× 10−3). Recall
that membrane localisation is a desirable property of drug target genes.374 Out of 117,
the following 23 genes are already known drug targets: CD1D, CD1A, FCGR3A, SELP,
FCGR3B, CD247, S100A12, FCER1G, FCER1A, CCT3, CHRNB2, NTRK1, SV2A, S100A7,
HSD17B7, NPR1, FCGR2A, CD55, IL6R, F5, SELE, KCNN3, and SLC19A2.
Analogously to the analysis done for the AMPL-stringent genes, we check the
human PPI network for influential interactors of the AMPL-extended gene set and
identify 226 of them. We find that 6 of them (listed in Table B.3) are present in the
core diseasome, which highlights their potential importance in the onset of breast
cancer. We verify the involvement of these 6 genes in breast cancer through literature:
• SHC1 gene couples activated growth factor receptors to signaling pathways and
has already been related to breast cancer.392
• ABL1, SP1 and PTPN11 are involved in cell growth and were shown to be implicated
in breast cancer.393,394
• MDM2 is involved in tumor protein p53 pathway395 and was also linked to breast
cancer.396 Its over-expression may result in excessive inactivation of tumor protein
p53, diminishing its tumor suppressor function.
• LYN transmits signals from cell surface receptors and, among other functions,
plays an important role in the regulation of response to growth factors.397 It was
also identified as a mediator of invasion and a possible new therapeutic target,
with particular relevance to clinically aggressive basal-like breast cancer.398
B.2.2.3 A sub-network of NCSTN-co-amplified genes reveals breast can-
cer cells’ propagation inhibiting pathway
In order to inspect whether the amplified genes from AMPL-stringent and AMPL-
extended sets form pathways which might play a role in breast cancer, or specifically
the amplification process, we check whether these genes form relevant connected
components in the human PPI network. We find that the sub-network formed from
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Table B.3. Influential interactors for AMPL-extended set that are in the core
diseasome. First column: influential interactors (defined in Section B.2.1.2), i.e. genes
in the human PPI network that interact with a statistically significantly high number
from AMPL-extended set that are in the core diseasome. Second column: genes from the
AMPL-extended set that are neighbours to the particular influential interactor. Third
column: p-value which denotes the probability that an influential interactor would interact
with the same or higher number of genes from the AMPL-extended set purely by chance.
Influential Neighbouring proteins p-value
interactors from AMPL-extended
ABL1 SHC1, PSMD4, NTRK1, SPTA1, SHE, MDM4 0.029954
SP1 ARNT, ZBTB7B, TPM3, NTRK1, POGZ, IFI16, DCAF6, MEF2D, ATF6, POU2F1 0.012628
MDM2 RPS27, PBX1, MDM4, PYHIN1, HIST2H2BE, PSMD4, GORAB, S100A4, S100A6,
S100A1, S100A2
0.018274
PTPN11 MPZL1, SELE, FCGR2B, CD84, LY9, SLAMF6, FCRL3, SLAMF1 0.000445
SHC1 HSPA6, DDR2, FCGR2B, HAX1, NTRK1, SPTA1, PIK3C2B, S100A9, S100A8,
S100A7, DUSP23, MAPKAPK2
0.001060
LYN MUC1, FCGR2A, FASLG, ADAM15, SHC1 0.028959
16 AMPL-stringent genes present in our PPI network does not form a connected
component. However, when we look at the sub-network formed from a larger set
of 308 AMPL-extended genes present in our PPI network, we find that it forms 17
connected components: the largest connected component has 16 genes; the second
largest component consists of 5 genes; and all remaining components have 4 or less
genes. This means that proteins which are co-amplified with nicastrin are mostly
disconnected and scattered around the PPI network. Surprisingly, adding the 6
influential interactors of AMPL-extended set which are present in the core diseasome
(SHC1, PTPN11, LYN, ABL1, MDM2 and SP1; see Section B.2.2.2) to the sub-network,
results in merging of several of these connected components. Note that influential
interactor SHC1 was already present in the sub-network as an amplified gene from
AMPL-extended.
The largest connected component of the above-described merged sub-network
consists of 64 genes (shown in Figure B.2). Among these 64 genes, the most highly
connected are the 6 added core diseasome genes, with SHC1 being the only highly
connected one which is simultaneously co-amplified with nicastrin (i.e. present in
AMPL-extended). Even more, SHC1 is the only AMPL-extended gene in the entire
PPI network which belongs to the core diseasome. This leads to a hypothesis that
SHC1 might drive the process of amplification in cases when nicastrin is amplified.
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Figure B.2. Summary of the breast cancer study results. The largest connected
component in the human PPI sub-network formed from AMPL-extended set of genes
(shown in green) and their influential interactors which are in the core diseasome (bordered
in red). SHC1 gene is also an amplified gene. Nicastrin (NSCTN) is bordered in yellow.
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Hence, we explore pathways which may facilitate the influence of SHC1 on nicastrin
amplification.
Nicastrin shares two interacting partners with SHC1 — amplified genes S100A8
and S100A9. Proteins from the S100 family are localised in the cytoplasm and
the nucleus of a cell, and play a role in cell cycle progression and differentiation
processes. Their coding genes cluster on chromosome 1q21399 close to both NCSTN and
SHC1. Little has experimentally been confirmed in terms of direct binding partners
of nicastrin in vivo. Co-immunoprecipitation experiments show that nicastrin, a
member of the γ-secretase complex, interacts with other members of the γ-secretase
complex, and proposes transient interactions between nicastrin’s substrate-binding
DYIGS domain (located on the extracellular portion of the protein) and substrates
of the γ-secretase.400 Our sub-network analysis suggests that proteins S100A8 and
S100A9, as interacting partners of nicastrin, might be involved in a pathway that
plays a role in the amplification process. The members of the S100 protein family
are commonly up-regulated in tumors which is associated with cancer progression.401
Cellular processes, that these proteins are involved in, range from proliferation,
chemoattraction of immunomodulatory cells, control of cellular actin-dynamics and
tubular-dynamics, etc. S100A8 and S100A9 are implicated in the metastatic process
facilitating the homing of tumor cells to pre-metastatic sites, particularly within the
lung parenchyma. They also increase the motility of circulating cancer cells, deemed
the culprits of disease relapse.
All this suggests that oncogenic signaling through nicastrin may feed into the
pro-metastatic functions of S100A8 and S100A9 in breast cancer. Our hypothesis,
therefore, is that attenuating nicastrin signaling will impinge on the S100A8/9 sig-
naling axis, providing a mechanism of inhibiting metastatic engraftment at the
secondary site and propagation of cancer cells therein. Given the fact that growth
of metastatic disease, still inadequately controlled by current therapies, inevitably
results in patients’ death, identifying targets that control this process is of paramount
importance. In support of our hypothesis, performing experiments as described in
Assessing validity of the neighbourhood analyses in an in vivo experimental model
system of nicastrin inhibition on page 206, we show that anti-nicastrin monoclonal
antibodies used for treatment of a breast cancer metastatic model to the lungs,
potently inhibit S100A8/9, as well as their downstream effectors CXCL1 and CXCL2
(Figure B.3).
Based on the above validation of the role of two interacting partners of SHC1 in
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Figure B.3. Relative fold change in gene expression levels. Relative fold change
of S100A8, S100A9, CXCL1 and CXCL2 gene expression levels in the excised lung metastasis
of animals treated with the rat IgG control and anti-nicastrin monoclonal antibody, in
the in vivo metastatic model of MDA-MB-231 cells inoculated through the tail vein of
BalbC nude mice. Gene expression levels in n = 4 animals per group were analysed and
compared.
breast cancer, the hub properties of all 6 core diseasome genes (SHC1, PTPN11, LYN,
ABL1, MDM2 and SP1), and the fact that those 6 genes could play a role in activation
of the amplification process (discussed in Section B.2.2.2), we propose to further
experimentally explore the involvement of the remaining 5 core diseasome genes in
breast cancer.
B.2.3 Conclusion
Many studies using comparative genomic hybridisation have highlighted sites of
DNA amplification in cancer that might harbour novel oncogenes. Here, we show
that nicastrin is amplified in a subset of breast cancers, and we identify a set of 22
genes co-amplified with nicastrin in at least 95% of cases in a large patient cohort
available on cBio Cancer Genomics Portal. We confirm that all 22 genes from the set
are located on the chromosome 1, proposing existence of a novel amplicon in breast
cancer tissues. Using functional siRNA screening approach, we plan to assess the
relative contribution of each of the genes pertaining to this amplicon towards breast
cancer cell proliferation and invasion. The relevance of nicastrin in these oncogenic
processes has already been validated in multiple in vitro and in vivo experimental
approaches.
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We further explore a set of top 5% co-amplified genes and find that statistically
significant number of them is found in the plasma membrane. Among them we find
genes that are already known to be drug targets. Also, a statistically significant
number of amplified genes is involved in biological processes closely related to cancer
development and progression.
To study the key proteins involved in breast cancer, we refer to the core diseasome
(Chapter 3) since it contains therapeutically relevant genes which are known to
trigger disease onset. We find core diseasome genes which interact with a statistically
significantly high number of genes co-amplified with nicastrin, and show that they
have already been linked to breast cancer, indicating that they might play a key role
in the onset of this disease. We identify SHC1 as the only gene co-amplified with
nicastrin which is present in the core diseasome. SHC1 is involved in the highest
number of interactions among genes co-amplified with nicastrin, which suggests its
high influence in nicastrin co-amplification. We identify a link between nicastrin
and SHC1 which involves S100A8 and S100A9 genes, and postulate that S100A8 and
S100A9 genes, as interacting partners of nicastrin, may be implicated in a pathway
significant for breast invasive carcinoma progression. In support of this hypothesis
we experimentally show that anti-nicastrin antibodies inhibit S100A8 and S100A9
genes and their downstream effectors CXCL1 and CXCL2, not only confirming our
bioinformatics analysis, but also identifying a downstream signaling mechanism of
nicastrin in breast cancer cells.
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B.3 Application to complex diseases: cardiovascular
disease study
This study addresses an important, but difficult problem, and presents an approach
that combines multiple methods in a novel way. We extract the key cardiovascular
disease (CVD) genes that are enriched in drug targets and driver genes and that have
a large overlap with the core diseasome. We validate a over 70% of our predicted
CVD-related genes in the literature.
This study is a result of collaborative work and was published in Sarajlić†, A.,
Janjić†, V., Stojković, N., Radak, D. and Pržulj, N. Network topology reveals key
cardiovascular disease genes. PLoS One, 8(8):e71537, 2013.253
B.3.1 Methods and data
B.3.1.1 Data
Human PPI network. We use the human PPI network data from the Interologous
Interaction Database (I2D) version 2.053 and remove all self-interactions, as well as
any low confidence (originating from only one source) and predicted interactions. To
further reduce noise in the PPI network, we remove all proteins of degree less than 4
since their low connectivity may be a result of a lack of experiments performed for
detecting their interactions, i.e. they may be involved in false negative interactions.
The resulting human PPI network has 82 649 interactions between 7 551 proteins.
CVD-related genes. We obtain the list of genes involved in CVDs from two
sources to increase coverage: (i) Disease Ontology Lite (DOLite)144 and (ii) path-
ways from KEGG,292 downloaded in September 2012. The list includes genes
related to the following CVDs from DOLite: aortic-aneurysm, atherosclerosis, brain-
ischemia, cardiovascular-disease, cerebrovascular disorder, heart-disease, heart-failure,
intermediate-coronary-syndrome, ischemia, moyamoya-disease, pseudoxanthoma-
elasticum (which later may result in the form of premature atherosclerosis), stroke,
Takayasu’s-arteritis, thrombophilia, thrombophlebitis, vascular-dementia, vascular-
disease, and vasculitis. The list CVD-related KEGG pathways consists of: hy-
pertrophic cardiomyopathy, arythmogenicright ventricular cardiomyopathy, dilated
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cardiomyopathy, and viral myocarditis. This results in the set of 656 CVD-related
genes, out of which we analyse 423 genes that are present in our human PPI network.
Drug–target data. We download the drug–target data from DrugBank.293 There
are 1 245 drug targets in our PPI network, among which 199 are known CVD genes.
B.3.1.2 Clustering methods
Note that the success of a particular clustering method is data-dependent402 and
discussing the reasons for different performance of different clustering methods is
beyond the scope of this study.
Hierarchical clustering. This method creates a dendrogram that represents a
cluster tree, which is a multilevel hierarchy meaning that clusters at one level of the
hierarchy are joined into a cluster at the next level.403,404 The process of creating
clusters starts by assigning each node to its own cluster and follows by finding the
closest pair of clusters to merge into a single cluster. We specify the closeness between
a pair of nodes by their GDV similarity. If there are many closest pairs, a single
pair is chosen randomly. Next, the algorithm computes the closeness between the
newly formed cluster and each of the old clusters as the average of GDV similarities
between the nodes of the clusters. Again, the closest pair of clusters is merged into a
single cluster. This process is repeated until all nodes are clustered into one cluster.
In order to create the desired number of disjoint clusters it is necessary to cut the
hierarchical tree at some point. We denote the minimal number of clusters that are
obtained with a cut by KH .
k-medoids clustering. A medoid is a node in a cluster whose average distance
to all other nodes in the cluster is minimal. The algorithm randomly picks KKM
nodes as cluster medoids and assigns all remaining nodes to KKM clusters.405,406
Each node is assigned to the cluster with the medoid minimally distant from the
node in question. Ties are broken randomly. Then, in each cluster, a new medoid
node is found with respect to the nodes of the cluster. All non-medoid nodes in the
network are then reassigned to new KKM clusters with these new medoids. These
steps are repeated until the same set of nodes is chosen as cluster medoids.
Statistical significance of clusters. For each cluster obtained by using each of
the clustering methods described above, we compute the enrichment in CVD-related
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proteins. We compute the probability (p-value) of obtaining this or higher enrichment
purely by chance. The p-value is computed by using the hypergeometric cumulative
distribution as follows. We denote the number of genes in the human PPI network
with M , the number of genes that are involved in CVDs with K, and the size of the
cluster in question with N . The p-value, or the probability that X or more disease
genes will be found in the cluster by chance, is computed as follows:
p = 1−
X−1∑
i=0
(
K
i
)(
M−K
N−i
)
(
M
N
)
We apply Benjamini-Hochberg false discovery rate (FDR) correction372 on the res-
ulting p-values in order to take into account a possibility of obtaining significant
p-values in a large number of experiments purely by chance. We report such corrected
p-values. Sensible cut-offs for p-values are in the range from 10−2 to 10−8, depending
on the size of data.407 We use the p-value of 0.01 as a cut-off to define clusters
statistically significantly enriched in CVD-related genes.
First, we apply Hierarchical clustering to our PPI network. In different runs of
the algorithm, we choose the minimum number of resulting clusters KH to be: 50,
75, 100, 200, 500, 700, 1000 and 2000. These numbers are chosen to cover different
sizes of clusters in order to identify the optimal size at which the enrichment in
CVD genes would occur. Unfortunately, the obtained clusters were not statistically
significantly enriched with CVD genes, indicating that this methods cannot be used
to find clusters of CVD-enriched genes purely from the topology of the PPI network.
On the other hand, k-medoids method did produce clusters of proteins statistically
significantly enriched in CVD genes. The number of medoids (and therefore clusters),
KKM , that we used were: 50, 75, 100, 200, 300, 500, 700 and 1000. KKM values
larger than 1000 caused clusters to be too small for any statistical analyses. The
obtained clusters depend on the initial random choice of medoids, as previously
explained. Hence, for each value of KKM mentioned above, we repeat the experiment
five times. To increase coverage, we take a union of genes that are found in enriched
clusters for all five experiments per choice of KKM . As a result, in CVD enriched
clusters we identify gene sets shown in Table B.4.
To find the “most important” CVD genes, we apply one additional filter: we seek
CVD genes that can be found in the intersection of the obtained clusters of genes
(for all different values of KKM). We find 10 such genes (listed in Table B.5) and
analyse them further.
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Table B.4. Clusters enriched in CVD genes.
# of clusters, KKM 50 75 100 200 300 700
# of CVD genes 86 48 54 75 13 17
# of non-CVD genes 572 282 282 277 40 23
Comparison to other approaches. We check that same results could not have
been obtained using simpler network-based approaches, we compare our approach
with baseline network topology based ones to justify the use of GVD similarity in
our analysis.
When we examine clustering of proteins in the PPI network based only on the
degrees (i.e. connectivity) of the nodes in the network, this method fails to identify any
clusters statistically significantly enriched in CVD genes. Since a guilt-by-association
approach based on protein interactors (neighbours) has become a relatively standard
approach, we try to use that to identify key CVD genes; we look for enrichment in
CVD genes among the neighbours of each CVD gene in the network. There are 134
CVD genes that interact with sets of genes enriched in CVD genes. Therefore it may
be expected that these 134 CVD genes could be key for disease onset and therapy,
but this is not a case as the set of 134 genes is not enriched in the driver genes, nor
does it have a statistically significant overlap with the core diseasome and kmax-core
of the PPI network. Hence, guilt-by-association can not be used to define key CVD
genes.
To verify that our methodology did not produce enriched clusters purely by chance,
we randomised the topology of the PPI network respecting the degree distribution
and performed the above described analysis on randomised networks. We repeated
the randomisation 30 times both for k-medoids and hierarchical clustering. This did
not yield any clusters enriched in CVD genes, which shows that specific topology
around genes in the PPI network is a major contributor to identifying key CVD
genes and making predictions.
Note that analysis of all CVD genes and prediction of new ones has not previously
been done using solely network topology. That is, our study is the first to use only
topology to examine importance of CVD genes and predict new ones.
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B.3.2 Results and discussion
B.3.2.1 Identifying key cardiovascular disease genes
By using GDV similarity between proteins in the human PPI network, we clusters pro-
teins with similar wiring around them in the PPI network (see Section 1.4.2 Graphlets
and graphlet-based heuristics on page 27 for GDV similarity). Some clustering meth-
ods, such as k-nearest neighbours (KNN), produce overlapping clusters, while others,
such as k-medoids, or Hierarchical clustering, produce clusters with non-overlapping
sets of elements. We use a method that produces non-overlapping clusters to avoid
enrichments in clusters that are due to cluster overlap. Also, since the choice of the
best clustering method is heavily data-dependent, we try multiple methods (described
in Clustering methods on page 217). This gives us a consensus of 10 stable CVD
genes (i.e. they appear together in multiple clustering runs). These 10 genes are
given in Table B.5.
To investigate the importance of these 10 CVD related genes, we find the core
of the human PPI network (computed like in Section 3.2.3, but on a human PPI
from a different source) and check if these 10 genes are in it. We find 44 proteins
in the intersection between the core of our human PPI network and the set of 423
known CVD genes, with all 10 of our genes present in them. The p-values for this
to occur using the hypergeometric cumulative distribution with respect to entire
human PPI network and with respect to 423 CVD-related genes are 7.5× 10−14 and
5.5× 10−11, respectively. Also, by using the same k-core decomposition approach
used in Section 3.2.3, we find the core of the PPI sub-network consisting only of
CVD related genes and we check whether our 10 genes of interest appear in that
core. The connected CVD sub-network has 362 proteins, and its core consists of 43
genes, again with all 10 of our CVD genes present in it (p-value = 2× 10−10 with
respect to the 362 CVD proteins).
Since the core of the PPI network is known to contain driver genes and drug
targets,370 we examine if any of the 10 genes are among the 15 known driver genes,
or are drug targets.85,229–231 We find that 3 of the 10 key CVD genes (ABL1, CTNNB1,
and EGFR) are among the 15 known driver genes (p-values are 7.5× 10−7 with respect
to entire PPI network, and 1.85×10−4 with respect to 423 CVD genes). We find that
6 of the 10 key CVD genes are among the 1 245 known drug targets that are present
in the human PPI network. Table B.6 lists 6 key CVD genes that are known drug
targets and number of drugs from DrugBank that target them (p-value = 0.0023).
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Table B.5. 10 key cardiovascular disease genes. First column lists the ten key CVD
genes. Second column has the GO terms that the genes are significantly enriched in and
that correspond to biological functions that the three drug mechanisms of interest rely on.
Third column shows CVDs associated with the genes.
gene GO term cardiovascular disease
ABL1 intracellular signaling cascade,
signal transducer activity
viral myocarditis
SHC1 intracellular signaling cascade,
signal transducer activity
atherosclerosis
SP1 enzyme binding trombophlebitis
AR intracellular signaling cascade,
intracellular receptor-mediated signaling pathway,
signal transducer activity
atherosclerosis
CTNNB1 intracellular signaling cascade,
intracellular receptor-mediated signaling pathway,
enzyme binding,
signal transducer activity
arythmogenic right ventricular
cardiomyopathy
FYN intracellular signaling cascade viral myocarditis
ACTB enzyme binding arythmogenic right ventricular
cardiomyopathy,
hypertrophic cardiomyopathy,
viral myocarditis,
dilated cardiomyopathy
HDAC5 heart failure
EGFR intracellular signaling cascade,
enzyme binding,
signal transducer activity
trombophlebitis,
stroke
ESR1 intracellular signaling cascade,
intracellular receptor-mediated signaling pathway,
signal transducer activity
stroke,
atherosclerosis,
cerebrovascular disorder
Table B.6. 6 known drug targets among the 10 key cardiovascular disease
genes. First column lists the six genes, and the second column has the total number of
drugs that are known to target each one.
gene AR ESR1 ABL1 CTTNNB1 FYN EGFR
# of drugs 40 61 11 1 2 10
221
B Appendix to Chapter 3: The core of the interactome
We check our key CVD genes against the actual core diseasome (from Sec-
tion 3.2.3), which is computed on PPI network from a different source to check the
robustness of our findings (i.e. that the results are not data set dependent). Indeed,
we still find 8 out of 10 key CVD genes (p-value = 9.9× 10−15): SHC1, EGFR, ABL1,
CTNNB1, ESR1, AR, SP1, HDAC5 (Figure B.4).
B.3.2.2 Predicting new cardiovascular disease genes
Using the same clustering approach as above, we identify 17 genes not currently
known to be involved in CVDs that appear in the clusters which are enriched in
CVD genes. All 17 genes shown in Table B.7) are statistically significantly similar
to known CVD genes in terms of GDV-based similarity computed on their 4-node
deep neighbourhoods like described in Section 1.4.2 Graphlets and graphlet-based
heuristics on page 27. To validate our predictions, perform literature curation using
CiteXplore1 and find the following.
CREBBP gene is mentioned in relation to pathophysiological changes in cerebral
vessels predisposing to stroke.408 Gerzanich et al. 408 study three models of human
conditions associated with stroke: chronic angiotensin II-hypertension, chronic nicot-
ine administration and oxidative endothelial injury. All three models show significant
up-regulation of expression of proliferative cell nuclear antigen (PCNA) in arterioles
in situ, which is associated with increased activation of the nuclear transcription
factor, phospho-cAMP response element binding protein (phospho-CREB). It is shown
that dilated cardiomyopathy tissues contain elevated levels of p53 and its regulators
MDM2 and HAUSP (p-value ≤ 0.01) compared to non-failing hearts.409 Also, regula-
tion of MDM2 is critical in cardiac endocardial cushion morphogenesis during heart
development.410 Chen et al. 411 show that down-regulation of HDAC1 gene and the
modifications on histone 3 lysine 4 (H3K4) and H3K9 significantly affect microRNA-
29b expression in the context of signalling regulation of microRNA-29b, which is
connected to novel mechanisms for cardiovascular diseases.
Aneurysms-osteoarthritis syndrome is a newly discovered autosomal dominant
syndromic form of thoracic aortic aneurysms and dissections, that is characterised
by the presence of arterial aneurysms and tortuosity, mild craniofacial, skeletal and
cutaneous anomalies, and early-onset osteoarthritis. It is caused by mutations in the
SMAD3 gene.412 It is known that aggressive cardiovascular phenotype of aneurysms-
osteoarthritis syndrome is caused by pathogenic SMAD3 variants.413 Also, SMAD2
1 http://www.ebi.ac.uk/citexplore/
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dysregulation is associated with thoracic aortic aneurysms.414 Inhibition of SMAD2
phosphorylation preserves cardiac function during pressure overload.415 JUN gene is
linked to different types of mitral valvular disease, including mitral regurgitation and
mitral stenosis.416 It is shown that c-Jun mRNA are significantly upregulated in
patients with mitral stenosis compared with those with mitral regurgitation and that
phosphorylated c-Jun N-terminal kinase in the mitral regurgitation group of patients
is significantly greater than that in the mitral stenosis group (p-value ≤ 0.001).
Proper expression of MYC in cardiac fibroblasts and myocytes is essential to cardiac
angiogenesis, therefore MYC is required for proper coronary vascular formation.417 It
is shown that SRC protein regulates focal adhesion protein function, which influences
contractility of vascular smooth muscle.418 This also points to novel therapeutic
approaches to CVDs, in terms of targeting SRC protein.418 BRCA1 is an essential
regulator of heart function.419 BRCA1 and MYC are also driver genes85(see Figure B.4).
Inhibition of EP300 can neutralise deficiency of KLF15 which is shown to be a mo-
lecular link between heart failure and aortic aneurysm formation.420 Tp53 is known
to be involved in the functioning of the cardiovascular system421 and is one of
the candidate genes associated with proatherogenic and inflammatory processes in
chronic kidney disease (CKD) whereby Zawada et al. 422 point to new therapeutic
strategies in CKD-associated atherosclerotic disease. GRB2 was shown to play a role
in the signalling pathway for cardiac hypertrophy and fibrosis.423
We found no literature evidence of CVD link for genes IKBKG, HSP90AA1,
HSP90AA2, PIK3R1, YWHAZ, and YWHAQ, but due to the high literature validation
score of our CVD gene predictions (over 70% of our predictions are successfully valid-
ated in the literature), we predict that these genes are also involved in the processes
related to cardiovascular diseases. Two of these genes (PIK3R1 and HSP90AA1) are
part of the core diseasome, as shown in Figure B.4. PIK3R1 is associated with cancer
and over-nutrition, while HSP90AA1 is associated with Alzheimer’s disease, cancer,
eating disorder, herpes, and Fanconi’s anemia.
B.3.2.3 Therapeutic properties of key and predicted genes
The most common mechanisms by which drugs work are: (1) antibiotics, which dis-
rupt bacterial cells causing them to die, or interfere with their essential reproduction
machinery; (2) replacement drugs, which work by replacing substances missing from
the body; (3) enzyme-acting drugs, which modify the enzymatic activity; (4) receptor-
acting drugs, that either deliberately trigger cell surface receptors to activate the
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Table B.7. 17 predicted CVD genes. First column lists the seventeen predicted CVD
genes. Second column has the GO terms that these genes are significantly enriched in and
that correspond to biological functions that the three drug mechanisms of interest rely on.
Third column shows CVDs associated with the genes. Third column shows the PubMed
ID(s)367 of the supporting reference.
gene GO term PubMed ID
CREBBP receptor binding, signal transduction 14724353
MDM2 enzyme binding 18375498,
22821713
HDAC1 enzyme binding 22226905
SMAD3 enzyme binding, receptor binding, enzyme linked receptor protein
signaling pathway
22167769,
22633655
SMAD2 enzyme binding, receptor binding, signal transduction, intracellular
signaling cascade, enzyme linked receptor protein signaling pathway
20829218,
22049534
JUN,
c-JUN
signal transduction, response to drug, enzyme linked receptor protein
signaling pathway.
22664133
BRCA1 enzyme binding, receptor binding, signal transduction, intracellular
signaling cascade
22186889
MYC 22402364
SRC signal transduction, intracellular signaling cascade, enzyme linked
receptor protein signaling pathway
22287273
EP300 receptor binding, signal transduction, response to drug 20375365
tp53 enzyme binding, signal transduction, intracellular signaling cascade,
response to drug
23074332,
22189267
GRB2 receptor binding, signal transduction, intracellular signaling cascade,
enzyme linked receptor protein signaling pathway
12639989
IKBKG signal transduction, intracellular signaling cascade
HSP90AA1,
HSP90AA2
signal transduction
PIK3R1 enzyme binding, receptor binding, signal transduction, intracellular
signaling cascade, enzyme linked receptor protein signaling pathway
YWHAZ signal transduction, response to drug
YWHAQ signal transduction, intracellular signaling cascade
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signalling machinery, or bind to those receptors to prevent ligands from performing
their intended function; and (5) inter-cellular transport altering drugs, which modify
the flow of molecules to and from a cell, thus changing their chemical composition
and hijacking communication channels. Currently, therapeutic treatment of CVDs is
achieved through drug mechanism types (3), (4) and (5), 424–426 while (1) is argued
to have non-beneficial, or even harmful effects in treatment of CVDs.427 This means
that to be a CVD drug target, a protein would need to have a biological function
that would facilitate the workings of the three above-mentioned drug mechanism
types, (3), (4) and (5).
We compute Gene Ontology (GO) terms enrichments for the set of 17 predicted
and 10 key CVD proteins. We upload each gene set separately to DAVID and
use the entire set of human genes as a background set. We consider GO terms
that correspond to enrichments with p-values ≤ 0.05 after applying Benjamini-
Hochberg false discovery rate (FDR) correction and find that the 10 key CVD
genes are enriched in the following GO terms which correspond to biological func-
tions that the three drug mechanisms discussed above rely on: intracellular
signalling cascade, intracellular receptor-mediated signaling pathway,
signal transducer activity, and enzyme binding. We list these GO terms with
their corresponding genes in Table B.5. We find that the 17 predicted genes are
enriched with the following GO terms which correspond to biological functions that
the three drug mechanisms discussed above rely on: intracellular signalling
cascade, signal transduction, enzyme linked receptor protein signalling
pathway, response to drug, enzyme binding, and receptor binding. We list
these GO terms with their corresponding genes in Table B.7. We also check 199
known drug targets among CVD genes and find that they are statistically significantly
enriched, with p-values ≤ 0.05, in biological functions that we list in Tables B.5
and B.7. This indicates that our methodology identifies important drug targets.
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Figure B.4. Summary of the cardiovascular study results. The core diseasome
from Figure 3.4 is overlaid with the results of this study. Green nodes are the Key CVD
Genes (from Table B.5), which are in the core diseasome. Blue nodes are predicted CVD
genes (from Table B.7) that we validated in the literature and that are in the core diseasome.
Red nodes are non-validated CVD gene predictions (from Table B.7) that are in the core
diseasome. Triangular nodes are drug targets. Driver genes are bordered in red.
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B.4 Network analysis of the new G-protein-coupled
receptor interactome
We performed a network analysis of this new GPCR interactome by looking at it in
the context the the entire human PPI network, as well as looking at it on its own.
This analysis showed a sub-network of the entire human PPI network constructed
from the signalling pathways in which the new GPCRs are involved forms a “spine”
through the PPI network in the sense that almost all other proteins in the human
PPI network are directly linked to it. In graph theory, this phenomenon is called
domination (explained in Section B.4.1.6 Dominating sets on page 230). Considering
this, we can interpret the sub-network as follows: the new interactions participate in
cellular processes where information has to be sent quickly to all parts of the cell
(i.e. PPI network); otherwise, the structure of the network would have been different.
In addition, we find that this sub-network has different structural and functional
characteristics to the rest of the human PPI network, and is rich in protein complexes
(even though it is constructed using only curated pathways). We also find that the
core of the the new GPCR network — with 68% of the its proteins expressed in
the brain — is enriched in neuro-developmental disorders, diseases of the nervous
system, and mental disorders.
B.4.1 Data preparation
B.4.1.1 Human PPI network
We analyse a subset of the human PPI network obtained from the Interologous
Interaction Database (I2D) version 2.0.53 This subset comprises high confidence inter-
actions, verified by at least two experimental sources. It contains 41 143 interactions
among 9 647 proteins. In the text below, we refer to this subset as I2D.
B.4.1.2 Building of the GPCR interactome
We received the GPCR interactome data from our collaborators in September 2012.
The data set contains 997 unique interactions between 699 proteins, including 368
membrane proteins (approximately 37% of the interactome). The intersection of this
GPCR network and the I2D PPI network contains 31 out of the 50 GPCR baits
(62%) and 401 out of 651 (61.5%) preys. Hence, a large portion of the baits and
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preys was already present in I2D. However, out of the 996 interactions captured by
the new GPCR screen, only 1 was already present in I2D, so 99.8% of the GPCR
interactions are novel. The proteins from the new GPCR screen are also involved in
120 interactions with proteins of the I2D network that are not in the new GPCR
screen. Comprehensive network analysis of the GPCR interactome identified topo-
logically important proteins in the network, the core nodes, which are significantly
enriched for nervous system diseases and may play key roles in cell signalling. These
results point to the value of the interactome for understanding disease mechanisms
and identifying clinically relevant proteins and signalling pathways. A significant
number of the bait GPCRs are already targeted by drugs (30 of 50 proteins, p-value
≤ 3.0× 10−9 relative to all proteins). These drugs comprise a variety of categories,
such as vasodilator, antiparkinson and andidepressive agents, and affect diverse organ
systems, including nervous, cardiovascular, and respiratory.
B.4.1.3 Signalling pathways and construction of G-PATH
We collect signalling pathway data from two sources: 1) Reactome2, curated with
stable IDs, and 2) Nature’s Pathway Interacting Database, which is curated by
National Cancer Institute (NCINature PID)3. The union of these two databases
comprises 240 pathways. Out of these 240 signalling pathways, we find all those that
contain at least one of the proteins from the new GPCR screen. We form a sub-graph
of the I2D network that contains all proteins from these pathways (so it also contains
all proteins from the new GPCR screen as well) and we preserve all interactions
from I2D between these proteins, as well as include the new GPCR interactions. We
call this network G-PATH and it contains 20 438 interactions among 4 739 proteins;
recall that the I2D network has 41 143 interactions among 9 647 proteins, so G-PATH
has about half of its proteins and interactions but, as we demonstrate below, it has
different structure, function, and protein complex content from the rest of the I2D
network.
B.4.1.4 Gene Ontology
We use Gene Ontology (GO) data version 1.1.3488 from September 2012. This
ontology is represented as a directed acyclic graph (DAG) and defines 38 115 unique
terms out of which 24 669 belong to the biological process (BP) category which
2 http://www.reactome.org/
3 http://pid.nci.nih.gov/
228
B.4 Network analysis of the new G-protein-coupled receptor interactome
is the one we focus on. Every gene–term relation is labelled by an evidence code
that supports it. GO contains a total of 21 evidence codes, out of which 8 are
experimentally obtained or curated, and 11 are inferred through computational
analysis. These codes and their descriptions are given in Table B.8.
Table B.8. Gene Ontology evidence codes and their descriptions. The first
two columns contain evidence codes and descriptions of experimentally obtained or cur-
ated annotations. The second two columns contain evidence codes and descriptions of
computationally inferred annotations.
Code Experimental/curated evidence Code Computationally inferred evidence
EXP experiment ISS sequence or structural similarity
IDA direct assay ISO sequence orthology
IPI physical interaction ISA sequence alignment
IMP mutant phenotype IBA biological aspect of ancestor
IGI genetic interaction IBD biological aspect of descendant
IEP expression pattern ISM sequence model
TAS traceable author statement IGC genomic context
IC curator IKR key residues
IRD rapid divergence
RCA reviewed computational analysis
IEA electronic annotation
We performed two types of GO analyses: one, using all evidence codes from
Table B.8, and the other using only gene annotations supported by the 8 experi-
mentally validated codes in column 1 of Table B.8. In the first analysis, there are
13 082 genes annotated with 12 454 GO terms out of which 8 228 are in the BP class.
In the second analysis, there are 8 323 genes annotated with 7 305 GO terms out of
which 4 645 are in the BP class. Since there were no significant discrepancies between
results obtained from these two analyses and the experimental subset is less likely to
contains false positives, in the main text we present the results from experimentally
validated annotations.
B.4.1.5 GO slim
The slimming of Gene Ontology terms represents cutting-down the full GO DAG
into a smaller subset of terms which help give a broader overview of the ontological
content by mapping low-level, fine-grained terms onto their parents. This is useful
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for summarizing the resulting annotations in a more concise way. We use the Generic
GO slim DAG developed by the Gene Ontology Consortium 280 which contains 148
selected higher-order GO terms. In addition, to further refine our GO results so that
we are left with just the most relevant biological descriptors, we exclude annotations
that are linked to only one gene in the entire human PPI network as these are more
likely to be lower confidence annotations.
B.4.1.6 Dominating sets
A dominating set of a network is defined as the set of nodes in a network such that
all nodes are either in it or adjacent to it (i.e. direct neighbours of nodes in the
dominating set). Hence, a dominating set is positioned in the network to allow rapid
reaching of all parts of the network. For example, dominating sets are used in city
planning: fire stations are positioned along roads that form a dominating set in the
network of city roads, so that fire trucks could reach any part of the city quickly. By
analogy, a dominating set in a PPI network would allow for rapid propagation of
signal throughout the cell. Finding a dominating set of minimum size for a given
network is another computationally intractable problem, so heuristics are sought. It
was shown that proteins in a dominating set of the human PPI network constitute
the “spine” of the PPI network: this dominating set was found to be statistically
significantly enriched with disease, ageing, and proteins participating in signalling
pathways428.
B.4.2 Results and discussion
B.4.2.1 GPCRs as the signalling “spine” of the human interactome
Inspired by the graph-theoretic properties of dominating sets, we test whether the
network structure of the GPCR interactome is designed so that inter- and intra-
cellular signals can spread efficiently throughout the human PPI network; i.e. whether
rapid signal propagation is somehow imprinted into the network structure. We do this
by constructing the G-PATH sub-network as described in Data preparation on page
227. Indeed, we find G-PATH to have such network structure. It is an almost-perfect
dominating set within the I2D network: proteins in G-PATH together with proteins
directly linked to them constitute 91% of the proteins of the I2D network — only
911 proteins are not in the union of G-PATH and their first neighbours in I2D. If
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we add the second neighbours to this union, then only 41 proteins (≈ 0.3%) remain
outside the union of G-PATH with its first and second neighbours in I2D.
The above described observation that G-PATH acts as a “spine” (almost a
dominating set, where “almost” may be due to noise that is still present even in
the high confidence version of any PPI network) of the I2D network is further
corroborated by noticing that the diameter (the maximum distance between any two
nodes in the network) of I2D is 13 while it is 11 in G-PATH. Since the diameter in
G-PATH is only 2 smaller than in I2D, this means that G-PATH is “elongated” along
I2D network. The diameter of REST (remember that REST is obtained by removing
from I2D network all G-PATH proteins along with their interactions) is 15, so it
is increased when compared to I2D, meaning that it is G-PATH that contributes
to bringing proteins “closer together” (and hence increasing the speed of signal
transduction) in the human PPI network.
B.4.2.2 Perfect separation of biological function
Next, we find the statistically significant enrichment of Gene Ontology (GO) terms
in the G-PATH and REST sub-networks (see Gene Ontology on page 228 for details).
We test for enrichment of GO’s biological process (BP) terms by using p-value cut-off
of 0.01. The enrichment was computed using hypergeometric distribution after which
the Benjamini-Hochberg statistical correction for multiple hypothesis testing was
applied to control for the expected proportion of incorrectly rejected null hypotheses
(i.e. to minimise the false discovery rate). This yielded 1 991 enriched GO terms
in G-PATH, and 438 in REST. The sets of terms enriched in G-PATH and REST
are completely distinct, that is, there is no overlap between the biological processes
enriched in these two sub-networks. This shows that pathways in which the new set
of GPCR interactions is involved play a very specific role in the cell which is distinct
from the rest of the network.
B.4.2.3 Biological processes of the “spine”
Since the results of the GO term enrichment analysis give us thousands of GO terms,
we further apply GO slimming over the obtained sets of enriched GO terms (see GO
slim on page 229 for details). This produces 49 higher-level annotations for G-PATH
and 22 for REST.
The GO Slim enrichments in I2D are taken as baselines, that is, as reference points
for comparing what is obtained from GO Slims of G-PATH and REST sub-networks.
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G-PATH’s enrichment in signal transduction terms clearly increases, for obvious
reasons (that is how we constructed G-PATH). Apart from signal transduction,
when compared to the baseline, the G-PATH sub-graph has increased enrichment
in immune system process, cell death and biosynthetic process terms, while
its cellular protein modification process involvement dropped by roughly 13 .
On the other hand, REST sub-network is enriched in terms that seem to describe
the supporting the machinery for transducing signals, i.e. transport GO terms (also
called carrier proteins/membrane transport in some versions of the Slim classi-
fication). The cellular protein modification process increases from a 26.72%
baseline in I2D to 57.83% in REST. It is interesting that REST also has increased
involvement in cellular protein modification process, ribonucleoprotein
complex assembly, cellular component assembly.
Another noticeable change is in the immune system process term, where it goes
from a baseline of 5.64% up to 12.30% in G-PATH, while at the same time dropping
down to 0.60% in REST. Table B.9 summarises these biological processes.
Table B.9. Summary of change in enriched GO Slim terms. A green arrow (↑)
signifies that the enrichment of functionality has increased compared to the baseline and a
small red arrow (↓) denotes a decrease in enrichment of that particular biological process.
GO term G-PATH REST
signal transduction ↑ ↓
immune system process ↑ ↓
cell death ↑ ↓
catabolic process ↑ ↓
growth ↑ ↓
biosynthetic process ↓ ↑
small molecule metabolic process ↓ ↑
vesicle-mediated transport ↓ ↑
anatomical structure formation involved in morphogenesis ↓ ↑
cellular protein modification process ↓ ↑
cellular component assembly ↓ ↑
pigmentation ↓ ↑
The structure of the “spine”. To get insight into the structure of G-PATH
and REST, we compare them to different random network models. We construct
random model networks with the same number of nodes and edges as described in
Section 1.5.1 Random network models on page 31, and find that G-PATH is best
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modelled with STICKY, while REST is best modelled by GEO network model (with
no overlap in standard deviations). Hence, there is observable structural difference
between REST and G-PATH. Why is this the case? We try to answer below.
First, we note that proteins of G-PATH network participate in 1 602 protein
complexes, while proteins of REST participate in 485 protein complexes. The
intersection between the two sets of protein complexes (those with proteins in G-
PATH and those with proteins in REST) is 406 complexes, so 1 196 complexes are
characteristic of G-PATH only, while 79 are characteristic of REST. In G-PATH,
1 588 proteins participate in 1 602 complexes, while in REST 502 proteins participate
in 485 complexes.
Next, proteins of G-PATH have higher degrees than proteins of REST, but the
shapes of their degree distributions are similar, so it might be expected that both
networks would be best modelled by the same network model (Figure B.5, left panel).
However, proteins in G-PATH that participate in complexes participate in many
more complexes than those in REST. In particular, the largest number of complexes
that a protein from G-PATH participates in is 61, while in REST that number is
26. In G-PATH, 16 proteins participate in more than 27 complexes, while none
of the proteins from REST participate in 27 or more complexes (Figure B.5, right
panel). Hence, the structure of REST is “more uniform” (the uniformity of structure
is a characteristic of GEO model) than the structure of G-PATH in the sense that
G-PATH has many more and higher linked hubs, which is characteristic to STICKY
model (and STICKY models G-PATH the best, while GEO models REST the best,
as described above). These findings fit in perfectly with the results on the duality of
PPI network structure from Chapter 2 Biotechnological biases and the growth of
interactome data, specifically Section 2.3.2 on page 48 and Section 2.3.3 on page 52.
B.4.2.4 The core of the GPCR interactome
We searched for GO term enrichments in new GPCR interactome and only found
the expected ones, such as signal transductions. Hence, we wanted to dig deeper
into the structure and function of GPCR network. Since we have seen in Chapter 3
that the core of the human PPI network is not only topologically and functionally
homogeneous, but also enriched in disease genes, drug targets and driver genes, we
found the core of GPCR network and analysed proteins in it.
We perform k-shell decomposition of the GPCR network (kmax = 4, i.e. there exist
4 levels of pruning) and find that its core contains 25 proteins with 68 interactions
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Figure B.5. Degree distribution and protein complexes in the GPCR network.
Left — The degree distribution of G-PATH and REST networks. Right — The number
(x-axis) and size (y-axis) or protein complexes in G-PATH and REST networks.
between them. Out of these 25 proteins, 13 are baits and 12 are preys (the entire
GPCR network and its core are shown in Figure B.6). The core is enriched (p-value
≤ 0.01) in proteins involved in the following diseases: attention deficit hyperactivity
disorder, weight gain, bipolar disorder, antipsychotic agent-induced weight gain, at-
tention deficit disorder/conduct disorder/oppositional defiant disorder, schizophrenia,
weight loss, obesity, mood disorders, tardive dyskinesia, and personality traits. 17
out of these 25 proteins are expressed in brain.
B.4.2.5 Proteins with similar wiring to GPCR baits
We find 11 proteins in the I2D network which are not in the set of 50 GPCR baits
but have wiring similar to them. The next paragraph describes how we identified
these 11 proteins.
As a measure of similarity in wiring around proteins in the PPI network, we use
graphlet degree vectors (GDVs, see Section 1.4.2 Graphlets and graphlet-based heur-
istics on page 27). We choose the similarity threshold to be statistically significant
at p-value ≤ 0.01. We bin node GDV similarities into bins of 1% each. Using the
hypergeometric distribution statistics, we find the z-scores for each bin in the distri-
bution of GDV similarities and see that the p-value of 0.01 corresponds to a GDV
similarity threshold of ≥ 91%. We find that 11 proteins are above 91% GDV-similar
to the same 6 GPCR baits. These 11 proteins and their brief descriptions are listed
in Table B.10. These 11 proteins may be including some GPCRs that are not in the
set of the 50 GPCRs, but also some predictions of new GPCRs (e.g. chromosome 20
open reading frame 39, TMEM90B).
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Figure B.6. The GPCR network. The 25 core protein are marked in red.
Table B.10. The 11 proteins that are statistically significantly GDV-similar to
the 6 GPCR baits.
Gene symbol Description
TMEM90B chromosome 20 open reading frame 39
Rnpep arginyl aminopeptidase (aminopeptidase B)
Man1b1 mannosidase, alpha, class 1B, member 1
RHOT2 ras homolog gene family, member T2
loh12cr1 loss of heterozygosity, 12, chromosomal region 1
Fam105b family with sequence similarity 105, member B
MOV10 Mov10, Moloney leukemia virus 10, homolog (mouse)
EOMES eomesodermin homolog (Xenopus laevis)
DDI1 DDI1, DNA-damage inducible 1, homolog 1 S. cerevisiae
fgf12 fibroblast growth factor 12
SCYL2 SCY1-like 2 S. cerevisiae
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AppendixC
Appendix to Chapter 4: Integration
of molecular data
C.1 Rank parameter selection
C.1.1 Factorisation rank parameters of the integration al-
gorithm for the disease reclassification study
Parameters of the fusion algorithm are factorisation ranks, ki, which determine the
degree of dimension reduction for four object types in our fusion schema. These
factorisation ranks are selected from a predefined set of possible values to optimise
the quality of the model in its ability to reconstruct the input data from gene-disease
relation matrix R12. For example, gene–disease profiles of length ≈1 500 in the
original space are reduced to profiles with ≈70 factors in data fusion space. We find
this approach to be robust and small variations in initial parameter tuning do not
impede the overall final quality of the fused system (data not shown). In our study,
factorisation ranks of 50 to 80 yield models of similar quality. In general, we find that
if the data contain meaningful information (as opposed to randomised input), the
optimised factorisation ranks are much smaller than input dimensions because these
data can be effectively compressed, and low-dimensional representation will provide
a good estimate of the target relation matrix. Conversely, this would not hold true if
we were to predict arbitrarily assigned labels. In that case factorisation ranks would
have to be substantially larger in order to produce somewhat comparable models.
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C.1.2 Factorisation rank parameters of the integration al-
gorithm for the gene function association study
Input parameters of our algorithm are factorisation ranks, k1 and k2, which we
systematically examine and choose to achieve a correct reduction of dimensionality
of our data. These factorisation ranks capture the meaningful information that can
further be decomposed into clusters.
There is no agreed-upon procedure for choosing the right factorisation ranks.
The most common approach, widely used in many dimension reduction problems is
cophenetic correlation coefficient, as a quantitative measure of stability for cluster-
ing.311 For a given factorisation rank, cophenetic correlation coefficient is computed
over the values of the consensus matrix, ρ(C). It is defined as the Pearson’s correla-
tion coefficient between the distance matrix, 1−C, and the matrix of cophenetic
distances obtained by the linkage used in hierarchical clustering for re-ordering C.
If the clustering is stable, i.e. the entries in C are close to 0 or 1, then ρ(C) ≈ 1,
otherwise, if the entries are scattered between 0 and 1, ρ(C) < 1.
A simple generalisation of this procedure applied to two types of our data (genes
and GO terms) includes computation of cophenetic correlation coefficient for each of
the consensus matrices, Cg (for genes), CGO (for GO terms), and then we define the
average cophenetic correlation coefficient as:
ρavg =
ρ(Cg) + ρ(CGO)
2
We search for the values of, k1 and k2, that maximise ρavg. We do this by running our
algorithm for all (k1, k2) pairs such that 0 < k1, k2 < 60, so that we would capture
the best dimensionality of our data.
C.2 Supplementary Tables
See Table C.1 Fourteen predicted disease–disease associations on page 239.
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Table C.1. 14 predicted disease–disease associations currently not captured by the
semantic structure of Disease Ontology. Literature support for them is listed under the
column denoted by “Refs.”. Reported p-values measure how likely it would be for a disease association
to emerge if gene-disease relation matrix was permuted, as described in Section 4.2.8 on page 106.
Disease pair Literature evidence (quoted verbatim from the referenced source) Refs. p-value
vitamin B deficiency
(DOID:8449)
endogenous depression
(DOID:1595)
“Vitamin B complex deficiency causes the psychiatric symptoms of atyp-
ical endogenous depression. Dementia and depression have been associ-
ation with this deficiency possibly from under production of methionine.”
429,430 < 0.001
gastric lymphoma
(DOID:10540)
crescentic glomerulonephritis
(DOID:13139)
“Mixed cryoglobulinemia-associated membranoproliferative glomeru-
lonephritis disclosed gastric MALT lymphoma. Glomerulonephritis and
lymphoma tend to co-exist in the same patients (relative risk 34.0; p-value
< 0.0001).”
431–433 < 0.001
thyroid medullary carcinoma
(DOID:3973)
cholestasis (DOID:13580)
“Paraneoplastic cholestasis and hypercoagulability associated with me-
dullary thyroid carcinoma. Cholestasis is likely a paraneoplastic effect
of thyroid medullary carcinoma.”
434 0.001
crescentic glomerulonephritis
(DOID:13139)
miliary tuberculosis
(DOID:9861)
“Complex-mediated diffuse proliferative glomerulonephritis with crescentic
formation is associated with miliary tuberculosis. Antituberculous agents
successfully treat miliary tuberculosis and recovered renal function.”
435,436 0.001
thyroid adenoma (DOID:2891)
thymoma (DOID:3275)
“Coexistence of bilateral paraganglioma of the A. carotis, thymoma and
thyroid adenoma. A common neuroectodermal origin is proposed as an
explanation for the coexistence of the carotid body tumor and multiple
endocrine tumors.”
437 0.001
early myoclonic
encephalopathy (DOID:308)
Angelman syndrome
(DOID:1932)
“Angelman syndromes share a range of clinical characteristics, including
intellectual disability with or without regression and infantile encephalo-
pathy. It presents in infancy with nonspecific features, such as psychomo-
tor delay and seizures. This can lead to the descriptive labels of cerebral
palsy or static encephalopathy.”
438,439 < 0.001
autoimmune polyendocrine
syndrome (DOID:14040)
myositis (DOID:633)
“Autoimmune polyendocrine syndrome type 2 (known as Schmidt’s syn-
drome) can be associated with interstitial myositis, an inflammatory my-
opathy which can be pathologically distinguished from idiopathic polymy-
ositis and inclusion body myositis.”
440 < 0.001
primary hyperparathyroidism
(DOID:11202)
sarcoidosis (DOID:11335)
“Primary hyperparathyroidism simulates sarcoidosis. Coexisting
primary hyperparathyroidism and sarcoidosis cause increased Angiotensin-
converting enzyme and decreased parathyroid hormone and phosphate
levels.”
441 < 0.001
cerebrotendinous
xanthomatosis (DOID:4810)
viral hepatitis
(DOID:1884)
“Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of
infancy as well as cerebrotendinous xanthomatosis. Accumulation of cho-
lesterol and cholestanol can lead to the xanthomata, neurodegeneration,
cataracts and atherosclerosis that are typical of cerebrotendinous xantho-
matosis.”
442 < 0.001
lepromatous leprosy
(DOID:10887)
mental depression
(DOID:1596)
“The precipitating causes of relapse in leprosy include mental depression
which downgrades immunity. The prevalence of dementia and depression
in older leprosy patients is high.”
443 0.001
male infertility (DOID:12336)
DiGeorge syndrome
(DOID:11198)
“Complex chromosome rearrangements (CCR) are rare structural chromo-
some aberrations that can be found in patients with phenotypic abnor-
malities or in phenotypically normal patients presenting infertility. The
malsegregation of CCR can lead to partial 10p12.3 to 10p14 deletion, as-
sociated with the DiGeorge like phenotype.”
444,445 0.001
Cushing’s syndrome
(DOID:12252)
Hodgkin’s lymphoma
(DOID:8543)
“Hodgkin’s lymphoma is highly responsive to steroids and Cushing’s syn-
drome results from over exposure to corticosteroids, so it could be con-
sidered a treatment side effect. However, the co-existence in one patient of
Cushing’s disease (caused by a tumour in the pituitary) that suppressed
the Hodgkin’s lymphoma has been reported.”
446 < 0.001
crescentic glomerulonephritis
(DOID:13139)
prostate cancer (DOID:10283)
“There can be two potential causes for the association: 1) that the drugs
and treatment regimen that cancer patients are on causes the glomer-
ulonephritis, or 2) that features of the cancer may cause the glomeruloneph-
ritis with ANCA being associated in both cases.”
433 < 0.001
allergic bronchopulmonary
aspergillosis (DOID:13166)
myopathy (DOID:423)
“Allergic Bronchopulmonary aspergillosis is caused by a fungal disease.
Fungal diseases are often treated with triazoles. Drug-induced myopathies
are well recognised with triazole class of drugs. The association between
these two may therefore be based on the treatment and risk it carries,
rather than a common mechanism.”
447 < 0.001
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